PROFILAGGRIN mRNA EXPRESSION PROMOTER, INVOLUCRIN mRNA EXPRESSION PROMOTER, SERINE PALMITOYL TRANSFERASE mRNA EXPRESSION PROMOTER, HEME OXYGENASE 1 mRNA EXPRESSION PROMOTER, NAD(P)H QUINONE OXIDOREDUCTASE 1 mRNA EXPRESSION PROMOTER, GLUTATHIONE PRODUCTION PROMOTER, IL-1α PRODUCTION INHIBITOR, PROSTAGLANDIN E2 PRODUCTION INHIBITOR, AND ANTI-SACCHARIFICATION AGENT
Patent Information
- Application Number
- JP2024065685
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-27
- Filing Date
- 2024-04-15
- Publication Date
- 2024-12-04
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current compositions lack safety and efficacy in inducing skin barrier function and whitening, and there are no known agents that effectively inhibit glycation reactions in skin aging.
Development of a cyclic peroxide represented by chemical formula (I) for use in compositions that induce skin barrier function-related gene expression, inhibit melanin production, and prevent glycation reactions, combined with glycerin derivatives for improved safety and efficacy.
The cyclic peroxide compositions provide a safe and effective means to enhance skin barrier function, reduce melanin production, and inhibit glycation, addressing safety concerns of traditional peroxides while improving skin health and appearance.
Smart Images

Figure 00000004_0000 
Figure 00000004_0001 
Figure 00000094_0000
Abstract
Description
[Technical field]
[0001] The present invention relates to cyclic peroxides, oxidation reaction products, methods for producing oxidation reaction products, skin whitening compositions, skin whitening agents, compositions for inducing the expression of genes associated with skin barrier function, compositions for improving skin barrier function, inducers of genes associated with skin barrier function, agents for improving skin barrier function, compositions for inducing the expression of antioxidant stress response genes, inducers of antioxidant stress response genes, anti-inflammatory compositions, anti-inflammatory agents, anti-glycation compositions, and anti-glycation agents. [Background technology]
[0002] Peroxides such as hydrogen peroxide are substances that are used industrially due to their oxidizing ability. In the field of drug discovery, for example, hydrogen peroxide has been known to be a TRP channel activator. TRP channels (TRP receptors) are one of the ionotropic receptors (receptors) present in cell membranes, and are used as targets for drug discovery.
[0003] In the field of dermatology, it is believed that the amount and quality of melanin contained in the skin are important factors that determine the color of the skin. For this reason, whitening agents that suppress melanin production and reduce melanin in the skin have been developed as whitening ingredients. Patent Document 1 describes the use of plant extracts such as peppermint and lemon balm as whitening ingredients that promote melanin decomposition.
[0004] Furthermore, in the field of dermatology, it is known that the barrier function of the skin decreases with age, and the decrease in the barrier function of the skin is known to be associated with skin diseases such as atopic dermatitis (Non-Patent Document 1).
[0005] Furthermore, in the field of physical aging, it is known that glycation (Maillard reaction) is an enzyme-independent reaction in which proteins and carbohydrates such as reducing sugars combine, ultimately producing advanced glycation end products (AGEs). When proteins containing AGEs are produced from proteins in the body through the glycation reaction, the proteins cannot perform their original functions in the body due to the inclusion of AGEs. For this reason, AGEs are said to be related to the aging phenomenon. It has also been suggested that accumulation of AGEs in the skin can cause sagging, wrinkles, age spots, and the like. [Prior art documents] [Patent documents]
[0006] [Patent Document 1] JP 2020-059656 A [Non-patent literature]
[0007] [Non-Patent Document 1] Hironori Ishizuka, "Skin diseases involving skin barrier formation and barrier dysfunction," Jpn. J. Clin. Immunol., 40(6), 416-427, 2017. Summary of the Invention [Problem to be solved by the invention]
[0008] However, in the field of drug discovery, hydrogen peroxide has safety issues, such as being highly irritating and having the risk of explosion, due to its high reactivity.
[0009] In addition, in the field of dermatology, there is no known composition that induces the expression of genes related to the skin barrier function.Also, there is no known compound that contains a structure with oxidizing power that contributes to the induction of the expression of genes related to the skin barrier function and the improvement of the skin barrier function.
[0010] Furthermore, as mentioned above, in the field of physical aging, it is known that when proteins containing AGEs are produced from proteins in the body through the glycation reaction, the proteins containing AGEs are unable to perform their original functions in the body. For this reason, AGEs are said to be related to the aging phenomenon. It has also been suggested that accumulation of AGEs in the skin can cause sagging, wrinkles, age spots, etc.
[0011] Therefore, an object of the first aspect of the present invention is to provide a cyclic peroxide, an oxidation reaction product, and a method for producing the oxidation reaction product, which are highly safe.
[0012] The second object of the present invention is to provide a whitening composition and a whitening agent containing a new whitening ingredient.
[0013] The third aspect of the present invention aims to provide a composition for inducing the expression of skin barrier function-related genes, which contains a new component for inducing the expression of skin barrier function-related genes, and an inducer of the expression of skin barrier function-related genes.
[0014] The fourth aspect of the present invention aims to provide an anti-glycation composition and an anti-glycation agent containing a new anti-glycation component. [Means for solving the problem]
[0015] [Means for solving the problem in the first invention] In order to solve the above-mentioned safety problem, the cyclic peroxide in the first aspect of the present invention is characterized by being represented by the following chemical formula (I). [ka] In the above chemical formula (I), R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, may or may not have a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure, and may be a monocyclic ring or a condensed ring; R1 is a substituent, which may be one, multiple, or absent, and when multiple, they may be the same or different.
[0016] The oxidation reaction product in the first aspect of the present invention is an oxidation reaction product obtained by oxidizing an alcohol and characterized by containing a cyclic peroxide.
[0017] The method for producing an oxidation reaction product according to the first aspect of the present invention is a method for producing an oxidation reaction product according to the present invention, which comprises an alcohol oxidation step of oxidizing the alcohol.
[0018] [Means for solving the problem in the second invention] In order to provide a whitening composition and a whitening agent containing a new whitening ingredient, the whitening composition according to the second aspect of the present invention contains glycerin and / or a glycerin derivative and a whitening ingredient, The whitening ingredient contains, as an active ingredient, a cyclic peroxide represented by the following chemical formula (I) or a salt thereof: [ka] In the above chemical formula (I), R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, may or may not have a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure, and may be a monocyclic ring or a condensed ring; R 1 is a substituent, which may be one, multiple, or absent, and when multiple, they may be the same or different.
[0019] The skin whitening agent of the second invention of the present invention contains a cyclic peroxide represented by the following chemical formula (I) or a salt thereof: [ka] In the above chemical formula (I), R 100is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, may or may not have a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure, and may be a monocyclic ring or a condensed ring; R 1 is a substituent, which may be one, multiple, or absent, and when multiple, they may be the same or different.
[0020] [Means for solving the problems in the third invention] In order to provide a novel composition for inducing the expression of a skin barrier function-related gene, which contains a component for inducing the expression of a skin barrier function-related gene, and an inducer for inducing the expression of a skin barrier function-related gene, the composition for inducing the expression of a skin barrier function-related gene in the third aspect of the present invention contains glycerin and / or a glycerin derivative, and a component for inducing the expression of a skin barrier function-related gene, The component for inducing the expression of a skin barrier function-related gene contains, as an active ingredient, a cyclic peroxide represented by the following chemical formula (I) or a salt thereof: [ka] In the above chemical formula (I), R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, may or may not have a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure, and may be a monocyclic ring or a condensed ring; R 1 is a substituent, which may be one, multiple, or absent, and when multiple, they may be the same or different.
[0021] The composition for improving skin barrier function in the third invention of the present invention comprises the composition for inducing expression of a skin barrier function-related gene described in the third invention of the present invention.
[0022] The expression inducer of a skin barrier function-related gene in the third aspect of the present invention comprises a cyclic peroxide represented by the following chemical formula (I) or a salt thereof: [ka] In the above chemical formula (I), R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, may or may not have a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure, and may be a monocyclic ring or a condensed ring; R 1 is a substituent, which may be one, multiple, or absent, and when multiple, they may be the same or different.
[0023] The skin barrier function improver in the third invention of the present invention comprises the skin barrier function-related gene inducer in the third invention of the present invention.
[0024] The composition for inducing expression of an antioxidant stress response gene in the third aspect of the present invention comprises glycerin and / or a glycerin derivative and a component for inducing expression of an antioxidant stress response gene, The component for inducing expression of an antioxidant stress response gene contains, as an active ingredient, a cyclic peroxide represented by the following chemical formula (I) or a salt thereof: [ka] In the above chemical formula (I), R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, may or may not have a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure, and may be a monocyclic ring or a condensed ring; R 1 is a substituent, which may be one, multiple, or absent, and when multiple, they may be the same or different.
[0025] The expression inducer of an antioxidant stress response gene in the third aspect of the present invention comprises a cyclic peroxide represented by the following chemical formula (I) or a salt thereof: [ka] In the above chemical formula (I), R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, may or may not have a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure, and may be a monocyclic ring or a condensed ring; R 1 is a substituent, which may be one, multiple, or absent, and when multiple, they may be the same or different.
[0026] The anti-inflammatory composition according to the third aspect of the present invention comprises glycerin and / or a glycerin derivative and an anti-inflammatory component, The anti-inflammatory component contains, as an active ingredient, a cyclic peroxide represented by the following chemical formula (I) or a salt thereof: [ka] In the above chemical formula (I), R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, may or may not have a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure, and may be a monocyclic ring or a condensed ring; R 1 is a substituent, which may be one, multiple, or absent, and when multiple, they may be the same or different.
[0027] The anti-inflammatory agent according to the third aspect of the present invention comprises a cyclic peroxide represented by the following chemical formula (I) or a salt thereof: [ka] In the above chemical formula (I), R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, may or may not have a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure, and may be a monocyclic ring or a condensed ring; R 1 is a substituent, which may be one, multiple, or absent, and when multiple, they may be the same or different.
[0028] [Means for solving the problems in the fourth aspect of the invention] In order to provide an anti-glycation composition and an anti-glycation agent containing a new anti-glycation component, the anti-glycation composition (hereinafter also referred to as "composition") in the fourth aspect of the present invention contains glycerin and / or a glycerin derivative, and an anti-glycation component, The anti-glycation component contains, as an active ingredient, a cyclic peroxide represented by the following chemical formula (I) or a salt thereof: [ka] In the above chemical formula (I), R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, may or may not have a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure, and may be a monocyclic ring or a condensed ring; R 1 is a substituent, which may be one, multiple, or absent, and when multiple, they may be the same or different. Includes things.
[0029] The anti-glycation agent in the fourth aspect of the present invention includes a cyclic peroxide represented by the following chemical formula (I) or a salt thereof: [ka] In the above chemical formula (I), R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, may or may not have a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure, and may be a monocyclic ring or a condensed ring; R 1is a substituent, which may be one, multiple, or absent, and when multiple, they may be the same or different. Effect of the Invention
[0030] [Effects of the first invention] According to the first aspect of the present invention, it is possible to provide a highly safe cyclic peroxide, an oxidation reaction product, and a method for producing an oxidation reaction product.
[0031] [Effects of the second invention] According to the second aspect of the present invention, it is possible to provide a whitening composition and a whitening agent containing a new whitening ingredient.
[0032] [Effects of the third invention] According to the third aspect of the present invention, it is possible to provide a composition for inducing the expression of skin barrier function-related genes, which contains a new component for inducing the expression of skin barrier function-related genes, and an inducer of the expression of skin barrier function-related genes.
[0033] [Effects of the fourth invention] According to the fourth aspect of the present invention, it is possible to provide an anti-glycation composition and an anti-glycation agent containing a new anti-glycation component. [Brief description of the drawings]
[0034] [Figure 1-1] FIG. 1-1 shows the 1H NMR spectrum of the reaction mixture (TLC 1 spot) of glycerin ozone oxidation measured at 300 K (27° C.) using DMSO-d6 as a solvent. [Figure 1-2] FIG. 1-2 shows the 13C NMR spectrum of the reaction mixture (TLC 1 spot) of the ozone oxidation of glycerin, measured at a temperature of 300 K (27° C.) using DMSO-d6 as a solvent. [Figure 1-3] FIG. 1-3 shows the 13C DEPT135 NMR spectrum of the reaction mixture (TLC 1 spot) of the ozone oxidation of glycerin, measured at 300 K (27° C.) using DMSO-d6 as a solvent. [Figure 1-4] FIG. 1-4 shows the COSY NMR spectrum of the reaction mixture (TLC 1 spot product) of the ozone oxidation of glycerin, measured at a temperature of 300 K (27° C.) using DMSO-d6 as a solvent. [Figure 1-5] FIG. 1-5 shows the HSQC NMR spectrum of the reaction mixture (TLC 1 spot) of glycerin ozone oxidation measured at 300 K (27° C.) using DMSO-d6 as a solvent. [Figure 1-6] FIG. 1-6 shows the HMBC NMR spectrum of the reaction mixture (TLC 1 spot product) of the ozone oxidation of glycerin, measured at a temperature of 300 K (27° C.) using DMSO-d6 as a solvent. [Figure 1-7] FIG. 1-7 shows total ion chromatograms (ESI-negative mode) in the precision preparative LC (liquid chromatography) of a sample prepared (diluted) from the reaction mixture (TLC 1 spot product) with acetonitrile to about 3% by mass, and a blank. [Figure 1-8] FIG. 1-8 is a mass spectrum diagram of peaks F, G and H (Fraction F, Fraction G and Fraction H) in FIG. 1-7. [Figure 1-9] FIG. 1-9 shows the results of an investigation into the improvement of separation (improvement of separation conditions) in HILIC (high performance liquid chromatography). [Figure 1-10] FIG. 1-10 is a diagram showing the mass spectrum (after improved separation) of peaks 1 to 3 in FIG. 1-9. [Figure 1-11] FIG. 1-11 is a diagram showing the mass spectrum (after improved separation) of peaks 4 to 6 in FIG. 1-9. [Figure 1-12] FIG. 1-12 is a diagram showing the mass spectrum (after improved separation) of peaks 7 and 8 in FIG. 1-9. [Figure 1-13] FIG. 1-13 shows microscopic Raman spectrum diagrams of a fractionated sample of peak 2 (Mw=180) in FIG. 1-9 and an ozonide standard. [Figure 1-14] FIG. 1-14 is a 1H NMR spectrum of peak 2 (Mw=180) in FIG. 1-9. [Figure 1-15] FIG. 1-15 is a 13C NMR spectrum of peak 2 (Mw=180) in FIG. 1-9. [Figure 1-16] FIG. 1-16 is a two-dimensional (1H-13C COSY) NMR spectrum of peak 2 (Mw=180) in FIG. 1-9. [Figure 1-17] FIG. 1-17 shows HILIC (high performance liquid chromatography) chromatograms of the TLC1 spot product and glyceraldehyde dimer under the HILIC conditions of FIG. 1-9. [Figure 1-18] FIG. 1-18 shows HILIC (high performance liquid chromatography) chromatograms of one TLC spot and glyceraldehyde dimer under reversed phase HILIC conditions. [Figure 1-19] FIG. 1-19 is an enlarged view of a portion of FIG. 1-18. [Figure 1-20] FIG. 1-20 shows the ESR spectrum of the TLC 1 spot and peak 2 (Mw=180) in FIG. 1-9. [Figure 1-21] FIG. 1-21 is an ESR spectrum of ozonized methyl linolenate. [Figure 1-22] FIG. 1-22 is an ESR spectrum diagram of peaks 1 to 8 in FIG. 1-9. [Figure 1-23] FIG. 1-23 shows the results of measuring the activities of peaks 1 to 8 in FIG. 1-9 by chemiluminescence. [Figure 1-24] FIG. 1-24 shows the effect of adding G (glycerin), OG (ozonized glycerin), LOG (ozonized oxide), and HOG (heat-treated ozonized glycerin) to TRPM2 (expressing cells) and Vector (TRPM2 non-expressing cells). [Figure 1-25] FIG. 1-25 shows the TRP channel activity of G and OG against TRPM2 (expressing cells) under the same conditions as in FIG. 1-24, except that the aqueous solution concentration (mass %) was changed. [Figure 1-26]FIG. 1-26 shows the TRP channel activity of G, OG, LOG and HOG against TRPM2 (expressing cells). [Figure 1-27] Figure 1-27 shows the TRP channel activity of LOG and OG against TRPM2 (expressing cells) under the same conditions as in Figure 1-24, except that 500 units / ml of catalase was added, and compared with the results when no catalase was added. [Figure 1-28] FIG. 1-28 shows the TRP channel activity of OG and LOG against TRPM2 (expressing cells) under the same conditions as in FIG. 1-24, except that the aqueous solution concentration (mass %) was changed. [Figure 1-29] Figure 1-29 shows the TRP channel activity for TRPM2 (expressing cells) at 0.1 mass% LOG under the same conditions as Figure 1-24, except that catalase was added at 100 unit / ml or PJ34 (trade name of Chemscene) was added at 1 μm, and compared with the results when catalase and PJ34 were not added. [Figure 1-30] Figure 1-30 shows the TRP channel activity for TRPM2 (expressing cells) at 0.1 mass% LOG under the same conditions as Figure 1-24, except that 100 μm of dipyridyl (α,α'-dipyridyl) was added, and compared with the case when dipyridyl was not added. [Figure 1-31] Figure 1-31 shows the TRP channel activity of LOG in each cell under the same conditions as in Figure 1-24, except that the concentration (mass%) of the aqueous solution was changed and TRPM1 HEK (expressing cells) or HEK (expressing cells) was used instead of TRPM2 (expressing cells). [Figure 1-32] FIG. 1-32 shows the results of examining the TRP channel activity of F7 at various concentrations against TRPM2 (expressing cells) and TRPMA1 (expressing cells) in the same manner as in FIG. 1-31. [Figure 1-33] FIG. 1-33 is a diagram showing the TRP channel activity of F7 at various concentrations against TRPM2 (expressing cells) and TRPMA1 (expressing cells) examined in the same manner as in FIG. 1-31. [Figure 2-1] FIG. 2-1 is a graph showing the results of melanin measurements over time in Example 2-1. [Figure 2-2] FIG. 2-2 is a graph showing the change in melanin measurement value over time in Example 2-1. [Figure 2-3] FIG. 2-3 shows the 1H NMR spectrum of the reaction mixture (TLC 1 spot) of the ozone oxidation of glycerin, measured at 300 K (27° C.) using DMSO-d6 as a solvent. [Figure 2-4] FIG. 2-4 shows the 13C NMR spectrum of the reaction mixture (TLC 1 spot) of the ozone oxidation of glycerin, measured at a temperature of 300 K (27° C.) using DMSO-d6 as a solvent. [Figure 2-5] FIG. 2-5 shows the 13C DEPT135 NMR spectrum of the reaction mixture (TLC 1 spot) of the ozone oxidation of glycerin, measured at 300 K (27° C.) using DMSO-d6 as a solvent. [Figure 2-6] FIG. 2-6 shows the COSY NMR spectrum of the reaction mixture (TLC 1 spot product) of the ozone oxidation of glycerin, measured at a temperature of 300 K (27° C.) using DMSO-d6 as a solvent. [Figure 2-7] FIG. 2-7 shows the HSQC NMR spectrum of the reaction mixture (TLC 1 spot) of glycerin ozone oxidation measured at 300 K (27° C.) using DMSO-d6 as a solvent. [Figure 2-8] FIG. 2-8 shows the HMBC NMR spectrum of the reaction mixture (TLC 1 spot product) of the ozone oxidation of glycerin, measured at a temperature of 300 K (27° C.) using DMSO-d6 as a solvent. [Figure 2-9] FIG. 2-9 shows total ion chromatograms (ESI-negative mode) in the precision preparative LC (liquid chromatography) of a sample prepared (diluted) from the reaction mixture (TLC 1 spot product) with acetonitrile to about 3% by mass, and a blank. [Figure 2-10] FIG. 2-10 is a mass spectrum diagram of peaks F, G and H (F fraction, G fraction and H fraction) in FIG. 2-9. [Figure 2-11] FIG. 2-11 shows the results of an investigation into the improvement of separation (improvement of separation conditions) in HILIC (high performance liquid chromatography). [Figure 2-12] FIG. 2-12 is a diagram showing the mass spectrum (after improved separation) of peaks 1 to 3 in FIG. 2-11. [Figure 2-13] FIG. 2-13 is a diagram showing the mass spectrum (after improved separation) of peaks 4 to 6 in FIG. 2-11. [Figure 2-14] FIG. 2-14 is a diagram showing the mass spectrum (after improved separation) of peaks 7 and 8 in FIG. 2-11. [Figure 2-15] FIG. 2-15 shows the microscopic Raman spectrum of a fractionated sample of peak 2 (Mw=180) in FIG. 2-11, together with an ozonide standard. [Figure 2-16] FIG. 2-16 is a 1H NMR spectrum of peak 2 (Mw=180) in FIG. 2-11. [Figure 2-17] FIG. 2-17 is a 13C NMR spectrum of peak 2 (Mw=180) in FIG. 2-11. [Figure 2-18] FIG. 2-18 is a two-dimensional (1H-13C COSY) NMR spectrum of peak 2 (Mw=180) in FIG. 2-11. [Figure 2-19] FIG. 2-19 shows HILIC (high performance liquid chromatography) chromatograms of the TLC1 spot product and glyceraldehyde dimer under the HILIC conditions of FIG. 2-11. [Figure 2-20] FIG. 2-20 shows HILIC (high performance liquid chromatography) chromatograms of one TLC spot and glyceraldehyde dimer under reversed phase HILIC conditions. [Figure 2-21] FIG. 2-21 is an enlarged view of a portion of FIG. 2-20. [Figure 2-22] FIG. 2-22 shows the ESR spectrum of the TLC 1 spot product and peak 2 (Mw=180) in FIG. 2-9. [Figure 2-23]Figure 2-23 is an ESR spectrum of ozonized methyl linolenate. [Figure 2-24] FIG. 2-24 is an ESR spectrum diagram of peaks 1 to 8 in FIG. 2-11. [Figure 2-25] FIG. 2-25 shows the results of measuring the activities of peaks 1 to 8 in FIG. 2-11 by chemiluminescence. [Figure 3-1] FIG. 3-1 is a graph showing the expression levels of skin barrier function-related genes in Example 3-1. [Figure 3-2] FIG. 3-2 is a graph showing the expression levels of antioxidant stress response genes in Example 3-1. [Figure 3-3] FIG. 3-3 is a graph showing the amount of glutathione peptide in Example 3-1. [Diagram 3-4] FIG. 3-4 is a graph showing the cell viability in Example 3-1. [Figure 3-5] FIG. 3-5 is a graph showing the amount of IL-1α produced in Example 3-1. [Diagram 3-6] FIG. 3-6 is a graph showing the amount of prostaglandin E2 produced in Example 3-1. [Diagram 3-7] FIG. 3-7 shows the 1H NMR spectrum of the reaction mixture (TLC 1 spot) of the ozone oxidation of glycerin, measured at 300 K (27° C.) using DMSO-d6 as a solvent. [Diagram 3-8] FIG. 3-8 shows the 13C NMR spectrum of the reaction mixture (TLC 1 spot) of the ozone oxidation of glycerin, measured at 300 K (27° C.) using DMSO-d6 as a solvent. [Diagram 3-9] FIG. 3-9 shows the 13C DEPT135 NMR spectrum of the reaction mixture (TLC 1 spot) of the ozone oxidation of glycerin, measured at 300 K (27° C.) using DMSO-d6 as a solvent. [Figure 3-10] FIG. 3-10 shows the COSY NMR spectrum of the reaction mixture (TLC 1 spot product) of the ozone oxidation of glycerin, measured at a temperature of 300 K (27° C.) using DMSO-d6 as a solvent. [Figure 3-11] FIG. 3-11 shows the HSQC NMR spectrum of the reaction mixture (TLC 1 spot product) of the ozone oxidation of glycerin, measured at a temperature of 300 K (27° C.) using DMSO-d6 as a solvent. [Figure 3-12] FIG. 3-12 is an HMBC NMR spectrum of the reaction mixture (TLC 1 spot product) of the ozone oxidation of glycerin, measured at a temperature of 300 K (27° C.) using DMSO-d6 as a solvent. [Figure 3-13] FIG. 3-13 shows total ion chromatograms (ESI-negative mode) in the precision preparative LC (liquid chromatography) of a sample prepared (diluted) from the reaction mixture (TLC 1 spot product) with acetonitrile to about 3% by mass, and a blank. [Figure 3-14] FIG. 3-14 is a mass spectrum diagram of peaks F, G and H (F fraction, G fraction and H fraction) in FIG. 3-13. [Figure 3-15] FIG. 3-15 shows the results of an investigation into the improvement of separation (improvement of separation conditions) in HILIC (high performance liquid chromatography). [Figure 3-16] FIG. 3-16 is a diagram showing the mass spectrum (after improved separation) of peaks 1 to 3 in FIG. 3-15. [Figure 3-17] FIG. 3-17 is a diagram showing the mass spectrum (after improved separation) of peaks 4 to 6 in FIG. 3-15. [Figure 3-18] FIG. 3-18 is a diagram showing the mass spectrum (after improved separation) of peaks 7 and 8 in FIG. 3-15. [Figure 3-19] FIG. 3-19 shows microscopic Raman spectrum diagrams of a fractionated sample of peak 2 (Mw=180) in FIG. 3-15 and an ozonide standard. [Figure 3-20] FIG. 3-20 is a 1H NMR spectrum of peak 2 (Mw=180) in FIG. 3-15. [Figure 3-21] FIG. 3-21 is a 13C NMR spectrum of peak 2 (Mw=180) in FIG. 3-15. [Figure 3-22]FIG. 3-22 is a two-dimensional (1H-13C COSY) NMR spectrum of peak 2 (Mw=180) in FIG. 3-15. [Figure 3-23] FIG. 3-23 shows HILIC (high performance liquid chromatography) chromatograms of the TLC1 spot product and glyceraldehyde dimer under the HILIC conditions of FIG. 3-15. [Figure 3-24] FIG. 3-24 shows HILIC (high performance liquid chromatography) chromatograms of one TLC spot and glyceraldehyde dimer under reversed phase HILIC conditions. [Figure 3-25] FIG. 3-25 is an enlarged view of a portion of FIG. 3-24. [Figure 3-26] FIG. 3-26 shows the ESR spectrum of the TLC 1 spot product and peak 2 (Mw=180) in FIG. 3-9. [Figure 3-27] FIG. 3-27 is an ESR spectrum of ozonized methyl linolenate. [Figure 3-28] FIG. 3-28 is an ESR spectrum diagram of peaks 1 to 8 in FIG. 3-15. [Figure 3-29] FIG. 3-29 is a diagram showing the results of measuring the activities of peaks 1 to 8 in FIG. 3-15 by chemiluminescence. [Figure 4-1] FIG. 4-1 is a graph showing the anti-glycation rate in Example 4-1. [Figure 4-2] FIG. 4-2 shows the 1H NMR spectrum of the reaction mixture (TLC 1 spot) of the ozone oxidation of glycerin, measured at a temperature of 300 K (27° C.) using DMSO-d6 as a solvent. [Figure 4-3] FIG. 4-3 shows the 13C NMR spectrum of the reaction mixture (TLC 1 spot) of the ozone oxidation of glycerin, measured at a temperature of 300 K (27° C.) using DMSO-d6 as a solvent. [Figure 4-4] FIG. 4-4 shows the 13C DEPT135 NMR spectrum of the reaction mixture (TLC 1 spot) of the ozone oxidation of glycerin, measured at 300 K (27° C.) using DMSO-d6 as a solvent. [Figure 4-5] FIG. 4-5 shows the COSY NMR spectrum of the reaction mixture (TLC 1 spot) of the ozone oxidation of glycerin, measured at 300 K (27° C.) using DMSO-d6 as a solvent. [Figure 4-6] FIG. 4-6 shows the HSQC NMR spectrum of the reaction mixture (TLC 1 spot) of glycerin ozone oxidation measured at 300 K (27° C.) using DMSO-d6 as a solvent. [Figure 4-7] FIG. 4-7 shows the HMBC NMR spectrum of the reaction mixture (TLC 1 spot) of the ozone oxidation of glycerin, measured at 300 K (27° C.) using DMSO-d6 as a solvent. [Figure 4-8] FIG. 4-8 shows total ion chromatograms (ESI-negative mode) in the precision preparative LC (liquid chromatography) of a sample prepared (diluted) from the reaction mixture (TLC 1 spot product) with acetonitrile to about 3% by mass, and a blank. [Figure 4-9] FIG. 4-9 is a mass spectrum diagram of peaks F, G and H (Fraction F, Fraction G and Fraction H) in FIG. 4-8. [Figure 4-10] FIG. 4-10 shows the results of an investigation into the improvement of separation (improvement of separation conditions) in HILIC (high performance liquid chromatography). [Figure 4-11] FIG. 4-11 is a diagram showing the mass spectrum (after improved separation) of peaks 1 to 3 in FIG. 4-10. [Figure 4-12] FIG. 4-12 is a diagram showing the mass spectrum (after improved separation) of peaks 4 to 6 in FIG. 4-10. [Figure 4-13] FIG. 4-13 is a diagram showing the mass spectrum (after improved separation) of peaks 7 and 8 in FIG. 4-10. [Figure 4-14] FIG. 4-14 shows the microscopic Raman spectrum of a fractionated sample of peak 2 (Mw=180) in FIG. 4-10, together with an ozonide standard. [Figure 4-15] FIG. 4-15 is a 1H NMR spectrum of peak 2 (Mw=180) in FIG. 4-10. [Figure 4-16] FIG. 4-16 is a 13C NMR spectrum of peak 2 (Mw=180) in FIG. 4-10. [Figure 4-17] FIG. 4-17 is a two-dimensional (1H-13C COSY) NMR spectrum of peak 2 (Mw=180) in FIG. 4-10. [Figure 4-18] FIG. 4-18 shows HILIC (high performance liquid chromatography) chromatograms of the TLC1 spot product and glyceraldehyde dimer under the HILIC conditions of FIG. 4-10. [Figure 4-19] FIG. 4-19 shows HILIC (high performance liquid chromatography) chromatograms of one TLC spot and glyceraldehyde dimer under reversed phase HILIC conditions. [Figure 4-20] FIG. 4-20 is an enlarged view of a portion of FIG. 4-19. [Figure 4-21] FIG. 4-21 shows the ESR spectrum of the TLC 1 spot product and peak 2 (Mw=180) in FIG. 4-4. [Figure 4-22] Figure 4-22 is an ESR spectrum of ozonized methyl linolenate. [Figure 4-23] FIG. 4-23 is an ESR spectrum diagram of peaks 1 to 8 in FIG. 4-10. [Figure 4-24] FIG. 4-24 is a diagram showing the results of measuring the activities of peaks 1 to 8 in FIG. 4-10 by chemiluminescence. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0035] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to the following description.
[0036] [First embodiment of the invention] First, an embodiment of the first aspect of the present invention will be described. However, the first aspect of the present invention is not limited to the following description.
[0037] In the first invention of the present invention, when a compound has isomers such as tautomers or stereoisomers (e.g., geometric isomers, conformational isomers, and optical isomers), any of the isomers can be used in the first invention of the present invention, unless otherwise specified. In addition, in the first invention of the present invention, when a substance can form a salt, the salt can also be used in the first invention of the present invention, unless otherwise specified. The salt may be an acid addition salt or a base addition salt. Furthermore, the acid that forms the acid addition salt may be an inorganic acid or an organic acid, and the base that forms the base addition salt may be an inorganic base or an organic base. The inorganic acid is not particularly limited, but examples thereof include sulfuric acid, phosphoric acid, hydrofluoric acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, hypofluorite acid, hypochlorous acid, hypobromite acid, hypoiodite acid, fluorite acid, chlorous acid, bromite acid, iodite acid, fluorine acid, chlorine acid, bromine acid, iodic acid, perfluorine acid, perchloric acid, perbromine acid, and periodic acid. The organic acid is also not particularly limited, but examples thereof include p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromobenzenesulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, and acetic acid. The inorganic base is not particularly limited, but examples thereof include ammonium hydroxide, alkali metal hydroxide, alkaline earth metal hydroxide, carbonate, and hydrogen carbonate, and more specifically, examples thereof include sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, calcium hydroxide, and calcium carbonate. The organic base is also not particularly limited, but examples thereof include ethanolamine, triethylamine, and tris(hydroxymethyl)aminomethane. The method for producing these salts is also not particularly limited, and for example, they can be produced by a method in which the above-mentioned acid or base is appropriately added to the compound by a known method.
[0038] In the first invention of the present invention, examples of the aromatic ring that does not contain a heteroatom include a benzene ring, a naphthalene ring, an anthracene ring, a phenanthrene ring, and a pyrene ring. Examples of the heteroaromatic ring include a pyridine ring and a thiophene ring. The nitrogen-containing aromatic ring may or may not have a positive charge. Examples of the nitrogen-containing aromatic ring that does not have a positive charge include a pyrroline ring, a pyridine ring, a pyridazine ring, a pyrimidine ring, a pyrazine ring, a quinoline ring, an isoquinoline ring, an acridine ring, a 3,4-benzoquinoline ring, a 5,6-benzoquinoline ring, a 6,7-benzoquinoline ring, a 7,8-benzoquinoline ring, a 3,4-benzoisoquinoline ring, a 5,6-benzoisoquinoline ring, a 6,7-benzoisoquinoline ring, and a 7,8-benzoisoquinoline ring. Examples of the nitrogen-containing aromatic ring having a positive charge include a pyrrolinium ring, a pyridinium ring, a pyridazinium ring, a pyrimidinium ring, a pyrazinium ring, a quinolinium ring, an isoquinolinium ring, an acridinium ring, a 3,4-benzoquinolinium ring, a 5,6-benzoquinolinium ring, a 6,7-benzoquinolinium ring, a 7,8-benzoquinolinium ring, a 3,4-benzoisoquinolinium ring, a 5,6-benzoisoquinolinium ring, a 6,7-benzoisoquinolinium ring, a 7,8-benzoisoquinolinium ring, etc. Examples of the oxygen-containing aromatic ring or sulfur-containing aromatic ring include an aromatic ring in which at least one of the carbon atom or nitrogen atom of the aromatic ring or nitrogen-containing aromatic ring not containing a heteroatom is replaced with at least one of an oxygen atom and a sulfur atom.
[0039] In the first aspect of the present invention, examples of the "substituent" include a hydroxyl group (-OH), an aldehyde group (formyl group), a hydroxyalkyl group, a sulfo group, a nitro group, a diazo group, an alkyl group, an unsaturated aliphatic hydrocarbon group, an aryl group, a heteroaryl group, a halogen, a mercapto group (-SH), an alkylthio group (-SR, R is an alkyl group), and the like.
[0040] In the first invention of the present invention, the chain-like substituent (e.g., a hydrocarbon group such as an alkyl group or an unsaturated aliphatic hydrocarbon group) may be linear or branched unless otherwise specified, and the number of carbon atoms is not particularly limited, but may be, for example, 1 to 40, 1 to 32, 1 to 24, 1 to 18, 1 to 12, 1 to 6, or 1 to 2 (2 or more in the case of an unsaturated hydrocarbon group). In addition, in the first invention of the present invention, the number of ring members (the number of atoms constituting the ring) of a cyclic group (e.g., an aryl group, a heteroaryl group, etc.) is not particularly limited, but may be, for example, 5 to 32, 5 to 24, 6 to 18, 6 to 12, or 6 to 10. In addition, when an isomer exists in a substituent or the like, any isomer may be used unless otherwise specified, for example, when simply referring to a "butyl group", it may be an n-butyl group, a sec-butyl group, or a tert-butyl group, and when simply referring to a "naphthyl group", it may be a 1-naphthyl group or a 2-naphthyl group.
[0041] The first invention of the present invention will be described in more detail below with examples. However, the first invention of the present invention is not limited by the following explanation. In addition, each explanation in the first invention of the present invention can be mutually incorporated unless otherwise specified. In this specification, when the expression "~" is used, it is used to mean including the numerical value or physical value before and after it. In addition, in this specification, the expression "A and / or B" includes "A only", "B only", and "both A and B".
[0042] [1. Cyclic peroxides] As described above, the cyclic peroxide of the first aspect of the present invention is characterized by being represented by the following chemical formula (I). [ka] In the above chemical formula (I), R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, may or may not have a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure, and may be a monocyclic ring or a condensed ring; R 1is a substituent, which may be one, multiple, or absent, and when multiple, they may be the same or different.
[0043] The heteroatom refers to an atom other than carbon and hydrogen, and may be, for example, one selected from the group consisting of oxygen, nitrogen, sulfur, selenium, boron, and silicon. The substituent is not particularly limited, and may include, for example, a hydroxyl group, and may be, for example, one selected from the group consisting of the above-mentioned hydroxyl group (-OH), aldehyde group (formyl group), hydroxyalkyl group, sulfo group, nitro group, diazo group, alkyl group, unsaturated aliphatic hydrocarbon group, aryl group, heteroaryl group, halogen, mercapto group (-SH), and alkylthio group (-SR, R is alkyl group).
[0044] The cyclic peroxide of the first invention in the present invention is, for example, a compound represented by the above chemical formula (I): 100 However, it may be a cyclic structure having 5 to 10 ring members.
[0045] The cyclic peroxide of the first aspect of the present invention may be, for example, a cyclic peroxide represented by the following chemical formula (II). [ka] In the above chemical formula (II), Each R 11 may be the same or different, and each is a hydrogen atom or a substituent. Two R 11 may be joined together to form an oxo group (=O) or a thioxo group (=S).
[0046] The cyclic peroxide of the first invention in the present invention is, for example, R 11In the above, each of the substituents may be a hydroxyl group (-OH), an aldehyde group (formyl group), a hydroxyalkyl group, a sulfo group, a nitro group, a diazo group, an alkyl group, an unsaturated aliphatic hydrocarbon group, an aryl group, a heteroaryl group, a halogen, a mercapto group (-SH), or an alkylthio group (-SR, where R is an alkyl group).
[0047] The cyclic peroxide of the first invention in the present invention may be, for example, a cyclic peroxide represented by the following chemical formula (1). Note that the cyclic peroxide represented by the following chemical formula (1) is a cyclic peroxide represented by the following chemical formula (II) in which all R 11 is a hydrogen atom. [ka]
[0048] The method for producing the cyclic peroxide of the first invention of the present invention is not particularly limited, but for example, the cyclic peroxide can be produced by oxidizing an alcohol by the method for producing an oxidation reaction product of the first invention of the present invention described below. In this case, for example, the produced oxidation reaction product may be used as it is without purification, or only the cyclic peroxide of the first invention of the present invention may be isolated and purified and used.
[0049] The present inventors were the first to discover the phenomenon that cyclic peroxides are obtained by the oxidation of alcohols, for example, the oxidation of glycerin with ozone. Although the mechanism by which cyclic peroxides are obtained is unclear, it is speculated that, for example, by extending the reaction time of the oxidation reaction of alcohols as described below, a reaction product different from that of conventional reactions is obtained.
[0050] The cyclic peroxide of the first aspect of the present invention is chemically stable and easy to handle compared to, for example, radicals, and can be isolated and formulated.
[0051] In general, cyclic peroxides are substances that are used industrially due to their oxidizing ability, etc. In particular, artemisinin, which has a seven-membered ring (trioxolane) skeleton similar to the structure of the cyclic peroxide of the first invention in the present invention, is useful for antimalarial purposes and was awarded the Nobel Prize in 2015, and its derivatives are currently being researched.
[0052] However, the supply of artemisinin was unstable when it was extracted and purified from natural products. In addition, since artemisinin is neither water-soluble nor fat-soluble, there were many challenges in formulating it. On the other hand, as mentioned above, hydrogen peroxide is an example of a water-soluble oxidizing substance, but it is highly reactive and unstable, and has only been used for external disinfection of living organisms.
[0053] In contrast, according to the first invention of the present invention, for example, a cyclic peroxide and an oxidation reaction product that are highly safe and have excellent water solubility, and a method for producing such an oxidation reaction product can be provided. As an evaluation method for the water solubility and oxidizing ability of the cyclic peroxide of the first invention of the present invention or the oxidation reaction product of the first invention of the present invention, for example, as described in Example 1 below, a method for evaluating the activity against the TRP channel, which is also used as a target for drug discovery, can be mentioned. The mechanism by which the cyclic peroxide of the first invention of the present invention or the oxidation reaction product of the first invention of the present invention exhibits TRP channel activity is not particularly limited, but it is considered that, for example, it exhibits TRP channel activity by slowly decomposing to generate hydrogen peroxide.
[0054] [2. Oxidation reaction products] As described above, the oxidation reaction product of the first invention of the present invention is an oxidation reaction product obtained by oxidizing an alcohol and characterized by containing a cyclic peroxide. However, the method for producing the oxidation reaction product of the first invention of the present invention is not limited to the oxidation of an alcohol, and any method for producing the oxidation reaction product may be used as long as the product has the same structure.
[0055] The method of oxidizing the alcohol is not particularly limited. For example, the oxidation of the alcohol may be at least one of ozone oxidation and hydrogen peroxide oxidation. However, as described above, the method of producing the oxidation reaction product of the first invention in the present invention is not limited to ozone oxidation and hydrogen peroxide oxidation of the alcohol, and any method of production may be used as long as the substance has the same structure.
[0056] The oxidation reaction product of the first aspect of the present invention may be, for example, a mixture containing a plurality of oxidation reaction products.
[0057] The oxidation reaction product of the first aspect of the present invention may have, for example, an oxidizing ability.
[0058] The oxidation reaction product of the first aspect of the present invention may have, for example, reducing ability.
[0059] The oxidation reaction product of the first aspect of the present invention may contain, for example, a TRP channel active substance.
[0060] In the oxidation reaction product of the first invention of the present invention, the alcohol serving as a raw material is not particularly limited. For example, in the oxidation reaction product of the first invention of the present invention, the alcohol may be a saturated alcohol.
[0061] In the oxidation reaction product of the first aspect of the present invention, for example, the alcohol may be a polyhydric alcohol.
[0062] In the oxidation reaction product of the first aspect of the present invention, for example, the alcohol may be at least one of glycerin and a glycerin derivative.
[0063] The oxidation reaction product of the first aspect of the present invention may include, for example, an oxidation reaction product obtained by bonding two or more molecules of the alcohol.
[0064] The oxidation reaction product of the first aspect of the present invention may contain, for example, the cyclic peroxide of the first aspect of the present invention.
[0065] The alcohol used as the raw material for the oxidation reaction product of the first invention of the present invention is not particularly limited, and may be, for example, a saturated alcohol or an unsaturated alcohol as described above. The alcohol may be linear or branched, and may or may not contain a cyclic structure. The alcohol may be, for example, a polyhydric alcohol or a monohydric alcohol. The valence of the polyhydric alcohol is also not particularly limited, and may be, for example, dihydric, trihydric, or tetrahydric. Examples of monohydric saturated alcohols include saturated alcohols having 1 to 40, 1 to 32, 1 to 24, 1 to 18, 1 to 12, 1 to 6, or 1 to 2 carbon atoms, and the saturated alcohol may be linear or branched, and may or may not contain a cyclic structure. Specific examples of the saturated alcohol include methanol, ethanol, n-propyl alcohol, isopropyl alcohol, n-butyl alcohol, sec-butyl alcohol, and tert-butyl alcohol. Examples of the saturated polyhydric alcohol include saturated polyhydric alcohols having 1 to 40, 1 to 32, 1 to 24, 1 to 18, 1 to 12, 1 to 6, or 1 to 2 carbon atoms. The saturated polyhydric alcohol may be linear or branched, and may or may not contain a cyclic structure. Specific examples of the saturated polyhydric alcohol include ethylene glycol (ethane-1,2-diol), propylene glycol (propane-1,2-diol), glycerin, and glycerin derivatives. The glycerin derivative is not particularly limited, and may be, for example, a polymer of glycerin or a compound in which at least one hydrogen atom of glycerin is substituted with a substituent (for example, an alkyl group). Examples of the glycerin derivative include diglycerin and polyglycerin.
[0066] The oxidation reaction product of the first invention of the present invention may be, for example, a substance having reducing ability, as described above. For example, the oxidation reaction product of the first invention of the present invention may have a functional group having reducing ability, and thus have reducing ability derived from the functional group. Specifically, for example, the oxidation reaction product of the first invention of the present invention may have reducing ability due to having an aldehyde group (formyl group), and the TRP channel active substance of the first invention of the present invention may have reducing ability due to being a keto-enol tautomer. For example, the oxidation reaction product of the first invention of the present invention obtained in Example 1 described later contains an acetal structure in the skeleton as confirmed by NMR, and is therefore considered to develop color in the DNPH (dinitrophenylhydrazine: ketone-aldehyde derived) reaction derived from ketones and aldehydes.
[0067] The oxidation reaction product of the first invention in the present invention may be, for example, a substance obtained by binding two or more molecules of the alcohol as described above. Specifically, for example, it may be a structure in which two or more molecules of the alcohol are bound and further oxidized. The form of "binding" of the two or more molecules of the alcohol is not particularly limited, and may be, for example, addition, condensation, etc.
[0068] The oxidation reaction product of the first aspect of the present invention is chemically stable and easy to handle compared to, for example, radicals, and can therefore be isolated and formulated.
[0069] [3. Method for producing oxidation reaction product] As described above, the method for producing an oxidation reaction product of the first invention in the present invention is a method for producing an oxidation reaction product of the first invention in the present invention, which includes an alcohol oxidation step of oxidizing the alcohol.
[0070] In the alcohol oxidation step, the method for oxidizing the alcohol is not particularly limited. In the method for producing an oxidation reaction product of the first aspect of the present invention, for example, in the alcohol oxidation step, the alcohol may be oxidized by at least one of ozone oxidation and hydrogen peroxide oxidation.
[0071] In the method for producing an oxidation reaction product according to the first aspect of the present invention, the reaction time of the alcohol oxidation step is not particularly limited. The reaction time of the alcohol oxidation step may be, for example, 24 hours or more or 1 day or more, 48 hours or more or 2 days or more, 72 hours or more or 3 days or more, 120 hours or more or 5 days or more, or 168 hours or more or 7 days or more. The upper limit of the reaction time of the alcohol oxidation step is not particularly limited, but may be, for example, 720 hours or less or 30 days or less, or 360 hours or less or 15 days or less.
[0072] In the method for producing an oxidation reaction product of the first invention of the present invention, in order to obtain a reaction product containing the cyclic peroxide of the first invention of the present invention, it is preferable to extend the reaction time of the alcohol oxidation step. For example, it is considered that by extending the reaction time of the alcohol oxidation step, the cyclic peroxide of the first invention of the present invention, which could not be obtained by conventional ozone oxidation reaction of glycerin, can be produced. In the method for producing an oxidation reaction product of the first invention of the present invention, it is preferable that the reaction time of the alcohol oxidation step is not too long in terms of production efficiency.
[0073] As described above, the method for producing an oxidation reaction product according to the first aspect of the present invention includes an alcohol oxidation step of oxidizing the alcohol. However, as described above, the oxidation reaction product according to the first aspect of the present invention is not limited to a substance produced by this production method, and may be a substance produced by any production method as long as it has the same structure. Hereinafter, the method for producing an oxidation reaction product according to the first aspect of the present invention will be described in more detail with reference to examples.
[0074] In the following, an example will be described in which glycerin is used as the alcohol and ozone oxidation is performed. However, as mentioned above, the following description is merely an example, and the method for producing an oxidation reaction product of the first invention of the present invention is not limited to the following description. For example, the following method can be performed in the same manner using other alcohols instead of glycerin. For example, in the method for producing an oxidation reaction product of the first invention of the present invention, the method for oxidizing the alcohol in the alcohol oxidation step is not particularly limited and is optional, and is not limited to ozone oxidation. The oxidation method may be, for example, at least one of ozone oxidation and hydrogen peroxide oxidation. In addition, for example, not only the type of alcohol and the method for oxidizing the alcohol, but also the concentration of each substance, reaction temperature, reaction time, and other reaction conditions can be appropriately changed.
[0075] The oxidation reaction product of the first invention of the present invention can be produced by a production method including a step of oxidizing glycerin by contacting glycerin with ozone, more specifically, by mixing glycerin with ozone (corresponding to the "alcohol oxidation step" of the first invention of the present invention). The step of oxidizing glycerin may be, for example, a step of oxidizing glycerin by gas-liquid contacting a glycerin solution with a gas containing ozone.
[0076] The glycerin solution preferably has a high concentration of glycerin. As the high concentration glycerin solution, for example, a glycerin solution having a glycerin concentration of 75% or more can be used. Specifically, a glycerin solution having a glycerin concentration of 84 to 87% by weight as specified in the Japanese Pharmacopoeia is preferable, a concentrated glycerin solution having a glycerin concentration of 98% by weight or more as specified in the Japanese Pharmacopoeia is more preferable, and a purified glycerin solution having a concentration of 98.5% by weight or more is even more preferable. The glycerin solution can treat ozone at a higher concentration, for example, as the glycerin concentration is relatively higher. In the glycerin solution, the solvent for glycerin is not particularly limited, and is, for example, an aqueous solvent such as water.
[0077] The ozone-containing gas preferably has a high ozone concentration. The method for producing the gas with a high ozone concentration is not particularly limited, and for example, an ozone generator that generates ozone by silently discharging oxygen gas can be used. When oxygen gas is used, for example, a medical oxygen cylinder can be used, or oxygen gas produced by an oxygen generator can be used.
[0078] The method of gas-liquid contact between the glycerin solution and the ozone-containing gas is not particularly limited, and for example, there is a method in which a high-concentration (e.g., 98% by weight or more) glycerin solution is placed in a tank, and the gas with a high ozone concentration is released into the tank as fine bubbles using an aeration tube. Specifically, for example, an ozone-treated glycerin solution with an equivalent hydrogen peroxide concentration of about 4000 ppm can be produced by aerating a gas with an ozone concentration of about 37000 ppm into the concentrated glycerin solution for about 7 days. The aeration time is not particularly limited, and for example, an ozone-treated glycerin solution containing the oxidation reaction product of the first invention in the present invention at a higher concentration can be produced by aerating for a relatively longer period of time.
[0079] The oxidation reaction product of the first invention of the present invention may be used as it is without being separated from the mixture after the reaction (for example, the ozone-treated glycerin solution), or may be used after being separated from the mixture after the reaction. The method of separation is not particularly limited, but for example, the oxidation reaction product of the first invention of the present invention can be separated from the mixture after the reaction by chromatography such as preparative thin layer chromatography.
[0080] Conventionally, production of substances such as peroxides having oxidizing power required a complicated system. According to the method for producing an oxidation reaction product of the first aspect of the present invention, for example, an oxidation reaction product having oxidizing power can be produced in a very simple and easy manner.
[0081] The oxidation reaction product of the first invention of the present invention can generate, for example, hydrogen peroxide. The oxidation reaction product of the first invention of the present invention can generate, for example, 1 to 4000 ppm, 10 to 4000 ppm, or 100 to 4000 ppm of hydrogen peroxide per about 4000 ppm of the oxidation reaction product of the first invention of the present invention in terms of hydrogen peroxide concentration.
[0082] [4. Use of cyclic peroxides and oxidation reaction products] The method of using the cyclic peroxide of the first invention of the present invention and the oxidation reaction product of the first invention of the present invention is not particularly limited. For example, when the cyclic peroxide of the first invention of the present invention or the oxidation reaction product of the first invention of the present invention has TRP channel activity, it may be used as a TRP channel active substance. In that case, the method of use is not particularly limited, and may be the same as the method of using a general TRP channel active substance, for example. As described above, the cyclic peroxide of the first invention of the present invention and the oxidation reaction product of the first invention of the present invention are highly safe, so they can be used safely. In addition, the method of using the cyclic peroxide of the first invention of the present invention and the oxidation reaction product of the first invention of the present invention may be, for example, as described above, used as it is without being separated from the mixture after the reaction, or may be used after separating the cyclic peroxide of the first invention of the present invention or the oxidation reaction product of the first invention of the present invention from the mixture after the reaction.
[0083] As described above, the cyclic peroxide of the first invention of the present invention and the oxidation reaction product of the first invention of the present invention are highly safe with suppressed explosiveness, irritation, etc., and are therefore extremely useful. The cyclic peroxide of the first invention of the present invention and the oxidation reaction product of the first invention of the present invention can act on ion channels (e.g., TRPA1, etc.) related to itching, pain, etc., and can therefore be used in the development of medicines, etc.
[0084] Furthermore, the uses of the cyclic peroxide of the first invention in the present invention and the oxidation reaction product of the first invention in the present invention are not limited thereto, and they can be used in various applications such as cosmetics, pharmaceuticals, foods, or supplements.
[0085] [Embodiment for carrying out the second invention] Next, an embodiment of the second aspect of the present invention will be described. However, the second aspect of the present invention is not limited to the following description.
[0086] In the second invention of the present invention, when a compound has isomers such as tautomers or stereoisomers (e.g., geometric isomers, conformational isomers, and optical isomers), any isomer can be used in the second invention of the present invention, unless otherwise specified. In addition, in the second invention of the present invention, when a substance can form a salt, the salt can also be used in the second invention of the present invention, unless otherwise specified. The salt may be an acid addition salt or a base addition salt. Furthermore, the acid that forms the acid addition salt may be an inorganic acid or an organic acid, and the base that forms the base addition salt may be an inorganic base or an organic base. The inorganic acid is not particularly limited, but examples thereof include sulfuric acid, phosphoric acid, hydrofluoric acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, hypofluorite acid, hypochlorous acid, hypobromite acid, hypoiodite acid, fluorite acid, chlorous acid, bromite acid, iodite acid, fluorine acid, chlorine acid, bromine acid, iodic acid, perfluorine acid, perchloric acid, perbromine acid, and periodic acid. The organic acid is also not particularly limited, but examples thereof include p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromobenzenesulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, and acetic acid. The inorganic base is not particularly limited, but examples thereof include ammonium hydroxide, alkali metal hydroxide, alkaline earth metal hydroxide, carbonate, and hydrogen carbonate, and more specifically, examples thereof include sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, calcium hydroxide, and calcium carbonate. The organic base is also not particularly limited, but examples thereof include ethanolamine, triethylamine, and tris(hydroxymethyl)aminomethane. The method for producing these salts is also not particularly limited, and for example, they can be produced by a method in which the above-mentioned acid or base is appropriately added to the compound by a known method.
[0087] In the second invention of the present invention, examples of the aromatic ring that does not contain a heteroatom include a benzene ring, a naphthalene ring, an anthracene ring, a phenanthrene ring, and a pyrene ring. Examples of the heteroaromatic ring include a pyridine ring and a thiophene ring. The nitrogen-containing aromatic ring may or may not have a positive charge. Examples of the nitrogen-containing aromatic ring that does not have a positive charge include a pyrroline ring, a pyridine ring, a pyridazine ring, a pyrimidine ring, a pyrazine ring, a quinoline ring, an isoquinoline ring, an acridine ring, a 3,4-benzoquinoline ring, a 5,6-benzoquinoline ring, a 6,7-benzoquinoline ring, a 7,8-benzoquinoline ring, a 3,4-benzoisoquinoline ring, a 5,6-benzoisoquinoline ring, a 6,7-benzoisoquinoline ring, and a 7,8-benzoisoquinoline ring. Examples of the nitrogen-containing aromatic ring having a positive charge include a pyrrolinium ring, a pyridinium ring, a pyridazinium ring, a pyrimidinium ring, a pyrazinium ring, a quinolinium ring, an isoquinolinium ring, an acridinium ring, a 3,4-benzoquinolinium ring, a 5,6-benzoquinolinium ring, a 6,7-benzoquinolinium ring, a 7,8-benzoquinolinium ring, a 3,4-benzoisoquinolinium ring, a 5,6-benzoisoquinolinium ring, a 6,7-benzoisoquinolinium ring, a 7,8-benzoisoquinolinium ring, etc. Examples of the oxygen-containing aromatic ring or sulfur-containing aromatic ring include an aromatic ring in which at least one of the carbon atom or nitrogen atom of the aromatic ring or nitrogen-containing aromatic ring not containing a heteroatom is replaced with at least one of an oxygen atom and a sulfur atom.
[0088] In the second aspect of the present invention, examples of the "substituent" include a hydroxyl group (-OH), an aldehyde group (formyl group), a hydroxyalkyl group, a sulfo group, a nitro group, a diazo group, an alkyl group, an unsaturated aliphatic hydrocarbon group, an aryl group, a heteroaryl group, a halogen, a mercapto group (-SH), an alkylthio group (-SR, R is an alkyl group) and the like.
[0089] In the second aspect of the present invention, the chain-like substituent (e.g., a hydrocarbon group such as an alkyl group or an unsaturated aliphatic hydrocarbon group) may be linear or branched unless otherwise specified, and the number of carbon atoms is not particularly limited, but may be, for example, 1 to 40, 1 to 32, 1 to 24, 1 to 18, 1 to 12, 1 to 6, or 1 to 2 (2 or more in the case of an unsaturated hydrocarbon group). In addition, in this specification, the number of ring members (the number of atoms constituting the ring) of a cyclic group (e.g., an aryl group, a heteroaryl group, etc.) is not particularly limited, but may be, for example, 5 to 32, 5 to 24, 6 to 18, 6 to 12, or 6 to 10. In addition, when an isomer exists in a substituent or the like, any isomer may be used unless otherwise specified, for example, when simply referring to a "butyl group", it may be an n-butyl group, a sec-butyl group, or a tert-butyl group, and when simply referring to a "naphthyl group", it may be a 1-naphthyl group or a 2-naphthyl group.
[0090] In the second aspect of the present invention, "skin whitening" refers to the prevention and / or improvement of pigmentation. Specifically, the "skin whitening" refers to the prevention and / or improvement of pigmentation symptoms caused by melanin production or enhancement, melanin production, excessive accumulation, and / or abnormal melanin deposition, such as age spots, dullness, freckles, sunburn, skin inflammation, and darkening due to skin irritation; pigmentation symptoms caused by diseases that cause pigmentation, such as skin melanosis caused by drugs such as steroids; and the like.
[0091] The second invention of the present invention will be described in more detail below with examples. However, the second invention of the present invention is not limited by the following explanation. In addition, each explanation in the second invention of the present invention can be mutually incorporated unless otherwise specified. In this specification, when the expression "~" is used, it is used to mean including the numerical value or physical value before and after it. In addition, in this specification, the expression "A and / or B" includes "A only", "B only", and "both A and B".
[0092] <Whitening composition> The whitening composition (hereinafter referred to as "composition") of the second invention of the present invention contains glycerin and / or a glycerin derivative and a whitening ingredient, and the whitening ingredient contains a cyclic peroxide or a salt thereof as an active ingredient. The composition of the second invention of the present invention is characterized by containing the cyclic peroxide or a salt thereof, and other configurations and conditions are not particularly limited. The cyclic peroxide is presumed to promote the decomposition of melanin, as described below. Therefore, according to the composition of the second invention of the present invention, for example, when applied to the skin, a whitening effect on the skin can be obtained.
[0093] The whitening composition of the second invention in the present invention can also be referred to as, for example, a composition for improving spots, dullness, or freckles, a composition for inhibiting melanin production, a composition for decomposing melanin, a composition for promoting the excretion of melanin, a composition for reducing skin pigmentation, a composition for whitening skin, etc.
[0094] [1. Whitening ingredients] The composition of the second invention of the present invention contains a whitening ingredient as described above. The composition of the second invention of the present invention may contain the cyclic peroxide as an active ingredient of the whitening ingredient, or may contain an oxidation reaction product containing the cyclic peroxide as described below, or may contain both. The cyclic peroxide may be a compound represented by the following chemical formula (I), or may be a cyclic peroxide contained in an oxidation reaction product obtained by oxidizing an alcohol as described below.
[0095] In the composition of the second invention of the present invention, the content of the whitening ingredient is, for example, 0.001 to 10 w / v%, 0.05 to 5 w / v%, or 0.01 to 1 w / v%. In the composition of the second invention of the present invention, the content of the cyclic peroxide is, for example, 0.001 to 10 w / v%, 0.05 to 5 w / v%, or 0.01 to 1 w / v%.
[0096] [2. Cyclic peroxides] The cyclic peroxide is represented by the following chemical formula (I): [ka] In the above chemical formula (I), R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, may or may not have a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure, and may be a monocyclic ring or a condensed ring; R 1 is a substituent, which may be one, multiple, or absent, and when multiple, they may be the same or different.
[0097] The heteroatom refers to an atom other than carbon and hydrogen, and may be, for example, one selected from the group consisting of oxygen, nitrogen, sulfur, selenium, boron, and silicon. The substituent is not particularly limited, and may include, for example, a hydroxyl group, and may be, for example, one selected from the group consisting of the above-mentioned hydroxyl group (-OH), aldehyde group (formyl group), hydroxyalkyl group, sulfo group, nitro group, diazo group, alkyl group, unsaturated aliphatic hydrocarbon group, aryl group, heteroaryl group, halogen, mercapto group (-SH), and alkylthio group (-SR, R is alkyl group).
[0098] The cyclic peroxide is, for example, represented by the formula (I): 100 However, it may be a cyclic structure having 5 to 10 ring members.
[0099] The cyclic peroxide may be, for example, a cyclic peroxide represented by the following chemical formula (II). [ka] In the above chemical formula (II), Each R 11 may be the same or different, and each is a hydrogen atom or a substituent. Two R 11 may be joined together to form an oxo group (=O) or a thioxo group (=S).
[0100] The cyclic peroxide is, for example, R 11 In the above, each of the substituents may be a hydroxyl group (-OH), an aldehyde group (formyl group), a hydroxyalkyl group, a sulfo group, a nitro group, a diazo group, an alkyl group, an unsaturated aliphatic hydrocarbon group, an aryl group, a heteroaryl group, a halogen, a mercapto group (-SH), or an alkylthio group (-SR, where R is an alkyl group).
[0101] The cyclic peroxide may be, for example, a cyclic peroxide represented by the following chemical formula (1). The cyclic peroxide represented by the following chemical formula (1) is a cyclic peroxide represented by the following chemical formula (II) in which all R 11 is a hydrogen atom. [ka]
[0102] The method for producing the cyclic peroxide is not particularly limited, and for example, the cyclic peroxide can be produced by oxidizing an alcohol using the method for producing the oxidation reaction product described below. In this case, for example, the produced oxidation reaction product may be used as it is without purification, or only the cyclic peroxide may be isolated and purified for use.
[0103] The inventors of the present invention were the first to discover that cyclic peroxides can be obtained by the oxidation of alcohols, for example, the oxidation of glycerin with ozone. Although the mechanism by which cyclic peroxides are obtained is unclear, it is speculated that, for example, by extending the reaction time of the oxidation reaction of alcohols as described below, a reaction product different from that of conventional reactions can be obtained.
[0104] The cyclic peroxides are chemically stable and easy to handle compared to radicals, for example, and therefore can be isolated and formulated.
[0105] In general, cyclic peroxides are substances that are used industrially due to their oxidizing ability, etc. In particular, artemisinin, which has a seven-membered ring (trioxolane) skeleton similar to the structure of the cyclic peroxides, is useful as an antimalarial agent and was awarded the Nobel Prize in 2015, and its derivatives are currently being researched.
[0106] However, the supply of artemisinin was unstable when it was extracted and purified from natural products. In addition, since artemisinin is neither water-soluble nor fat-soluble, there were many challenges in formulating it. On the other hand, hydrogen peroxide is an example of a water-soluble oxidizing substance, but it is highly reactive and unstable, and has only been used externally for disinfection of living organisms.
[0107] In contrast, according to the second aspect of the present invention, for example, a cyclic peroxide and an oxidation reaction product that are highly safe and have excellent water solubility are used, and therefore, they can be suitably used in living organisms. In addition, in the second aspect of the present invention, melanin can be decomposed by the oxidizing ability of the cyclic peroxide, and it is presumed that this provides a whitening effect. The whitening effect can be evaluated according to Example 2 described below.
[0108] In the composition of the second invention of the present invention, the cyclic peroxide may be a salt or a solvate such as a hydrate. The explanation of the cyclic peroxide can be applied to the explanation of the salt of the cyclic peroxide or the solvate thereof.
[0109] [3. Oxidation reaction products] As described above, the oxidation reaction product is an oxidation reaction product that is obtained by oxidizing an alcohol and contains a cyclic peroxide. However, the method for producing the oxidation reaction product is not limited to the oxidation of an alcohol, and any method for producing the oxidation reaction product may be used as long as the product has the same structure.
[0110] The method of oxidizing the alcohol is not particularly limited. For example, the oxidation of the alcohol may be at least one of ozone oxidation and hydrogen peroxide oxidation. However, as described above, the method of producing the oxidation reaction product is not limited to ozone oxidation and hydrogen peroxide oxidation of the alcohol, and any method of producing the oxidation reaction product may be used as long as the substance has the same structure.
[0111] The oxidation reaction product may be, for example, a mixture containing a plurality of oxidation reaction products.
[0112] The oxidation reaction product may have, for example, an oxidizing ability.
[0113] The oxidation reaction product may have, for example, reducing ability.
[0114] The oxidation reaction product may contain, for example, a substance having melanin decomposition activity, melanin production inhibitory activity, and / or melanin excretion promoting activity.
[0115] In the oxidation reaction product, the alcohol serving as a raw material is not particularly limited. For example, the alcohol in the oxidation reaction product may be a saturated alcohol.
[0116] The oxidation reaction product may be, for example, a polyhydric alcohol.
[0117] In the oxidation reaction product, for example, the alcohol may be at least one of glycerin and a glycerin derivative.
[0118] The oxidation reaction product may include, for example, an oxidation reaction product obtained by bonding two or more molecules of the alcohol.
[0119] The oxidation reaction product may include, for example, the cyclic peroxide.
[0120] The alcohol used as the raw material of the oxidation reaction product is not particularly limited, and may be, for example, a saturated alcohol or an unsaturated alcohol as described above. The alcohol may be linear or branched, and may or may not contain a cyclic structure. The alcohol may be, for example, a polyhydric alcohol or a monohydric alcohol. The valence of the polyhydric alcohol is also not particularly limited, and may be, for example, dihydric, trihydric, or tetrahydric. Examples of monohydric saturated alcohols include saturated alcohols having 1 to 40, 1 to 32, 1 to 24, 1 to 18, 1 to 12, 1 to 6, or 1 to 2 carbon atoms, and the saturated alcohol may be linear or branched, and may or may not contain a cyclic structure. Specific examples of the saturated alcohol include methanol, ethanol, n-propyl alcohol, isopropyl alcohol, n-butyl alcohol, sec-butyl alcohol, and tert-butyl alcohol. Examples of the saturated polyhydric alcohol include saturated polyhydric alcohols having 1 to 40, 1 to 32, 1 to 24, 1 to 18, 1 to 12, 1 to 6, or 1 to 2 carbon atoms. The saturated polyhydric alcohol may be linear or branched, and may or may not contain a cyclic structure. Specific examples of the saturated polyhydric alcohol include ethylene glycol (ethane-1,2-diol), propylene glycol (propane-1,2-diol), glycerin, and glycerin derivatives. The glycerin derivative is not particularly limited, and may be, for example, a polymer of glycerin or a compound in which at least one hydrogen atom of glycerin is substituted with a substituent (for example, an alkyl group). Examples of the glycerin derivative include diglycerin and polyglycerin. The glycerin derivative may be an oxidized product of glycerin.
[0121] The oxidation reaction product may be, for example, a substance having reducing ability, as described above. For example, the oxidation reaction product may have a functional group having reducing ability, and thus have reducing ability derived from the functional group. Specifically, for example, the oxidation reaction product may have reducing ability due to having an aldehyde group (formyl group), and may have reducing ability derived from the keto body due to being a keto-enol tautomer. For example, the oxidation reaction product obtained in Example 2 described later contains an acetal structure in the skeleton as confirmed by NMR, and is therefore considered to develop color in the DNPH (dinitrophenylhydrazine: ketone-aldehyde derived) reaction derived from a ketone or aldehyde.
[0122] The oxidation reaction product may be, for example, a substance obtained by binding two or more molecules of the alcohol as described above. Specifically, for example, the oxidation reaction product may be a structure in which two or more molecules of the alcohol are bound and further oxidized. The form of "binding" of the two or more molecules of the alcohol is not particularly limited, and may be, for example, addition, condensation, etc.
[0123] The oxidation reaction product is chemically stable and easy to handle compared to radicals, for example, and therefore can be isolated and formulated.
[0124] [4. Method for producing oxidation reaction product] As described above, the method for producing the oxidation reaction product includes an alcohol oxidation step of oxidizing the alcohol.
[0125] In the alcohol oxidation step, the method for oxidizing the alcohol is not particularly limited. In the method for producing the oxidation reaction product, for example, in the alcohol oxidation step, the alcohol may be oxidized by at least one of ozone oxidation and hydrogen peroxide oxidation.
[0126] In the method for producing the oxidation reaction product, the reaction time of the alcohol oxidation step is not particularly limited. The reaction time of the alcohol oxidation step may be, for example, 24 hours or more or 1 day or more, 48 hours or more or 2 days or more, 72 hours or more or 3 days or more, 120 hours or more or 5 days or more, or 168 hours or more or 7 days or more. The upper limit of the reaction time of the alcohol oxidation step is not particularly limited, but may be, for example, 720 hours or less or 30 days or less, or 360 hours or less or 15 days or less.
[0127] In the method for producing the oxidation reaction product, in order to obtain a reaction product containing the cyclic peroxide, it is preferable to extend the reaction time of the alcohol oxidation step. For example, it is considered that by extending the reaction time of the alcohol oxidation step, the cyclic peroxide that could not be obtained by conventional ozone oxidation reaction of glycerin can be produced. In the method for producing the oxidation reaction product, it is preferable that the reaction time of the alcohol oxidation step is not too long in order to ensure production efficiency.
[0128] As described above, the method for producing the oxidation reaction product includes an alcohol oxidation step of oxidizing the alcohol. However, as described above, the oxidation reaction product is not limited to a substance produced by this production method, and may be a substance produced by any production method as long as it has the same structure. Hereinafter, the method for producing the oxidation reaction product will be described in more detail with reference to examples.
[0129] In the following, an example will be described in which glycerin is used as the alcohol and ozone oxidation is performed. However, as described above, the following description is merely an example, and the method for producing the oxidation reaction product is not limited to the following description. For example, the following method can be performed in the same manner using other alcohols instead of glycerin. For example, in the method for producing the oxidation reaction product, the method for oxidizing the alcohol in the alcohol oxidation step is not particularly limited and is optional, and is not limited to ozone oxidation. The oxidation method may be, for example, at least one of ozone oxidation and hydrogen peroxide oxidation. In addition, for example, not only the type of alcohol and the method for oxidizing the alcohol, but also the concentration of each substance, reaction temperature, reaction time, and other reaction conditions can be appropriately changed.
[0130] The oxidation reaction product can be produced by a production method including a step of oxidizing glycerin by contacting glycerin with ozone, more specifically, by mixing glycerin with ozone (corresponding to the above-mentioned "alcohol oxidation step"). The step of oxidizing glycerin may be, for example, a step of oxidizing glycerin by gas-liquid contacting a glycerin solution with a gas containing ozone.
[0131] The glycerin solution preferably has a high concentration of glycerin. As the high concentration glycerin solution, for example, a glycerin solution having a glycerin concentration of 75% or more can be used. Specifically, a glycerin solution having a glycerin concentration of 84 to 87% by weight as specified in the Japanese Pharmacopoeia is preferable, a concentrated glycerin solution having a glycerin concentration of 98% by weight or more as specified in the Japanese Pharmacopoeia is more preferable, and a purified glycerin solution having a concentration of 98.5% by weight or more is even more preferable. The glycerin solution can treat ozone at a higher concentration, for example, as the glycerin concentration is relatively higher. In the glycerin solution, the solvent for glycerin is not particularly limited, and is, for example, an aqueous solvent such as water.
[0132] The ozone-containing gas preferably has a high ozone concentration. The method for producing the gas with a high ozone concentration is not particularly limited, and for example, an ozone generator that generates ozone by silently discharging oxygen gas can be used. When oxygen gas is used, for example, a medical oxygen cylinder can be used, or oxygen gas produced by an oxygen generator can be used.
[0133] The method of gas-liquid contact between the glycerin solution and the ozone-containing gas is not particularly limited, and for example, there is a method in which a high-concentration (e.g., 98% by weight or more) glycerin solution is placed in a tank, and the gas with a high ozone concentration is released into the tank as fine bubbles using an air diffuser. Specifically, for example, an ozone-treated glycerin solution with an equivalent hydrogen peroxide concentration of about 4000 ppm can be produced by aerating a gas with an ozone concentration of about 37000 ppm into the concentrated glycerin solution for about 7 days. The aeration time is not particularly limited, and for example, an ozone-treated glycerin solution containing the oxidation reaction product at a higher concentration can be produced by aerating for a relatively longer period of time.
[0134] The oxidation reaction product may be used as it is without being separated from the mixture after the reaction (e.g., the ozone-treated glycerin solution), or may be used after being separated from the mixture after the reaction. The method for separation is not particularly limited, but for example, the oxidation reaction product can be separated from the mixture after the reaction by chromatography such as preparative thin layer chromatography.
[0135] Conventionally, production of substances such as peroxides having oxidizing power required a complicated system. According to the method for producing an oxidation reaction product, for example, an oxidation reaction product having oxidizing power can be produced in a very simple and easy manner.
[0136] The oxidation reaction product can generate, for example, hydrogen peroxide. The oxidation reaction product can generate, for example, 1 to 4000 ppm, 10 to 4000 ppm, or 100 to 4000 ppm of hydrogen peroxide per about 4000 ppm of the oxidation reaction product in terms of hydrogen peroxide concentration.
[0137] [5. Glycerin] In the composition of the second invention of the present invention, the glycerin may be glycerin or the above-mentioned glycerin derivative. In the composition of the second invention of the present invention, the cyclic peroxide can be stably maintained by coexisting with the glycerin.
[0138] In the composition of the second aspect of the present invention, the content of the glycerin is, for example, 0.1 to 100 w / v %, preferably 0.1 to 50 w / v %.
[0139] [6. Other whitening ingredients] The composition of the second invention of the present invention may contain, as the active ingredient of the whitening component, in addition to the cyclic peroxide and / or the oxidation reaction product containing the cyclic peroxide, other whitening ingredients, such as arbutin, tranexamic acid, and ascorbic acid or derivatives thereof.
[0140] [7. Other Ingredients] The composition of the second invention of the present invention may contain other components added to the formulation to be applied to the skin. Specific examples of the other components include components added to skin external preparations and components added to cosmetics (including quasi-drugs). Examples of the components added to the skin external preparations include pharma- ceutically acceptable carriers. Examples of the other components include components added when applied to the skin or when applied transdermally, and specific examples include aqueous solvents such as water, alcohols, moisturizers, oils, softeners (emollients), surfactants (solubilizers, emulsifiers), salts, thickeners, pH adjusters, ultraviolet absorbers, drugs, buffers, colorants, preservatives, fragrances, etc.
[0141] [8. Dosage form, method of use, and application] The composition of the second invention of the present invention is, for example, a solid or liquid. The form of the composition of the second invention of the present invention can be, for example, a lotion type; an emulsion type such as a milky lotion or cream; an oil type: a gel type; an ointment, a pack, a cleanser, etc.
[0142] The subject of the use of the composition of the second invention of the present invention is a human or a non-human animal. The composition of the second invention of the present invention can be used, for example, on the part of the subject that contains melanin, specifically, the skin. The amount of the composition of the second invention of the present invention to be used is not particularly limited, and can be an amount that is usually used depending on the dosage form of the composition of the second invention of the present invention.
[0143] The composition of the second aspect of the present invention can be suitably used as an external preparation for the skin, such as a cosmetic product.
[0144] <Whitening agent> The whitening agent of the second invention of the present invention contains a cyclic peroxide or a salt thereof. The whitening agent of the second invention of the present invention is characterized by containing a cyclic peroxide or a salt thereof, and other configurations and conditions are not particularly limited. The cyclic peroxide is presumed to promote the decomposition of melanin. Therefore, according to the whitening agent of the second invention of the present invention, for example, when applied to the skin, a whitening effect on the skin can be obtained.
[0145] The whitening agent of the second invention in the present invention can also be described as, for example, an agent for improving spots, dullness, or freckles, a melanin production inhibitor, a melanin decomposition agent, an agent for reducing skin pigmentation, a whitening agent, or the like.
[0146] In the whitening agent of the second invention of the present invention, the cyclic peroxide may be a compound represented by the following chemical formula (I), or may be a cyclic peroxide contained in an oxidation reaction product obtained by oxidizing the above-mentioned alcohol. [ka] In the above chemical formula (I), R100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, may or may not have a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure, and may be a monocyclic ring or a condensed ring; R 1 is a substituent, which may be one, multiple, or absent, and when multiple, they may be the same or different.
[0147] The explanation of the cyclic peroxide and the oxidation reaction product can be made with reference to the explanation of the composition of the second invention of the present invention.
[0148] The explanation of the formulation and use of the skin whitening agent of the second invention of the present invention can be cited from the explanation of the composition of the second invention of the present invention.
[0149] <Whitening method> The whitening method of the second invention of the present invention uses the whitening composition of the second invention of the present invention and / or the whitening agent of the second invention of the present invention. The whitening method of the second invention of the present invention is characterized by using the whitening composition of the second invention of the present invention and / or the whitening agent of the second invention of the present invention, and other steps and conditions are not particularly limited. It is presumed that the cyclic peroxide contained in the composition and / or whitening agent of the second invention of the present invention promotes the decomposition of melanin. Therefore, the whitening agent of the second invention of the present invention can provide a whitening effect on the skin when applied to the skin, for example.
[0150] The whitening method of the second invention of the present invention can be carried out, for example, by applying the whitening composition and / or the whitening agent to the skin of the subject. More specifically, the whitening method of the second invention of the present invention can be carried out by contacting the skin of the subject with the whitening composition and / or the whitening agent.
[0151] <Use> The second invention of the present invention is a whitening composition of the second invention of the present invention and / or a whitening agent of the second invention of the present invention for use in whitening, or use thereof.
[0152] [Embodiment for carrying out the third invention] Next, an embodiment of the third aspect of the present invention will be described. However, the third aspect of the present invention is not limited to the following description.
[0153] In the third invention of the present invention, when a compound has isomers such as tautomers or stereoisomers (e.g., geometric isomers, conformational isomers, and optical isomers), any of the isomers can be used in the present invention, unless otherwise specified. In addition, in the third invention of the present invention, when a substance can form a salt, the salt can also be used in the third invention of the present invention, unless otherwise specified. The salt may be an acid addition salt or a base addition salt. Furthermore, the acid that forms the acid addition salt may be an inorganic acid or an organic acid, and the base that forms the base addition salt may be an inorganic base or an organic base. The inorganic acid is not particularly limited, but examples thereof include sulfuric acid, phosphoric acid, hydrofluoric acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, hypofluorite acid, hypochlorous acid, hypobromite acid, hypoiodite acid, fluorite acid, chlorous acid, bromite acid, iodite acid, fluorine acid, chlorine acid, bromine acid, iodic acid, perfluorine acid, perchloric acid, perbromine acid, and periodic acid. The organic acid is also not particularly limited, but examples thereof include p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromobenzenesulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, and acetic acid. The inorganic base is not particularly limited, but examples thereof include ammonium hydroxide, alkali metal hydroxide, alkaline earth metal hydroxide, carbonate, and hydrogen carbonate, and more specifically, examples thereof include sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, calcium hydroxide, and calcium carbonate. The organic base is also not particularly limited, but examples thereof include ethanolamine, triethylamine, and tris(hydroxymethyl)aminomethane. The method for producing these salts is also not particularly limited, and for example, they can be produced by a method in which the above-mentioned acid or base is appropriately added to the compound by a known method.
[0154] In the third invention of the present invention, examples of the aromatic ring that does not contain a heteroatom include a benzene ring, a naphthalene ring, an anthracene ring, a phenanthrene ring, and a pyrene ring. Examples of the heteroaromatic ring include a pyridine ring and a thiophene ring. The nitrogen-containing aromatic ring may or may not have a positive charge. Examples of the nitrogen-containing aromatic ring that does not have a positive charge include a pyrroline ring, a pyridine ring, a pyridazine ring, a pyrimidine ring, a pyrazine ring, a quinoline ring, an isoquinoline ring, an acridine ring, a 3,4-benzoquinoline ring, a 5,6-benzoquinoline ring, a 6,7-benzoquinoline ring, a 7,8-benzoquinoline ring, a 3,4-benzoisoquinoline ring, a 5,6-benzoisoquinoline ring, a 6,7-benzoisoquinoline ring, and a 7,8-benzoisoquinoline ring. Examples of the nitrogen-containing aromatic ring having a positive charge include a pyrrolinium ring, a pyridinium ring, a pyridazinium ring, a pyrimidinium ring, a pyrazinium ring, a quinolinium ring, an isoquinolinium ring, an acridinium ring, a 3,4-benzoquinolinium ring, a 5,6-benzoquinolinium ring, a 6,7-benzoquinolinium ring, a 7,8-benzoquinolinium ring, a 3,4-benzoisoquinolinium ring, a 5,6-benzoisoquinolinium ring, a 6,7-benzoisoquinolinium ring, a 7,8-benzoisoquinolinium ring, etc. Examples of the oxygen-containing aromatic ring or sulfur-containing aromatic ring include an aromatic ring in which at least one of the carbon atom or nitrogen atom of the aromatic ring or nitrogen-containing aromatic ring not containing a heteroatom is replaced with at least one of an oxygen atom and a sulfur atom.
[0155] In the third aspect of the present invention, examples of the "substituent" include a hydroxyl group (-OH), an aldehyde group (formyl group), a hydroxyalkyl group, a sulfo group, a nitro group, a diazo group, an alkyl group, an unsaturated aliphatic hydrocarbon group, an aryl group, a heteroaryl group, a halogen, a mercapto group (-SH), an alkylthio group (-SR, R is an alkyl group) and the like.
[0156] In the third invention of the present invention, the chain-like substituent (e.g., a hydrocarbon group such as an alkyl group or an unsaturated aliphatic hydrocarbon group) may be linear or branched unless otherwise specified, and the number of carbon atoms is not particularly limited, but may be, for example, 1 to 40, 1 to 32, 1 to 24, 1 to 18, 1 to 12, 1 to 6, or 1 to 2 (2 or more in the case of an unsaturated hydrocarbon group). In addition, in this specification, the number of ring members (the number of atoms constituting the ring) of a cyclic group (e.g., an aryl group, a heteroaryl group, etc.) is not particularly limited, but may be, for example, 5 to 32, 5 to 24, 6 to 18, 6 to 12, or 6 to 10. In addition, when an isomer exists in a substituent or the like, any isomer may be used unless otherwise specified, for example, when simply referring to a "butyl group", it may be an n-butyl group, a sec-butyl group, or a tert-butyl group, and when simply referring to a "naphthyl group", it may be a 1-naphthyl group or a 2-naphthyl group.
[0157] In the third aspect of the present invention, the "skin barrier function" means a function of preventing evaporation of moisture from inside the skin and / or a function of preventing the intrusion of substances from the outside into the skin.
[0158] In the third aspect of the present invention, "oxidative stress" refers to stress caused by reactive oxygen species. Specific examples of the oxidative stress include damage to biomolecules (e.g., proteins, lipids, nucleic acids, etc.) and damage to intracellular organelles caused by the reactive oxygen species.
[0159] In the third invention of the present invention, "induction of gene expression" may mean changing from a state in which the target gene is not expressed to a state in which the target gene is expressed, or it may mean increasing the expression level of the target gene.
[0160] In the third invention of the present invention, "treatment" means therapeutic treatment and / or preventive treatment. As used herein, "treatment" means treating, curing, preventing, suppressing, ameliorating, or improving a disease, pathology, or disorder, or stopping, suppressing, reducing, or delaying the progression of a disease, pathology, or disorder. As used herein, "prevention" means reducing the possibility of developing a disease or pathology, or delaying the onset of a disease or pathology. The "treatment" may be, for example, treatment of a patient who develops a target disease, or treatment of a model animal of the target disease.
[0161] The third invention of the present invention will be described in more detail below with examples. However, the third invention of the present invention is not limited by the following explanation. In addition, each explanation in the third invention of the present invention can be mutually incorporated unless otherwise specified. In this specification, when the expression "~" is used, it is used to mean including the numerical value or physical value before and after it. In addition, in this specification, the expression "A and / or B" includes "A only", "B only", and "both A and B".
[0162] <Composition for inducing the expression of genes related to skin barrier function> The composition for inducing the expression of skin barrier function-related genes in the third invention of the present invention (hereinafter referred to as "first composition") contains glycerin and / or a glycerin derivative and an expression-inducing component of skin barrier function-related genes, and the expression-inducing component of the skin barrier function-related genes contains a cyclic peroxide or a salt thereof as an active ingredient. The first composition of the third invention of the present invention is characterized in that it contains the cyclic peroxide or a salt thereof, and other configurations and conditions are not particularly limited. As described below, the cyclic peroxide induces the expression of a protein important for the skin barrier function, such as the profilaggrin gene, which is a skin barrier function-related gene. Therefore, according to the first composition of the third invention of the present invention, for example, when applied to the skin, an effect of inducing the expression of skin barrier function-related genes on the skin can be obtained.
[0163] [1. Induces expression of genes related to skin barrier function] The first composition of the third invention of the present invention contains a component for inducing the expression of a skin barrier function-related gene, as described above. The first composition of the third invention of the present invention may contain the cyclic peroxide as an active ingredient of the component for inducing the expression of a skin barrier function-related gene, or may contain an oxidation reaction product containing the cyclic peroxide, as described below, or may contain both. The cyclic peroxide may be a compound represented by the following chemical formula (I), or may be a cyclic peroxide contained in an oxidation reaction product obtained by oxidizing an alcohol, as described below.
[0164] In the first composition of the third invention of the present invention, the content of the component for inducing the expression of the skin barrier function-related gene may be an effective amount capable of inducing the expression of the skin barrier function-related gene, for example, 0.001 to 10 w / v%, 0.05 to 5 w / v%, or 0.01 to 1 w / v%. In the first composition of the third invention of the present invention, the content of the cyclic peroxide may be an effective amount capable of inducing the expression of the skin barrier function-related gene, for example, 0.001 to 10 w / v%, 0.05 to 5 w / v%, or 0.01 to 1 w / v%.
[0165] [2. Cyclic peroxides] The cyclic peroxide is represented by the following chemical formula (I): [ka] In the above chemical formula (I), R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, may or may not have a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure, and may be a monocyclic ring or a condensed ring; R 1 is a substituent, which may be one, multiple, or absent, and when multiple, they may be the same or different.
[0166] The heteroatom refers to an atom other than carbon and hydrogen, and may be, for example, one selected from the group consisting of oxygen, nitrogen, sulfur, selenium, boron, and silicon. The substituent is not particularly limited, and may include, for example, a hydroxyl group, and may be, for example, one selected from the group consisting of the above-mentioned hydroxyl group (-OH), aldehyde group (formyl group), hydroxyalkyl group, sulfo group, nitro group, diazo group, alkyl group, unsaturated aliphatic hydrocarbon group, aryl group, heteroaryl group, halogen, mercapto group (-SH), and alkylthio group (-SR, R is alkyl group).
[0167] The cyclic peroxide is, for example, represented by the formula (I): 100 However, it may be a cyclic structure having 5 to 10 ring members.
[0168] The cyclic peroxide may be, for example, a cyclic peroxide represented by the following chemical formula (II). [ka] In the above chemical formula (II), Each R 11 may be the same or different, and each is a hydrogen atom or a substituent. Two R 11 may be joined together to form an oxo group (=O) or a thioxo group (=S).
[0169] The cyclic peroxide is, for example, R 11 In the above, each of the substituents may be a hydroxyl group (-OH), an aldehyde group (formyl group), a hydroxyalkyl group, a sulfo group, a nitro group, a diazo group, an alkyl group, an unsaturated aliphatic hydrocarbon group, an aryl group, a heteroaryl group, a halogen, a mercapto group (-SH), or an alkylthio group (-SR, where R is an alkyl group).
[0170] The cyclic peroxide may be, for example, a cyclic peroxide represented by the following chemical formula (1). The cyclic peroxide represented by the following chemical formula (1) is a cyclic peroxide represented by the following chemical formula (II) in which all R 11 is a hydrogen atom. [ka]
[0171] The method for producing the cyclic peroxide is not particularly limited, and for example, the cyclic peroxide can be produced by oxidizing an alcohol using the method for producing the oxidation reaction product described below. In this case, for example, the produced oxidation reaction product may be used as it is without purification, or only the cyclic peroxide may be isolated and purified for use.
[0172] The inventors of the present invention were the first to discover that cyclic peroxides can be obtained by the oxidation of alcohols, for example, the oxidation of glycerin with ozone. Although the mechanism by which cyclic peroxides are obtained is unclear, it is speculated that, for example, by extending the reaction time of the oxidation reaction of alcohols as described below, a reaction product different from that of conventional reactions can be obtained.
[0173] The cyclic peroxides are chemically stable and easy to handle compared to radicals, for example, and therefore can be isolated and formulated.
[0174] In general, cyclic peroxides are substances that are used industrially due to their oxidizing ability, etc. In particular, artemisinin, which has a seven-membered ring (trioxolane) skeleton similar to the structure of the cyclic peroxides, is useful as an antimalarial agent and was awarded the Nobel Prize in 2015, and its derivatives are currently being researched.
[0175] However, the supply of artemisinin was unstable when it was extracted and purified from natural products. In addition, since artemisinin is neither water-soluble nor fat-soluble, there were many challenges in formulating it. On the other hand, hydrogen peroxide is an example of a water-soluble oxidizing substance, but it is highly reactive and unstable, and has only been used externally for disinfection of living organisms.
[0176] In contrast, according to the third aspect of the present invention, for example, a cyclic peroxide and an oxidation reaction product that are highly safe and have excellent water solubility are used, and therefore can be suitably used in living organisms. In addition, in the third aspect of the present invention, it is presumed that the oxidizing ability of the cyclic peroxide provides an effect of inducing the expression of skin barrier function-related genes. The effect of inducing the expression of skin barrier function-related genes can be evaluated according to Example 3 described below.
[0177] In the first composition of the third invention of the present invention, the cyclic peroxide may be a salt or a solvate such as a hydrate. The explanation of the cyclic peroxide can be applied to the explanation of the salt of the cyclic peroxide or the solvate thereof.
[0178] [3. Oxidation reaction products] As described above, the oxidation reaction product is an oxidation reaction product that is obtained by oxidizing an alcohol and contains a cyclic peroxide. However, the method for producing the oxidation reaction product is not limited to the oxidation of an alcohol, and any method for producing the oxidation reaction product may be used as long as the product has the same structure.
[0179] The method of oxidizing the alcohol is not particularly limited. For example, the oxidation of the alcohol may be at least one of ozone oxidation and hydrogen peroxide oxidation. However, as described above, the method of producing the oxidation reaction product is not limited to ozone oxidation and hydrogen peroxide oxidation of the alcohol, and any method of producing the oxidation reaction product may be used as long as the substance has the same structure.
[0180] The oxidation reaction product may be, for example, a mixture containing a plurality of oxidation reaction products.
[0181] The oxidation reaction product may have, for example, an oxidizing ability.
[0182] The oxidation reaction product may have, for example, reducing ability.
[0183] In the oxidation reaction product, the alcohol serving as a raw material is not particularly limited. For example, the alcohol in the oxidation reaction product may be a saturated alcohol.
[0184] The oxidation reaction product may be, for example, a polyhydric alcohol.
[0185] In the oxidation reaction product, for example, the alcohol may be at least one of glycerin and a glycerin derivative.
[0186] The oxidation reaction product may include, for example, an oxidation reaction product obtained by bonding two or more molecules of the alcohol.
[0187] The oxidation reaction product may include, for example, the cyclic peroxide.
[0188] The alcohol used as the raw material of the oxidation reaction product is not particularly limited, and may be, for example, a saturated alcohol or an unsaturated alcohol as described above. The alcohol may be linear or branched, and may or may not contain a cyclic structure. The alcohol may be, for example, a polyhydric alcohol or a monohydric alcohol. The valence of the polyhydric alcohol is also not particularly limited, and may be, for example, dihydric, trihydric, or tetrahydric. Examples of monohydric saturated alcohols include saturated alcohols having 1 to 40, 1 to 32, 1 to 24, 1 to 18, 1 to 12, 1 to 6, or 1 to 2 carbon atoms, and the saturated alcohol may be linear or branched, and may or may not contain a cyclic structure. Specific examples of the saturated alcohol include methanol, ethanol, n-propyl alcohol, isopropyl alcohol, n-butyl alcohol, sec-butyl alcohol, and tert-butyl alcohol. Examples of the saturated polyhydric alcohol include saturated polyhydric alcohols having 1 to 40, 1 to 32, 1 to 24, 1 to 18, 1 to 12, 1 to 6, or 1 to 2 carbon atoms. The saturated polyhydric alcohol may be linear or branched, and may or may not contain a cyclic structure. Specific examples of the saturated polyhydric alcohol include ethylene glycol (ethane-1,2-diol), propylene glycol (propane-1,2-diol), glycerin, and glycerin derivatives. The glycerin derivative is not particularly limited, and may be, for example, a polymer of glycerin or a compound in which at least one hydrogen atom of glycerin is substituted with a substituent (for example, an alkyl group). Examples of the glycerin derivative include diglycerin and polyglycerin. The glycerin derivative may be an oxidized product of glycerin.
[0189] The oxidation reaction product may be, for example, a substance having reducing ability, as described above. For example, the oxidation reaction product may have a functional group having reducing ability, and thus have reducing ability derived from the functional group. Specifically, for example, the oxidation reaction product may have reducing ability by having an aldehyde group (formyl group), and may have reducing ability derived from the keto body by being a keto-enol tautomer. For example, the oxidation reaction product obtained in Example 3 described later contains an acetal structure in the skeleton as confirmed by NMR, and is therefore considered to develop color in the DNPH (dinitrophenylhydrazine: ketone-aldehyde derived) reaction derived from a ketone or aldehyde.
[0190] The oxidation reaction product may be, for example, a substance obtained by binding two or more molecules of the alcohol as described above. Specifically, for example, the oxidation reaction product may be a structure in which two or more molecules of the alcohol are bound and further oxidized. The form of "binding" of the two or more molecules of the alcohol is not particularly limited, and may be, for example, addition, condensation, etc.
[0191] The oxidation reaction product is chemically stable and easy to handle compared to radicals, for example, and therefore can be isolated and formulated.
[0192] [4. Method for producing oxidation reaction product] As described above, the method for producing the oxidation reaction product includes an alcohol oxidation step of oxidizing the alcohol.
[0193] In the alcohol oxidation step, the method for oxidizing the alcohol is not particularly limited. In the method for producing the oxidation reaction product, for example, in the alcohol oxidation step, the alcohol may be oxidized by at least one of ozone oxidation and hydrogen peroxide oxidation.
[0194] In the method for producing the oxidation reaction product, the reaction time of the alcohol oxidation step is not particularly limited. The reaction time of the alcohol oxidation step may be, for example, 24 hours or more or 1 day or more, 48 hours or more or 2 days or more, 72 hours or more or 3 days or more, 120 hours or more or 5 days or more, or 168 hours or more or 7 days or more. The upper limit of the reaction time of the alcohol oxidation step is not particularly limited, but may be, for example, 720 hours or less or 30 days or less, or 360 hours or less or 15 days or less.
[0195] In the method for producing the oxidation reaction product, in order to obtain a reaction product containing the cyclic peroxide, it is preferable to extend the reaction time of the alcohol oxidation step. For example, it is considered that by extending the reaction time of the alcohol oxidation step, the cyclic peroxide that could not be obtained by conventional ozone oxidation reaction of glycerin can be produced. In the method for producing the oxidation reaction product, it is preferable that the reaction time of the alcohol oxidation step is not too long in order to ensure production efficiency.
[0196] As described above, the method for producing the oxidation reaction product includes an alcohol oxidation step of oxidizing the alcohol. However, as described above, the oxidation reaction product is not limited to a substance produced by this production method, and may be a substance produced by any production method as long as it has the same structure. Hereinafter, the method for producing the oxidation reaction product will be described in more detail with reference to examples.
[0197] In the following, an example will be described in which glycerin is used as the alcohol and ozone oxidation is performed. However, as described above, the following description is merely an example, and the method for producing the oxidation reaction product is not limited to the following description. For example, the following method can be performed in the same manner using other alcohols instead of glycerin. For example, in the method for producing the oxidation reaction product, the method for oxidizing the alcohol in the alcohol oxidation step is not particularly limited and is optional, and is not limited to ozone oxidation. The oxidation method may be, for example, at least one of ozone oxidation and hydrogen peroxide oxidation. In addition, for example, not only the type of alcohol and the method for oxidizing the alcohol, but also the concentration of each substance, reaction temperature, reaction time, and other reaction conditions can be appropriately changed.
[0198] The oxidation reaction product can be produced by a production method including a step of oxidizing glycerin by contacting glycerin with ozone, more specifically, by mixing glycerin with ozone (corresponding to the above-mentioned "alcohol oxidation step"). The step of oxidizing glycerin may be, for example, a step of oxidizing glycerin by gas-liquid contacting a glycerin solution with a gas containing ozone.
[0199] The glycerin solution preferably has a high concentration of glycerin. As the high concentration glycerin solution, for example, a glycerin solution having a glycerin concentration of 75% or more can be used. Specifically, a glycerin solution having a glycerin concentration of 84 to 87% by weight as specified in the Japanese Pharmacopoeia is preferable, a concentrated glycerin solution having a glycerin concentration of 98% by weight or more as specified in the Japanese Pharmacopoeia is more preferable, and a purified glycerin solution having a concentration of 98.5% by weight or more is even more preferable. The glycerin solution can treat ozone at a higher concentration, for example, as the glycerin concentration is relatively higher. In the glycerin solution, the solvent for glycerin is not particularly limited, and is, for example, an aqueous solvent such as water.
[0200] The ozone-containing gas preferably has a high ozone concentration. The method for producing the gas with a high ozone concentration is not particularly limited, and for example, an ozone generator that generates ozone by silently discharging oxygen gas can be used. When oxygen gas is used, for example, a medical oxygen cylinder can be used, or oxygen gas produced by an oxygen generator can be used.
[0201] The method of gas-liquid contact between the glycerin solution and the ozone-containing gas is not particularly limited, and for example, there is a method in which a high-concentration (e.g., 98% by weight or more) glycerin solution is placed in a tank, and the gas with a high ozone concentration is released into the tank as fine bubbles using an air diffuser. Specifically, for example, an ozone-treated glycerin solution with an equivalent hydrogen peroxide concentration of about 4000 ppm can be produced by aerating a gas with an ozone concentration of about 37000 ppm into the concentrated glycerin solution for about 7 days. The aeration time is not particularly limited, and for example, an ozone-treated glycerin solution containing the oxidation reaction product at a higher concentration can be produced by aerating for a relatively longer period of time.
[0202] The oxidation reaction product may be used as it is without being separated from the mixture after the reaction (e.g., the ozone-treated glycerin solution), or may be used after being separated from the mixture after the reaction. The method for separation is not particularly limited, but for example, the oxidation reaction product can be separated from the mixture after the reaction by chromatography such as preparative thin layer chromatography.
[0203] Conventionally, production of substances such as peroxides having oxidizing power required a complicated system. According to the method for producing an oxidation reaction product, for example, an oxidation reaction product having oxidizing power can be produced in a very simple and easy manner.
[0204] The oxidation reaction product can generate, for example, hydrogen peroxide. The oxidation reaction product can generate, for example, 1 to 4000 ppm, 10 to 4000 ppm, or 100 to 4000 ppm of hydrogen peroxide per about 4000 ppm of the oxidation reaction product in terms of hydrogen peroxide concentration.
[0205] [5. Glycerin] In the first composition of the third invention of the present invention, the glycerin may be glycerin or the above-mentioned glycerin derivative. In the first composition of the third invention of the present invention, the cyclic peroxide can be stably maintained by coexisting with the glycerin.
[0206] In the first composition of the third invention of the present invention, the content of the glycerin is, for example, 0.1 to 100 w / v %, preferably 0.1 to 50 w / v %.
[0207] [6. Skin barrier function-related genes] The skin barrier function-related gene may be any gene that encodes a protein that contributes to the skin barrier function. Examples of the skin barrier function-related gene include the profilaggrin gene, the involucrin gene, and the serine palmitoyltransferase gene. The skin barrier function-related gene whose expression is induced by the first composition of the third invention of the present invention may be, for example, one type or multiple types. Examples of the profilaggrin gene, the involucrin gene, and the serine palmitoyltransferase gene include polynucleotides consisting of base sequences identified by the following Genbank accession numbers as human genes. ·Profilaggrin gene: NM_002016.2 Involucrin gene: NM_005547.2 Serine palmitoyltransferase gene: NM_004863.3
[0208] [7. Other Ingredients] The first composition of the third invention of the present invention may contain other components added to the formulation to be applied to the skin. Specific examples of the other components include components added to skin external preparations and components added to cosmetics (including quasi-drugs). Examples of the components added to the skin external preparations include pharma- ceutically acceptable carriers. Examples of the other components include components added when applied to the skin or when applied transdermally, and specific examples include aqueous solvents such as water, alcohols, moisturizers, oils, softeners (emollients), surfactants (solubilizers, emulsifiers), salts, thickeners, pH adjusters, ultraviolet absorbers, drugs, buffers, colorants, preservatives, fragrances, etc.
[0209] [8. Dosage form, method of use, and application] The first composition of the third aspect of the present invention is, for example, solid or liquid. The form of the first composition of the third aspect of the present invention can be, for example, a lotion formulation; an emulsion formulation such as milky lotion or cream; an oil formulation: a gel formulation; an ointment, a pack, a cleanser, etc.
[0210] The subject of the use of the first composition of the third invention of the present invention is human or non-human animal.The first composition of the third invention of the present invention can be used, for example, on the skin of the subject.The amount of the first composition of the third invention of the present invention used is not particularly limited, and can be the amount normally used according to the dosage form of the first composition of the third invention of the present invention.
[0211] The first composition of the third aspect of the present invention can be suitably used as an external preparation for skin, such as a cosmetic.
[0212] <Expression inducer of genes related to skin barrier function> The expression inducer of the skin barrier function-related gene of the third invention of the present invention (hereinafter referred to as the "first inducer") contains a cyclic peroxide or a salt thereof. The expression inducer of the skin barrier function-related gene of the third invention of the present invention is characterized by containing a cyclic peroxide or a salt thereof, and other configurations and conditions are not particularly limited. As described above, the cyclic peroxide induces the expression of a protein important for the skin barrier function, such as the profilaggrin gene, which is the skin barrier function-related gene. Therefore, according to the first inducer of the third invention of the present invention, for example, when applied to the skin, it is possible to obtain an effect of inducing the expression of the skin barrier function-related gene on the skin.
[0213] In the first inducer of the third invention of the present invention, the content of the expression inducer component for skin barrier function-related genes may be an effective amount capable of inducing the expression of skin barrier function-related genes, for example, 0.001 to 10 w / v%, 0.05 to 5 w / v%, or 0.01 to 1 w / v%. In the first inducer of the third invention of the present invention, the content of the cyclic peroxide may be an effective amount capable of inducing the expression of skin barrier function-related genes, for example, 0.001 to 10 w / v%, 0.05 to 5 w / v%, or 0.01 to 1 w / v%.
[0214] In the first inducer of the third invention of the present invention, the cyclic peroxide may be a compound represented by the following chemical formula (I), or may be a cyclic peroxide contained in an oxidation reaction product obtained by oxidizing the above-mentioned alcohol. [ka] In the above chemical formula (I), R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, may or may not have a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure, and may be a monocyclic ring or a condensed ring; R 1is a substituent, which may be one, multiple, or absent, and when multiple, they may be the same or different.
[0215] The explanation of the cyclic peroxide and the oxidation reaction product can be made with reference to the explanation of the first composition of the third invention of the present invention.
[0216] The explanation of the dosage form and use of the first inducer of the third invention of the present invention can be cited from the explanation of the first composition of the third invention of the present invention.
[0217] <Composition for improving skin barrier function> The composition for improving skin barrier function of the third invention of the present invention (hereinafter referred to as "second composition") contains glycerin and / or a glycerin derivative and a skin barrier function improving component, and the skin barrier function improving component contains a cyclic peroxide or a salt thereof as an active ingredient. The second composition of the third invention of the present invention is characterized by containing the cyclic peroxide or a salt thereof, and other configurations and conditions are not particularly limited. As described above, the cyclic peroxide induces the expression of a protein important for the skin barrier function, such as the profilaggrin gene, which is a skin barrier function-related gene. Therefore, according to the second composition of the third invention of the present invention, for example, when applied to the skin, it is possible to obtain an effect of inducing the expression of the skin barrier function-related gene on the skin, thereby improving the skin barrier function.
[0218] In the second composition of the third invention of the present invention, the content of the skin barrier function improving component may be an effective amount capable of improving the skin barrier function, for example, 0.001 to 10 w / v%, 0.05 to 5 w / v%, or 0.01 to 1 w / v%. In the second composition of the third invention of the present invention, the content of the cyclic peroxide may be an effective amount capable of improving the skin barrier function, for example, 0.001 to 10 w / v%, 0.05 to 5 w / v%, or 0.01 to 1 w / v%.
[0219] In the second composition of the third invention of the present invention, the cyclic peroxide may be a compound represented by the following chemical formula (I), or may be a cyclic peroxide contained in an oxidation reaction product obtained by oxidizing the above-mentioned alcohol. [ka] In the above chemical formula (I), R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, may or may not have a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure, and may be a monocyclic ring or a condensed ring; R 1 is a substituent, which may be one, multiple, or absent, and when multiple, they may be the same or different.
[0220] The explanations regarding the cyclic peroxide, the oxidation reaction product, and glycerin can be found in the explanations regarding the first composition of the third aspect of the present invention.
[0221] The explanation of the dosage form and use of the second composition of the third invention of the present invention can be cited from the explanation of the first composition of the third invention of the present invention.
[0222] The second composition of the third aspect of the present invention can improve the skin barrier function, and therefore can be suitably used for treating, for example, atopic dermatitis, psoriasis vulgaris, and the like, in which the skin barrier function is impaired.
[0223] <Skin barrier function improver> The skin barrier function improver (hereinafter referred to as "improver") of the third invention of the present invention contains a cyclic peroxide or a salt thereof. The skin barrier function improver of the third invention of the present invention is characterized by containing a cyclic peroxide or a salt thereof, and other configurations and conditions are not particularly limited. As described above, the cyclic peroxide induces the expression of a protein important for the skin barrier function, such as the profilaggrin gene, which is the skin barrier function-related gene. Therefore, according to the improver of the third invention of the present invention, for example, when applied to the skin, it is possible to obtain an effect of inducing the expression of the skin barrier function-related gene on the skin, thereby improving the skin barrier function.
[0224] In the improving agent of the third invention of the present invention, the content of the skin barrier function improving component may be an effective amount capable of improving the skin barrier function, for example, 0.001 to 10 w / v%, 0.05 to 5 w / v%, or 0.01 to 1 w / v%. Also, in the improving agent of the third invention of the present invention, the content of the cyclic peroxide may be an effective amount capable of improving the skin barrier function, for example, 0.001 to 10 w / v%, 0.05 to 5 w / v%, or 0.01 to 1 w / v%.
[0225] In the improving agent of the third invention of the present invention, the cyclic peroxide may be a compound represented by the following chemical formula (I), or may be a cyclic peroxide contained in an oxidation reaction product obtained by oxidizing the above-mentioned alcohol. [ka] In the above chemical formula (I), R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, may or may not have a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure, and may be a monocyclic ring or a condensed ring; R 1 is a substituent, which may be one, multiple, or absent, and when multiple, they may be the same or different.
[0226] The explanation of the cyclic peroxide and the oxidation reaction product can be made with reference to the explanation of the first composition of the third invention of the present invention.
[0227] The explanation of the dosage form and use of the improving agent of the third invention of the present invention can be made by referring to the explanation of the first composition and the second composition of the third invention of the present invention.
[0228] <Composition for inducing expression of antioxidant stress response genes> The composition for inducing expression of an antioxidant stress response gene according to the third invention of the present invention (hereinafter referred to as the "third composition") contains glycerin and / or a glycerin derivative and an expression-inducing component of an antioxidant stress response gene, and the expression-inducing component of the antioxidant stress response gene contains a cyclic peroxide or a salt thereof as an active ingredient. The third composition according to the third invention of the present invention is characterized in that it contains the cyclic peroxide or a salt thereof, and other configurations and conditions are not particularly limited. As described above, the cyclic peroxide induces the expression of proteins important for antioxidant stress response, such as the heme oxygenase 1 gene and the NAD(P)H quinone oxidoreductase 1 gene, which are antioxidant stress response genes. Therefore, according to the third composition according to the third invention of the present invention, for example, when applied to the skin, it is possible to obtain an effect of inducing expression of an antioxidant stress response gene on the skin, thereby improving the antioxidant stress response.
[0229] In the third composition of the third invention of the present invention, the content of the antioxidant stress response gene expression-inducing component may be an effective amount capable of inducing the expression of the antioxidant stress response gene, for example, 0.001 to 10 w / v%, 0.05 to 5 w / v%, or 0.01 to 1 w / v%. Also, in the third composition of the third invention of the present invention, the content of the cyclic peroxide may be an effective amount capable of inducing the expression of the antioxidant stress response gene, for example, 0.001 to 10 w / v%, 0.05 to 5 w / v%, or 0.01 to 1 w / v%.
[0230] In the third composition of the third invention of the present invention, the cyclic peroxide may be a compound represented by the following chemical formula (I), or may be a cyclic peroxide contained in an oxidation reaction product obtained by oxidizing the above-mentioned alcohol. [ka] In the above chemical formula (I), R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, may or may not have a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure, and may be a monocyclic ring or a condensed ring; R 1 is a substituent, which may be one, multiple, or absent, and when multiple, they may be the same or different.
[0231] The antioxidant stress response gene may be any gene that encodes a protein that contributes to an oxidative stress response. Examples of the antioxidant stress response gene include heme oxygenase 1 (HO-1) gene, NAD(P)H quinone oxidoreductase 1 (NQO-1) gene, and / or glutathione gene. The antioxidant stress response gene whose expression is induced by the third composition of the third invention of the present invention may be, for example, one type or multiple types. Examples of the heme oxygenase 1 gene and NAD(P)H quinone oxidoreductase 1 gene include, for example, polynucleotides consisting of base sequences identified as human genes by the following Genbank accession numbers: Heme oxygenase 1 gene: NM_002133.3 ·NAD(P)H quinone oxidoreductase 1 gene: NM_000903.3
[0232] The explanations regarding the cyclic peroxide, the oxidation reaction product, and glycerin can be found in the explanations regarding the first composition of the third aspect of the present invention.
[0233] The explanation of the dosage form and use of the third composition of the third invention of the present invention can be cited from the explanation of the first composition of the third invention of the present invention.
[0234] The third composition of the third aspect of the present invention can improve the antioxidant stress response, and therefore can be suitably used for treating, for example, atopic dermatitis, in which the antioxidant stress response is reduced.
[0235] <Antioxidant stress function gene expression inducer> The expression inducer of an antioxidant stress response gene of the third invention of the present invention (hereinafter referred to as the "second inducer") contains a cyclic peroxide or a salt thereof. The expression inducer of an antioxidant stress response gene of the third invention of the present invention is characterized by containing a cyclic peroxide or a salt thereof, and other configurations and conditions are not particularly limited. As described above, the cyclic peroxide induces the expression of proteins important for antioxidant stress response, such as the antioxidant stress response genes, heme oxygenase 1 gene and NAD(P)H quinone oxidoreductase 1 gene. Therefore, according to the second inducer of the third invention of the present invention, for example, when applied to the skin, an effect of inducing the expression of antioxidant stress response genes in the skin can be obtained, thereby improving the antioxidant stress response.
[0236] In the second inducer of the third invention of the present invention, the content of the expression inducer component of the antioxidant stress response gene may be an effective amount capable of inducing the expression of the antioxidant stress response gene, for example, 0.001 to 10 w / v%, 0.05 to 5 w / v%, or 0.01 to 1 w / v%. Also, in the second inducer of the third invention of the present invention, the content of the cyclic peroxide may be an effective amount capable of inducing the expression of the antioxidant stress response gene, for example, 0.001 to 10 w / v%, 0.05 to 5 w / v%, or 0.01 to 1 w / v%.
[0237] In the second inducer of the third invention of the present invention, the cyclic peroxide may be a compound represented by the following chemical formula (I), or may be a cyclic peroxide contained in an oxidation reaction product obtained by oxidizing the above-mentioned alcohol. [ka] In the above chemical formula (I), R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, may or may not have a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure, and may be a monocyclic ring or a condensed ring; R 1 is a substituent, which may be one, multiple, or absent, and when multiple, they may be the same or different.
[0238] The explanation of the cyclic peroxide and the oxidation reaction product can be made with reference to the explanation of the first composition of the third invention of the present invention.
[0239] The explanation of the dosage form and use of the second inducer of the third invention of the present invention can be made by referring to the explanation of the first composition and the third composition of the third invention of the present invention.
[0240] <Anti-inflammatory composition> The anti-inflammatory composition of the third invention of the present invention (hereinafter referred to as the "fourth composition") contains glycerin and / or a glycerin derivative and an anti-inflammatory component, and the anti-inflammatory component contains a cyclic peroxide or a salt thereof as an active ingredient. The fourth composition of the third invention of the present invention is characterized by containing the cyclic peroxide or a salt thereof, and other configurations and conditions are not particularly limited. As described below, the cyclic peroxide suppresses the production of IL-1α and prostaglandin E2, which are anti-inflammatory cytokines. Therefore, according to the fourth composition of the third invention of the present invention, for example, when applied to the skin, an anti-inflammatory effect on the skin can be obtained.
[0241] In the anti-inflammatory composition of the third invention of the present invention, the content of the anti-inflammatory component may be an effective amount capable of suppressing inflammation, for example, 0.001 to 10 w / v%, 0.05 to 5 w / v%, or 0.01 to 1 w / v%. In the anti-inflammatory composition of the third invention of the present invention, the content of the cyclic peroxide may be an effective amount capable of suppressing inflammation, for example, 0.001 to 10 w / v%, 0.05 to 5 w / v%, or 0.01 to 1 w / v%.
[0242] In the fourth composition of the third invention of the present invention, the cyclic peroxide may be a compound represented by the following chemical formula (I), or may be a cyclic peroxide contained in an oxidation reaction product obtained by oxidizing the above-mentioned alcohol. [ka] In the above chemical formula (I), R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, may or may not have a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure, and may be a monocyclic ring or a condensed ring; R 1 is a substituent, which may be one, multiple, or absent, and when multiple, they may be the same or different.
[0243] The fourth composition of the third invention of the present invention, for example, suppresses the expression and / or production of the inflammatory cytokine. An example of the inflammatory cytokine is IL-1α. Therefore, the fourth composition of the third invention of the present invention can also be referred to as, for example, a composition for suppressing the expression of the IL-1α gene and / or a composition for suppressing the production of IL-1α. Furthermore, the fourth composition of the third invention of the present invention, for example, suppresses the production of a chemical mediator that induces inflammation. An example of the chemical mediator is prostaglandin E2. Therefore, the fourth composition of the third invention of the present invention can also be referred to as, for example, a composition for suppressing the production of prostaglandin E2.
[0244] The explanations regarding the cyclic peroxide, the oxidation reaction product, and glycerin can be found in the explanations regarding the first composition of the third aspect of the present invention.
[0245] The explanation of the dosage form and use of the fourth composition of the third invention of the present invention can be cited from the explanation of the first composition of the third invention of the present invention.
[0246] According to the fourth composition of the third invention of the present invention, inflammation can be suppressed. Therefore, the fourth composition of the third invention of the present invention can be suitably used for treating inflammatory diseases such as atopic dermatitis and psoriasis vulgaris. In addition, the fourth composition of the third invention of the present invention can suitably suppress inflammation in epidermal keratinocytes present in the skin. Therefore, the fourth composition of the third invention of the present invention can also be called, for example, a composition for suppressing inflammation in epidermal keratinocytes.
[0247] <Anti-inflammatory agents> The anti-inflammatory agent of the third invention of the present invention contains a cyclic peroxide or a salt thereof. The expression inducer of an antioxidant stress response gene of the third invention of the present invention is characterized by containing a cyclic peroxide or a salt thereof, and other configurations and conditions are not particularly limited. As described above, the cyclic peroxide suppresses the production of IL-1α, an anti-inflammatory cytokine. Therefore, according to the anti-inflammatory agent of the third invention of the present invention, for example, when applied to the skin, an anti-inflammatory effect on the skin can be obtained.
[0248] In the anti-inflammatory agent of the third invention of the present invention, the content of the anti-inflammatory component may be an effective amount capable of suppressing inflammation, for example, 0.001 to 10 w / v%, 0.05 to 5 w / v%, or 0.01 to 1 w / v%. Also, in the anti-inflammatory agent of the third invention of the present invention, the content of the cyclic peroxide may be an effective amount capable of suppressing inflammation, for example, 0.001 to 10 w / v%, 0.05 to 5 w / v%, or 0.01 to 1 w / v%.
[0249] In the anti-inflammatory agent of the third invention of the present invention, the cyclic peroxide may be a compound represented by the following chemical formula (I), or may be a cyclic peroxide contained in an oxidation reaction product obtained by oxidizing the above-mentioned alcohol. [ka] In the above chemical formula (I), R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, may or may not have a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure, and may be a monocyclic ring or a condensed ring; R 1 is a substituent, which may be one, multiple, or absent, and when multiple, they may be the same or different.
[0250] The anti-inflammatory agent of the third invention of the present invention, for example, suppresses the expression and / or production of the inflammatory cytokine. An example of the inflammatory cytokine is IL-1α. Therefore, the anti-inflammatory agent of the third invention of the present invention can also be referred to as, for example, an inhibitor of IL-1α gene expression and / or an inhibitor of IL-1α production. Furthermore, the anti-inflammatory agent of the third invention of the present invention, for example, suppresses the production of a chemical mediator that induces inflammation. An example of the chemical mediator is prostaglandin E2. Therefore, the anti-inflammatory agent of the third invention of the present invention can also be referred to as, for example, an inhibitor of prostaglandin E2 production.
[0251] The explanation of the cyclic peroxide and the oxidation reaction product can be made with reference to the explanation of the first composition of the third invention of the present invention.
[0252] The explanation of the dosage form and use of the anti-inflammatory agent of the third invention of the present invention can be made by referring to the explanation of the first composition and the fourth composition of the third invention of the present invention.
[0253] <Method for inducing expression of genes related to skin barrier function> The method for inducing expression of a skin barrier function-related gene of the third invention of the present invention (hereinafter also referred to as the "first induction method") uses the composition for inducing expression of a skin barrier function-related gene of the third invention of the present invention and / or the inducer of expression of a skin barrier function-related gene of the third invention of the present invention. The first induction method of the third invention of the present invention is characterized by using the first composition of the third invention of the present invention and / or the first inducer of the third invention of the present invention, and other steps and conditions are not particularly limited. The cyclic peroxide contained in the first composition of the third invention of the present invention and / or the first inducer of the third invention of the present invention induces the expression of a protein important for the skin barrier function, such as the profilaggrin gene, which is a skin barrier function-related gene. Therefore, according to the first induction method of the third invention of the present invention, for example, when applied to the skin, an effect of inducing expression of a skin barrier function-related gene on the skin can be obtained.
[0254] The first induction method of the third invention of the present invention can be carried out, for example, by applying the first composition and / or the first inducer to the skin of the subject. More specifically, the first induction method of the third invention of the present invention can be carried out by contacting the first composition and / or the first inducer to the skin of the subject.
[0255] The first induction method of the third invention in the present invention is, for example, in In vitro or in vivo This will be carried out.
[0256] <Methods for improving skin barrier function> The method for improving skin barrier function of the third invention of the present invention (hereinafter also referred to as "improvement method") uses the composition for improving skin barrier function of the third invention of the present invention and / or the improver of skin barrier function of the third invention of the present invention. The improvement method of the third invention of the present invention is characterized by using the second composition of the third invention of the present invention and / or the improver of the third invention of the present invention, and other steps and conditions are not particularly limited. The cyclic peroxide contained in the second composition and / or the improver of the third invention of the present invention induces the expression of a protein important for the skin barrier function, such as the profilaggrin gene, which is a skin barrier function-related gene. Therefore, according to the improvement method of the third invention of the present invention, for example, when applied to the skin, it is possible to obtain an effect of inducing the expression of the skin barrier function-related gene on the skin, thereby improving the skin barrier function.
[0257] The improvement method of the third invention of the present invention can be carried out, for example, by applying the second composition and / or the improving agent to the skin of the subject. More specifically, the improvement method of the third invention of the present invention can be carried out by contacting the second composition and / or the improving agent to the skin of the subject.
[0258] The improvement method of the third aspect of the present invention includes, for example, in In vitro or in vivo This will be carried out.
[0259] <Method for inducing expression of antioxidant stress response genes> The method for inducing expression of an antioxidant stress response gene according to the third invention of the present invention (hereinafter also referred to as the "second induction method") uses the composition for inducing expression of an antioxidant stress response gene according to the third invention of the present invention and / or the inducer for expression of an antioxidant stress response gene according to the third invention of the present invention. The second induction method according to the third invention of the present invention is characterized by using the third composition according to the third invention of the present invention and / or the second inducer according to the third invention of the present invention, and other steps and conditions are not particularly limited. The cyclic peroxide contained in the third composition according to the third invention of the present invention and / or the second inducer induces expression of proteins important for antioxidant stress response, such as heme oxygenase 1 gene and NAD(P)H quinone oxidoreductase 1 gene, which are antioxidant stress response genes. Therefore, according to the second induction method according to the third invention of the present invention, for example, when applied to the skin, an effect of inducing expression of an antioxidant stress response gene on the skin can be obtained, thereby improving the antioxidant stress response.
[0260] The second induction method of the third invention of the present invention can be carried out, for example, by applying the third composition and / or the second inducer to the skin of the subject. More specifically, the second induction method of the third invention of the present invention can be carried out by contacting the third composition and / or the second inducer to the skin of the subject.
[0261] The second induction method of the third invention in the present invention is, for example, in In vitro or in vivo This will be carried out.
[0262] <How to suppress inflammation> The method for suppressing inflammation according to the third invention of the present invention (hereinafter also referred to as the "suppression method") uses the fourth composition according to the third invention of the present invention and / or the anti-inflammatory agent according to the third invention of the present invention. The suppression method according to the third invention of the present invention is characterized by using the fourth composition according to the third invention of the present invention and / or the anti-inflammatory agent according to the third invention of the present invention, and other steps and conditions are not particularly limited. The cyclic peroxide contained in the fourth composition according to the third invention of the present invention and / or the anti-inflammatory agent suppresses the production of IL-1α, an anti-inflammatory cytokine, and the expression of prostaglandin E2. Therefore, according to the suppression method according to the third invention of the present invention, for example, when applied to the skin, an anti-inflammatory effect can be obtained in the skin.
[0263] The suppression method of the third invention of the present invention, for example, suppresses the expression and / or production of the inflammatory cytokine. An example of the inflammatory cytokine is IL-1α. Therefore, the suppression method of the third invention of the present invention can also be referred to as, for example, a method for suppressing the expression of the IL-1α gene and / or a method for suppressing the production of IL-1α. Furthermore, the suppression method of the third invention of the present invention, for example, suppresses the production of a chemical mediator that induces inflammation. An example of the chemical mediator is prostaglandin E2. Therefore, the suppression method of the third invention of the present invention can also be referred to as, for example, a method for suppressing the production of prostaglandin E2.
[0264] The suppression method of the third invention of the present invention can be carried out, for example, by applying the fourth composition and / or the anti-inflammatory agent to the skin of the subject. More specifically, the suppression method of the third invention of the present invention can be carried out by contacting the fourth composition and / or the anti-inflammatory agent to the skin of the subject.
[0265] The suppression method of the third invention in the present invention can be, for example, in In vitro or in vivo This will be carried out.
[0266] <Method of treating inflammatory diseases> The method for treating an inflammatory disease according to the third invention of the present invention (hereinafter also referred to as the "treatment method") includes an administration step of administering to a subject the anti-inflammatory composition according to the third invention of the present invention and / or the anti-inflammatory agent according to the third invention of the present invention. The treatment method according to the third invention of the present invention is characterized by administering the fourth composition according to the third invention of the present invention and / or the anti-inflammatory agent according to the third invention of the present invention (hereinafter also referred to as the "medicine"), and other steps and conditions are not particularly limited. The treatment method according to the third invention of the present invention can suppress inflammation because it uses the medicine. Therefore, the treatment method according to the third invention of the present invention can treat an inflammatory disease.
[0267] The treatment method of the third aspect of the present invention includes, for example, an administration step of administering the medicament, specifically, an administration step of administering the medicament to a subject. in In vitro or in vivo The subject and administration conditions of the pharmaceutical may be, for example, those described in the first composition of the third invention of the present invention. The subject is, for example, a subject for whom treatment is desired. As a specific example, the subject may be a patient suffering from the inflammatory disease, a patient predicted to suffer from the inflammatory disease, or a patient unknown to suffer from the inflammatory disease.
[0268] <Use> The third invention of the present invention is a composition for inducing expression of a skin barrier function-related gene of the third invention of the present invention and / or an inducer of expression of a skin barrier function-related gene of the third invention of the present invention, for use in inducing expression of a skin barrier function-related gene, or use thereof. The third invention of the present invention is a composition for improving skin barrier function of the third invention of the present invention and / or an inducer of expression of a skin barrier function of the third invention of the present invention, for use in improving skin barrier function, or use thereof. The third invention of the present invention is a composition for inducing expression of an antioxidant stress response gene of the third invention of the present invention and / or an inducer of expression of an antioxidant stress response gene of the third invention of the present invention, for use in inducing expression of an antioxidant stress response gene, or use thereof. The third invention of the present invention is an anti-inflammatory composition of the third invention of the present invention and / or an anti-inflammatory agent of the third invention of the present invention, for use in suppressing inflammation, or use thereof. The third invention of the present invention is the anti-inflammatory composition of the third invention of the present invention and / or the anti-inflammatory agent of the third invention of the present invention, or use thereof, for use in treating an inflammatory disease.
[0269] [Fourth embodiment of the invention] Next, an embodiment of the fourth aspect of the present invention will be described. However, the fourth aspect of the present invention is not limited to the following description.
[0270] In the fourth invention of the present invention, when a compound has isomers such as tautomers or stereoisomers (e.g., geometric isomers, conformational isomers, and optical isomers), any of the isomers can be used in the fourth invention of the present invention, unless otherwise specified. In addition, in the fourth invention of the present invention, when a substance can form a salt, the salt can also be used in the fourth invention of the present invention, unless otherwise specified. The salt may be an acid addition salt or a base addition salt. Furthermore, the acid that forms the acid addition salt may be an inorganic acid or an organic acid, and the base that forms the base addition salt may be an inorganic base or an organic base. The inorganic acid is not particularly limited, but examples thereof include sulfuric acid, phosphoric acid, hydrofluoric acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, hypofluorite acid, hypochlorous acid, hypobromite acid, hypoiodite acid, fluorite acid, chlorous acid, bromite acid, iodite acid, fluorine acid, chlorine acid, bromine acid, iodic acid, perfluorine acid, perchloric acid, perbromine acid, and periodic acid. The organic acid is also not particularly limited, but examples thereof include p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromobenzenesulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, and acetic acid. The inorganic base is not particularly limited, but examples thereof include ammonium hydroxide, alkali metal hydroxide, alkaline earth metal hydroxide, carbonate, and hydrogen carbonate, and more specifically, examples thereof include sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, calcium hydroxide, and calcium carbonate. The organic base is also not particularly limited, but examples thereof include ethanolamine, triethylamine, and tris(hydroxymethyl)aminomethane. The method for producing these salts is also not particularly limited, and for example, they can be produced by a method in which the above-mentioned acid or base is appropriately added to the compound by a known method.
[0271] In the fourth invention of the present invention, examples of the aromatic ring that does not contain a heteroatom include a benzene ring, a naphthalene ring, an anthracene ring, a phenanthrene ring, and a pyrene ring. Examples of the heteroaromatic ring include a pyridine ring and a thiophene ring. The nitrogen-containing aromatic ring may or may not have a positive charge. Examples of the nitrogen-containing aromatic ring that does not have a positive charge include a pyrroline ring, a pyridine ring, a pyridazine ring, a pyrimidine ring, a pyrazine ring, a quinoline ring, an isoquinoline ring, an acridine ring, a 3,4-benzoquinoline ring, a 5,6-benzoquinoline ring, a 6,7-benzoquinoline ring, a 7,8-benzoquinoline ring, a 3,4-benzoisoquinoline ring, a 5,6-benzoisoquinoline ring, a 6,7-benzoisoquinoline ring, and a 7,8-benzoisoquinoline ring. Examples of the nitrogen-containing aromatic ring having a positive charge include a pyrrolinium ring, a pyridinium ring, a pyridazinium ring, a pyrimidinium ring, a pyrazinium ring, a quinolinium ring, an isoquinolinium ring, an acridinium ring, a 3,4-benzoquinolinium ring, a 5,6-benzoquinolinium ring, a 6,7-benzoquinolinium ring, a 7,8-benzoquinolinium ring, a 3,4-benzoisoquinolinium ring, a 5,6-benzoisoquinolinium ring, a 6,7-benzoisoquinolinium ring, a 7,8-benzoisoquinolinium ring, etc. Examples of the oxygen-containing aromatic ring or sulfur-containing aromatic ring include an aromatic ring in which at least one of the carbon atom or nitrogen atom of the aromatic ring or nitrogen-containing aromatic ring not containing a heteroatom is replaced with at least one of an oxygen atom and a sulfur atom.
[0272] In the fourth aspect of the present invention, examples of the "substituent" include a hydroxyl group (-OH), an aldehyde group (formyl group), a hydroxyalkyl group, a sulfo group, a nitro group, a diazo group, an alkyl group, an unsaturated aliphatic hydrocarbon group, an aryl group, a heteroaryl group, a halogen, a mercapto group (-SH), an alkylthio group (-SR, R is an alkyl group) and the like.
[0273] In the fourth aspect of the present invention, the chain-like substituent (e.g., a hydrocarbon group such as an alkyl group or an unsaturated aliphatic hydrocarbon group) may be linear or branched unless otherwise specified, and the number of carbon atoms is not particularly limited, but may be, for example, 1 to 40, 1 to 32, 1 to 24, 1 to 18, 1 to 12, 1 to 6, or 1 to 2 (2 or more in the case of an unsaturated hydrocarbon group). In addition, in this specification, the number of ring members (the number of atoms constituting the ring) of a cyclic group (e.g., an aryl group, a heteroaryl group, etc.) is not particularly limited, but may be, for example, 5 to 32, 5 to 24, 6 to 18, 6 to 12, or 6 to 10. In addition, when an isomer exists in a substituent or the like, any isomer may be used unless otherwise specified, for example, when simply referring to a "butyl group", it may be an n-butyl group, a sec-butyl group, or a tert-butyl group, and when simply referring to a "naphthyl group", it may be a 1-naphthyl group or a 2-naphthyl group.
[0274] In the fourth aspect of the present invention, the term "protein" or "polypeptide" refers to a polymer composed of unmodified amino acids (natural amino acids), modified amino acids, and / or artificial amino acids. The polypeptide is, for example, a peptide having a length of 10 amino acids or more.
[0275] In the fourth aspect of the present invention, "glycation" refers to the modification of a protein, a polypeptide, and / or an amino acid with a sugar, for example, a reducing sugar such as glucose, fructose, lactose, etc.
[0276] In the fourth aspect of the present invention, the term "glycation reaction" refers to a condensation reaction (aminocarbonylation reaction) between an amino group-containing compound and a carbonyl group-containing compound. The amino group-containing compound may be a protein, a polypeptide, or an amino acid. The carbonyl group-containing compound may be a reducing sugar. The glycation reaction may be, for example, a Maillard reaction.
[0277] In the fourth aspect of the present invention, the term "glycation reaction product" refers to a substance produced by glycation reaction. Examples of the glycation reaction product include intermediate products and final products produced in the glycation reaction. Examples of the glycation reaction product include proteins or polypeptides containing the AGEs; proteins or polypeptides having a crosslinked structure due to AGEs; glycated proteins produced by glycation reaction; and the like. Examples of the intermediate reaction product include substances in the progress of glycation reaction, and specific examples include glyoxal, methylglyoxal, and 3-deoxyglucosone. Examples of the AGEs include pentosidine, crosslin, pyrrolysine, pyrraline, carboxymethyllysine (CML), carboxyethyllysine (CEL), carboxyethyllysine, carboxymethylarginine (CMA), argpyrimidine, imidazolone compounds, glyoxal-lysine dimer (GOLD), and methyl glyoxal-lysine dimer (MOLD).
[0278] The fourth invention of the present invention will be described in more detail below with examples. However, the fourth invention of the present invention is not limited by the following explanation. In addition, each explanation in the fourth invention of the present invention can be mutually incorporated unless otherwise specified. In this specification, when the expression "~" is used, it is used to mean including the numerical value or physical value before and after it. In addition, in this specification, the expression "A and / or B" includes "A only", "B only", and "both A and B".
[0279] <Anti-glycation composition> The anti-glycation composition of the fourth invention of the present invention contains glycerin and / or a glycerin derivative and an anti-glycation component, and the anti-glycation component contains a cyclic peroxide or a salt thereof as an active ingredient. The composition of the fourth invention of the present invention is characterized by containing the cyclic peroxide or a salt thereof, and other configurations and conditions are not particularly limited. The cyclic peroxide has the ability to decompose the crosslinked structure of AGEs, as described below. Therefore, the composition of the fourth invention of the present invention can provide an anti-glycation effect.
[0280] The composition of the fourth invention of the present invention can degrade AGEs generated by glycation reactions, for example, and therefore can be referred to as a composition for decomposing advanced glycation end products (AGEs), a composition for decomposing glycation reaction products, a composition for decomposing proteins or polypeptides having cross-linked structures due to advanced glycation end products, etc. Furthermore, the composition of the fourth invention of the present invention can repair proteins or polypeptides by removing AGEs or cross-linked structures of AGEs in glycated proteins, for example, and therefore can be referred to as a composition for repairing glycated proteins or glycated peptides.
[0281] [1. Anti-glycation component] The composition of the fourth invention of the present invention contains an anti-glycation component as described above. The composition of the fourth invention of the present invention may contain the cyclic peroxide as an active ingredient of the anti-glycation component, or may contain an oxidation reaction product containing the cyclic peroxide as described below, or may contain both. The cyclic peroxide may be a compound represented by the following chemical formula (I), or may be a cyclic peroxide contained in an oxidation reaction product obtained by oxidizing an alcohol as described below.
[0282] In the composition of the fourth invention of the present invention, the content of the anti-glycation component may be an effective amount capable of anti-glycation, more specifically, an effective amount capable of decomposing AGEs, for example, 0.001 to 10 w / v%, 0.05 to 5 w / v%, or 0.01 to 1 w / v%. In addition, in the composition of the fourth invention of the present invention, the content of the cyclic peroxide may be an effective amount capable of anti-glycation, for example, 0.001 to 10 w / v%, 0.05 to 5 w / v%, or 0.01 to 1 w / v%.
[0283] The anti-glycation component may exhibit anti-glycation activity by, for example, inhibiting the glycation reaction, thereby inhibiting the production of AGEs or the production of cross-linked structures of AGEs, or may exhibit anti-glycation activity by decomposing AGEs or cross-linked structures of AGEs generated by the glycation reaction, or may exhibit both activities.
[0284] [2. Cyclic peroxides] The cyclic peroxide is represented by the following chemical formula (I): [ka] In the above chemical formula (I), R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, may or may not have a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure, and may be a monocyclic ring or a condensed ring; R 1 is a substituent, which may be one, multiple, or absent, and when multiple, they may be the same or different.
[0285] The heteroatom refers to an atom other than carbon and hydrogen, and may be, for example, one selected from the group consisting of oxygen, nitrogen, sulfur, selenium, boron, and silicon. The substituent is not particularly limited, and may include, for example, a hydroxyl group, and may be, for example, one selected from the group consisting of the above-mentioned hydroxyl group (-OH), aldehyde group (formyl group), hydroxyalkyl group, sulfo group, nitro group, diazo group, alkyl group, unsaturated aliphatic hydrocarbon group, aryl group, heteroaryl group, halogen, mercapto group (-SH), and alkylthio group (-SR, R is alkyl group).
[0286] The cyclic peroxide is, for example, represented by the formula (I): 100 However, it may be a cyclic structure having 5 to 10 ring members.
[0287] The cyclic peroxide may be, for example, a cyclic peroxide represented by the following chemical formula (II). [ka] In the above chemical formula (II), Each R 11 may be the same or different, and each is a hydrogen atom or a substituent. Two R 11 may be joined together to form an oxo group (=O) or a thioxo group (=S).
[0288] The cyclic peroxide is, for example, R 11 In the above, each of the substituents may be a hydroxyl group (-OH), an aldehyde group (formyl group), a hydroxyalkyl group, a sulfo group, a nitro group, a diazo group, an alkyl group, an unsaturated aliphatic hydrocarbon group, an aryl group, a heteroaryl group, a halogen, a mercapto group (-SH), or an alkylthio group (-SR, where R is an alkyl group).
[0289] The cyclic peroxide may be, for example, a cyclic peroxide represented by the following chemical formula (1). The cyclic peroxide represented by the following chemical formula (1) is a cyclic peroxide represented by the following chemical formula (II) in which all R 11 is a hydrogen atom. [ka]
[0290] The method for producing the cyclic peroxide is not particularly limited, and for example, the cyclic peroxide can be produced by oxidizing an alcohol using the method for producing the oxidation reaction product described below. In this case, for example, the produced oxidation reaction product may be used as it is without purification, or only the cyclic peroxide may be isolated and purified for use.
[0291] The inventors of the present invention were the first to discover that cyclic peroxides can be obtained by the oxidation of alcohols, for example, the oxidation of glycerin with ozone. Although the mechanism by which cyclic peroxides are obtained is unclear, it is speculated that, for example, by extending the reaction time of the oxidation reaction of alcohols as described below, a reaction product different from that of conventional reactions can be obtained.
[0292] The cyclic peroxides are chemically stable and easy to handle compared to radicals, for example, and therefore can be isolated and formulated.
[0293] In general, cyclic peroxides are substances that are used industrially due to their oxidizing ability, etc. In particular, artemisinin, which has a seven-membered ring (trioxolane) skeleton similar to the structure of the cyclic peroxides, is useful as an antimalarial agent and was awarded the Nobel Prize in 2015, and its derivatives are currently being researched.
[0294] However, the supply of artemisinin was unstable when it was extracted and purified from natural products. In addition, since artemisinin is neither water-soluble nor fat-soluble, there were many challenges in formulating it. On the other hand, hydrogen peroxide is an example of a water-soluble oxidizing substance, but it is highly reactive and unstable, and has only been used externally for disinfection of living organisms.
[0295] In contrast, according to the fourth aspect of the present invention, for example, a cyclic peroxide and an oxidation reaction product that are highly safe and have excellent water solubility are used, and therefore, they can be suitably used in living organisms. In addition, in the fourth aspect of the present invention, it is presumed that an anti-glycation effect is obtained due to the oxidizing ability of the cyclic peroxide. The anti-glycation effect can be evaluated according to Example 4 described below.
[0296] In the composition of the fourth invention of the present invention, the cyclic peroxide may be a salt or a solvate such as a hydrate. The explanation of the cyclic peroxide can be applied to the explanation of the salt of the cyclic peroxide or the solvate thereof.
[0297] [3. Oxidation reaction products] As described above, the oxidation reaction product is an oxidation reaction product that is obtained by oxidizing an alcohol and contains a cyclic peroxide. However, the method for producing the oxidation reaction product is not limited to the oxidation of an alcohol, and any method for producing the oxidation reaction product may be used as long as the product has the same structure.
[0298] The method of oxidizing the alcohol is not particularly limited. For example, the oxidation of the alcohol may be at least one of ozone oxidation and hydrogen peroxide oxidation. However, as described above, the method of producing the oxidation reaction product is not limited to ozone oxidation and hydrogen peroxide oxidation of the alcohol, and any method of producing the oxidation reaction product may be used as long as the substance has the same structure.
[0299] The oxidation reaction product may be, for example, a mixture containing a plurality of oxidation reaction products.
[0300] The oxidation reaction product may have, for example, an oxidizing ability.
[0301] The oxidation reaction product may have, for example, reducing ability.
[0302] In the oxidation reaction product, the alcohol serving as a raw material is not particularly limited. For example, the alcohol in the oxidation reaction product may be a saturated alcohol.
[0303] The oxidation reaction product may be, for example, a polyhydric alcohol.
[0304] In the oxidation reaction product, for example, the alcohol may be at least one of glycerin and a glycerin derivative.
[0305] The oxidation reaction product may include, for example, an oxidation reaction product obtained by bonding two or more molecules of the alcohol.
[0306] The oxidation reaction product may include, for example, the cyclic peroxide.
[0307] The alcohol used as the raw material of the oxidation reaction product is not particularly limited, and may be, for example, a saturated alcohol or an unsaturated alcohol as described above. The alcohol may be linear or branched, and may or may not contain a cyclic structure. The alcohol may be, for example, a polyhydric alcohol or a monohydric alcohol. The valence of the polyhydric alcohol is also not particularly limited, and may be, for example, dihydric, trihydric, or tetrahydric. Examples of monohydric saturated alcohols include saturated alcohols having 1 to 40, 1 to 32, 1 to 24, 1 to 18, 1 to 12, 1 to 6, or 1 to 2 carbon atoms, and the saturated alcohol may be linear or branched, and may or may not contain a cyclic structure. Specific examples of the saturated alcohol include methanol, ethanol, n-propyl alcohol, isopropyl alcohol, n-butyl alcohol, sec-butyl alcohol, and tert-butyl alcohol. Examples of the saturated polyhydric alcohol include saturated polyhydric alcohols having 1 to 40, 1 to 32, 1 to 24, 1 to 18, 1 to 12, 1 to 6, or 1 to 2 carbon atoms. The saturated polyhydric alcohol may be linear or branched, and may or may not contain a cyclic structure. Specific examples of the saturated polyhydric alcohol include ethylene glycol (ethane-1,2-diol), propylene glycol (propane-1,2-diol), glycerin, and glycerin derivatives. The glycerin derivative is not particularly limited, and may be, for example, a polymer of glycerin or a compound in which at least one hydrogen atom of glycerin is substituted with a substituent (for example, an alkyl group). Examples of the glycerin derivative include diglycerin and polyglycerin. The glycerin derivative may be an oxidized product of glycerin.
[0308] The oxidation reaction product may be, for example, a substance having reducing ability, as described above. For example, the oxidation reaction product may have a functional group having reducing ability, and thus have reducing ability derived from the functional group. Specifically, for example, the oxidation reaction product may have reducing ability due to having an aldehyde group (formyl group), and may have reducing ability derived from the keto body due to being a keto-enol tautomer. For example, the oxidation reaction product obtained in Example 4 described later contains an acetal structure in the skeleton as confirmed by NMR, and is therefore considered to develop color in a DNPH (dinitrophenylhydrazine: ketone-aldehyde derived) reaction derived from a ketone or aldehyde.
[0309] The oxidation reaction product may be, for example, a substance obtained by binding two or more molecules of the alcohol as described above. Specifically, for example, the oxidation reaction product may be a structure in which two or more molecules of the alcohol are bound and further oxidized. The form of "binding" of the two or more molecules of the alcohol is not particularly limited, and may be, for example, addition, condensation, etc.
[0310] The oxidation reaction product is chemically stable and easy to handle compared to radicals, for example, and therefore can be isolated and formulated.
[0311] [4. Method for producing oxidation reaction product] As described above, the method for producing the oxidation reaction product includes an alcohol oxidation step of oxidizing the alcohol.
[0312] In the alcohol oxidation step, the method for oxidizing the alcohol is not particularly limited. In the method for producing the oxidation reaction product, for example, in the alcohol oxidation step, the alcohol may be oxidized by at least one of ozone oxidation and hydrogen peroxide oxidation.
[0313] In the method for producing the oxidation reaction product, the reaction time of the alcohol oxidation step is not particularly limited. The reaction time of the alcohol oxidation step may be, for example, 24 hours or more or 1 day or more, 48 hours or more or 2 days or more, 72 hours or more or 3 days or more, 120 hours or more or 5 days or more, or 168 hours or more or 7 days or more. The upper limit of the reaction time of the alcohol oxidation step is not particularly limited, but may be, for example, 720 hours or less or 30 days or less, or 360 hours or less or 15 days or less.
[0314] In the method for producing the oxidation reaction product, in order to obtain a reaction product containing the cyclic peroxide, it is preferable to extend the reaction time of the alcohol oxidation step. For example, it is considered that by extending the reaction time of the alcohol oxidation step, the cyclic peroxide that could not be obtained by conventional ozone oxidation reaction of glycerin can be produced. In the method for producing the oxidation reaction product, it is preferable that the reaction time of the alcohol oxidation step is not too long in order to ensure production efficiency.
[0315] As described above, the method for producing the oxidation reaction product includes an alcohol oxidation step of oxidizing the alcohol. However, as described above, the oxidation reaction product is not limited to a substance produced by this production method, and may be a substance produced by any production method as long as it has the same structure. Hereinafter, the method for producing the oxidation reaction product will be described in more detail with reference to examples.
[0316] In the following, an example will be described in which glycerin is used as the alcohol and ozone oxidation is performed. However, as described above, the following description is merely an example, and the method for producing the oxidation reaction product is not limited to the following description. For example, the following method can be performed in the same manner using other alcohols instead of glycerin. For example, in the method for producing the oxidation reaction product, the method for oxidizing the alcohol in the alcohol oxidation step is not particularly limited and is optional, and is not limited to ozone oxidation. The oxidation method may be, for example, at least one of ozone oxidation and hydrogen peroxide oxidation. In addition, for example, not only the type of alcohol and the method for oxidizing the alcohol, but also the concentration of each substance, reaction temperature, reaction time, and other reaction conditions can be appropriately changed.
[0317] The oxidation reaction product can be produced by a production method including a step of oxidizing glycerin by contacting glycerin with ozone, more specifically, by mixing glycerin with ozone (corresponding to the above-mentioned "alcohol oxidation step"). The step of oxidizing glycerin may be, for example, a step of oxidizing glycerin by gas-liquid contacting a glycerin solution with a gas containing ozone.
[0318] The glycerin solution preferably has a high concentration of glycerin. As the high concentration glycerin solution, for example, a glycerin solution having a glycerin concentration of 75% or more can be used. Specifically, a glycerin solution having a glycerin concentration of 84 to 87% by weight as specified in the Japanese Pharmacopoeia is preferable, a concentrated glycerin solution having a glycerin concentration of 98% by weight or more as specified in the Japanese Pharmacopoeia is more preferable, and a purified glycerin solution having a concentration of 98.5% by weight or more is even more preferable. The glycerin solution can treat ozone at a higher concentration, for example, as the glycerin concentration is relatively higher. In the glycerin solution, the solvent for glycerin is not particularly limited, and is, for example, an aqueous solvent such as water.
[0319] The ozone-containing gas preferably has a high ozone concentration. The method for producing the gas with a high ozone concentration is not particularly limited, and for example, an ozone generator that generates ozone by silently discharging oxygen gas can be used. When oxygen gas is used, for example, a medical oxygen cylinder can be used, or oxygen gas produced by an oxygen generator can be used.
[0320] The method of gas-liquid contact between the glycerin solution and the ozone-containing gas is not particularly limited, and for example, there is a method in which a high-concentration (e.g., 98% by weight or more) glycerin solution is placed in a tank, and the gas with a high ozone concentration is released into the tank as fine bubbles using an air diffuser. Specifically, for example, an ozone-treated glycerin solution with an equivalent hydrogen peroxide concentration of about 4000 ppm can be produced by aerating a gas with an ozone concentration of about 37000 ppm into the concentrated glycerin solution for about 7 days. The aeration time is not particularly limited, and for example, an ozone-treated glycerin solution containing the oxidation reaction product at a higher concentration can be produced by aerating for a relatively longer period of time.
[0321] The oxidation reaction product may be used as it is without being separated from the mixture after the reaction (e.g., the ozone-treated glycerin solution), or may be used after being separated from the mixture after the reaction. The method for separation is not particularly limited, but for example, the oxidation reaction product can be separated from the mixture after the reaction by chromatography such as preparative thin layer chromatography.
[0322] Conventionally, production of substances such as peroxides having oxidizing power required a complicated system. According to the method for producing an oxidation reaction product, for example, an oxidation reaction product having oxidizing power can be produced in a very simple and easy manner.
[0323] The oxidation reaction product can generate, for example, hydrogen peroxide. The oxidation reaction product can generate, for example, 1 to 4000 ppm, 10 to 4000 ppm, or 100 to 4000 ppm of hydrogen peroxide per about 4000 ppm of the oxidation reaction product in terms of hydrogen peroxide concentration.
[0324] [5. Glycerin] In the composition of the fourth invention of the present invention, the glycerin may be glycerin or the above-mentioned glycerin derivative. In the composition of the fourth invention of the present invention, the cyclic peroxide can be stably maintained by coexisting with the glycerin.
[0325] In the composition of the fourth aspect of the present invention, the content of the glycerin is, for example, 0.1 to 100 w / v %, preferably 0.1 to 50 w / v %.
[0326] [6. Other Ingredients] The composition of the fourth invention of the present invention may contain other components added to the formulation to be applied to the skin. Specific examples of the other components include components added to skin external preparations and components added to cosmetics (including quasi-drugs). Examples of the components added to the skin external preparations include pharma- ceutically acceptable carriers. Examples of the other components include components added when applied to the skin or when applied transdermally, and specific examples include aqueous solvents such as water, alcohols, moisturizers, oils, softeners (emollients), surfactants (solubilizers, emulsifiers), salts, thickeners, pH adjusters, ultraviolet absorbers, drugs, buffers, colorants, preservatives, fragrances, etc.
[0327] [7. Dosage form, method of use, and application] The composition of the fourth invention of the present invention is, for example, a solid or liquid form. The form of the composition of the fourth invention of the present invention can be, for example, a lotion form; an emulsion form such as a milky lotion or cream; an oil form: a gel form; an ointment, a pack, a cleanser, etc.
[0328] The subject of the use of the composition of the fourth invention of the present invention is human or non-human animal. The composition of the fourth invention of the present invention can be used, for example, on the skin of the subject. The amount of the composition of the fourth invention of the present invention used is not particularly limited, and can be the amount normally used according to the dosage form of the composition of the fourth invention of the present invention.
[0329] The composition according to the fourth aspect of the present invention can be suitably used as an external preparation for the skin, such as a cosmetic product.
[0330] <Anti-glycation agent> The anti-glycation agent of the fourth invention of the present invention contains a cyclic peroxide or a salt thereof. The anti-glycation agent of the fourth invention of the present invention is characterized by containing a cyclic peroxide or a salt thereof, and other configurations and conditions are not particularly limited. As described below, the cyclic peroxide has the ability to decompose the crosslinked structure of AGEs. Therefore, the anti-glycation agent of the fourth invention of the present invention can obtain an anti-glycation effect.
[0331] The anti-glycation agent of the fourth invention of the present invention can degrade AGEs generated by glycation reactions, and therefore can also be referred to as an agent for decomposing advanced glycation end products (AGEs), an agent for decomposing glycation reaction products, an agent for decomposing proteins or polypeptides having cross-linked structures due to advanced glycation end products, etc. Furthermore, the anti-glycation agent of the fourth invention of the present invention can repair proteins or polypeptides by removing the cross-linked structures of AGEs or AGEs in glycated proteins, and therefore can also be referred to as an agent for repairing glycated proteins or glycated peptides.
[0332] In the anti-glycation agent of the fourth invention of the present invention, the content of the anti-glycation component may be an effective amount capable of anti-glycation, more specifically, an effective amount capable of decomposing AGEs, for example, 0.001 to 10 w / v%, 0.05 to 5 w / v%, or 0.01 to 1 w / v%. Also, in the anti-glycation agent of the fourth invention of the present invention, the content of the cyclic peroxide may be an effective amount capable of anti-glycation, for example, 0.001 to 10 w / v%, 0.05 to 5 w / v%, or 0.01 to 1 w / v%.
[0333] In the anti-glycation agent of the fourth invention of the present invention, the cyclic peroxide may be a compound represented by the following chemical formula (I), or may be a cyclic peroxide contained in an oxidation reaction product obtained by oxidizing the above-mentioned alcohol. [ka] In the above chemical formula (I), R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, may or may not have a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure, and may be a monocyclic ring or a condensed ring; R 1 is a substituent, which may be one, multiple, or absent, and when multiple, they may be the same or different.
[0334] The explanation of the cyclic peroxide and the oxidation reaction product can be cited from the explanation of the composition of the fourth invention of the present invention.
[0335] The explanation of the dosage form and use of the anti-glycation agent of the fourth invention of the present invention can be cited from the explanation of the composition of the fourth invention of the present invention.
[0336] <Anti-glycation method> The anti-glycation method of the fourth invention of the present invention uses the anti-glycation composition of the fourth invention of the present invention and / or the anti-glycation agent of the fourth invention of the present invention. The anti-glycation method of the fourth invention of the present invention is characterized by using the composition of the fourth invention of the present invention and / or the anti-glycation agent of the fourth invention of the present invention, and other steps and conditions are not particularly limited. The cyclic peroxide contained in the composition and / or the anti-glycation agent of the fourth invention of the present invention has the ability to decompose the crosslinked structure of AGEs, as described below. Therefore, according to the anti-glycation method of the fourth invention of the present invention, an anti-glycation effect can be obtained.
[0337] The anti-glycation method of the fourth invention of the present invention can be carried out, for example, by applying the composition and / or the anti-glycation agent to the skin of the subject. More specifically, the anti-glycation method of the fourth invention of the present invention can be carried out by contacting the composition and / or the anti-glycation agent to the skin of the subject.
[0338] The anti-glycation method of the fourth invention in the present invention includes, for example, in In vitro or in vivo This will be carried out.
[0339] <Use> The fourth invention of the present invention is an anti-glycation composition of the fourth invention of the present invention and / or an anti-glycation agent of the fourth invention of the present invention for use in anti-glycation, or use thereof. EXAMPLES
[0340] Examples of the present invention will be described below, but the present invention is not limited to the following examples.
[0341] [Example of the first aspect of the invention] First, the first invention of the present invention will be described. However, the first invention of the present invention is not limited to the following examples. Commercially available reagents were used according to their protocols unless otherwise specified.
[0342] [Example 1] An oxidation reaction product containing the cyclic peroxide of the first invention of the present invention was produced by ozone oxidation of glycerin. Furthermore, the oxidation ability and TRP channel activity of the produced oxidation reaction product were confirmed. This example corresponds to an example in which the cyclic peroxide of the first invention of the present invention was produced and used, and also corresponds to an example in which the oxidation reaction product of the first invention of the present invention was produced and used, and further corresponds to an example of a method for producing the oxidation reaction product of the first invention of the present invention.
[0343] (1) Production of an oxidation reaction product containing the cyclic peroxide of the first aspect of the present invention Concentrated glycerin was subjected to gas-liquid contact with ozone to produce an ozone-treated glycerin solution (ozone gel) containing the oxidation reaction product of the first invention of the present invention, as described below. Here, the concentrated glycerin means glycerin having a concentration of 98% by weight or more of the Japanese Pharmacopoeia product. In addition, the oxidation reaction product of the first invention of the present invention produced in this example contains the cyclic peroxide of the first invention of the present invention, as described below.
[0344] A 50 L Teflon tank was used as the contact tank. An aeration tube was installed at the bottom of the tank, so that ozone could be supplied into the tank as fine bubbles. A silent discharge ozone generator was used, which uses high-concentration oxygen gas containing 90% or more by volume as the raw material and has an ozone generating capacity of 100 g per hour.
[0345] 22 kg of the concentrated glycerin was placed in the tank, and 20 L of the high-concentration oxygen gas was fed into the ozone generator at a rate of 20 L per minute to generate a gas containing ozone. The generated gas was released from the air diffuser into the tank for 7 days or more to obtain a glycerin solution in which ozone oxidants of glycerin were dissolved at a final concentration of 4000 ppm. This ozone oxidant of glycerin corresponds to the oxidation reaction product of the first aspect of the present invention. Furthermore, this ozone oxidant contained the cyclic peroxide of the first aspect of the present invention, as described below.
[0346] (2) Analysis of reaction mixture Glycerin was removed from the glycerin solution containing the ozone oxidized product of glycerin produced in the above "(1) Production of an oxidation reaction product containing the cyclic peroxide of the first invention of the present invention" using a silica gel column to obtain a reaction mixture containing the cyclic peroxide of the first invention of the present invention (hereinafter sometimes referred to as "TLC1 spot product"). As described below, the cyclic peroxide of the first invention of the present invention was not separated from this TLC1 spot product and was used as it was to confirm the oxidizing ability and TRP channel activity of the cyclic peroxide of the first invention of the present invention.
[0347] The NMR spectrum of the reaction mixture (TLC 1 spot) was measured at 300K (27°C) using DMSO-d6 as a solvent. The spectrum is shown in Figures 1-1 to 1-6. Figure 1-1 shows 1 1 H NMR spectrum. 13 C NMR spectrum. 13 C DEPT135 NMR spectrum. Figure 1-4 is a COSY NMR spectrum. Figure 1-5 is an HSQC NMR spectrum. Figure 1-6 is an HMBC NMR spectrum. As shown in Figures 1-1 to 1-6, complex peaks were observed, so it was speculated that the TLC1 spot was a mixture of multiple substances. Furthermore, according to LCMS, this TLC1 spot contained m / z 198,203 components.
[0348] (3) Separation and analysis of the reaction mixture The reaction mixture (TLC 1 spot product) was adjusted (diluted) to about 3% by mass with acetonitrile, filtered through a membrane filter, and the filtrate was subjected to LC measurement to optimize the separation conditions. Next, the mass of the peak observed in the LC measurement under the optimized conditions was confirmed, and precise separation of Mw=180 (peak 2) was performed. The obtained fraction solution was then freeze-dried, and the dried fraction was subjected to microscopic LR measurement and various NMR measurements. The measurement equipment (analyzer) and measurement conditions are as follows. [Measuring equipment (analyzer)] 1) Precision preparative LC: Waters, ACQUITY UPLC H-class Bio 2) Microscope LR: SNOM / AFM / Raman combination machine WITec alpha300RSA 3)NMR:Bruker Biospin,AVANCEIII-600 with Cryo Probe [Measurement conditions] 1)Precision preparative LC Column: Shodex Asahipak NH2P-50 (4.6 mmφ × 250 mm, 5 μm) Eluent composition: Water / acetonitrile gradient Time(min): 0 5 15 20 Wed: 5 10 50 50 Acetonitrile: 95 90 50 50 Flow rate: 1.0mL / min Detector: MS (QDa) Column temperature: 40℃ Injection volume: 50μL Ionization method: ESI (NEG.) Measurement mass range (m / z): 50-500 2) Microscope LR Excitation wavelength: 532 nm Measurement wave number range: approx. 125 to 3800 cm -1 Objective lens: x100 Detector: EMCCD 3) NMR Observation frequency: 600MHz ( 1 H), 150MHz ( 13 C) Measurement solvent: methanol-d4 Measurement temperature: 300K Chemical shift standard: measurement solvent [3.30 ppm ( 1 H), 49.80 ppm ( 13 C)]
[0349] FIG. 1-7 shows total ion chromatograms (ESI-negative mode) in the precision preparative LC (liquid chromatography) of a sample prepared (diluted) with acetonitrile to about 3% by mass of the reaction mixture (TLC1 spot product) and a blank. In FIG. 1-7, the vertical axis is intensity and the horizontal axis is retention time (min). In FIG. 1-7, the lower row "synthetic OG" is a chromatogram of the TLC1 spot product sample, and the upper row is a chromatogram of the blank (acetonitrile). As shown in the figure, components A to L were confirmed in the TLC1 spot product. Components A to L were separated and the presence or absence of coloring was confirmed with potassium iodide starch test paper, and component H was the most strongly colored.
[0350] Figure 1-8 also shows the mass spectra of peaks F, G, and H (F fraction, G fraction, and H fraction) in Figure 1-7. In Figure 1-8, the vertical axis represents intensity, and the horizontal axis represents mass-to-charge ratio (m / z). As shown in the figure, it was confirmed that peak F had Mw=180, peak G had Mw=226, and peak H had Mw=256.
[0351] Furthermore, FIG. 1-9 shows the results of the study on the improvement of separation (improvement of separation conditions) in HILIC (high performance liquid chromatography). In FIG. 1-9, the vertical axis is intensity, and the horizontal axis is retention time (min), which is the same for FIG. 1-17 to FIG. 1-19. In FIG. 1-9, the upper part is a chromatogram before separation improvement (same conditions as FIG. 1-8), and the lower part is a chromatogram after separation improvement. As shown in the figure, peaks 1 to 8 were observed after separation improvement. The molecular weights of the respective peaks were confirmed to be as shown in FIG. 1-9 by the mass spectrum described later.
[0352] Figure 1-10 shows the mass spectra (after improved separation) of peaks 1 to 3 in Figure 1-9. In Figure 1-10, the upper part is the mass spectrum of peak 1, the middle part is the mass spectrum of peak 2, and the lower part is the mass spectrum of peak 3. As shown in the figure, it was confirmed that peak 1 had Mw=196, peak 2 had Mw=180, and peak 3 had Mw=240.
[0353] Figure 1-11 shows the mass spectrum (after improved separation) of peaks 4 to 6 in Figure 1-9. In Figure 1-11, the upper part is the mass spectrum of peak 4, the middle part is the mass spectrum of peak 5, and the lower part is the mass spectrum of peak 6. As shown in the figure, it was confirmed that peak 4 has Mw=240, peak 5 has Mw=240, and peak 6 has Mw=226.
[0354] Figure 1-12 shows the mass spectrum (after improved separation) of peaks 7 and 8 in Figure 1-9. In Figure 1-12, the upper part is the mass spectrum of peak 7, and the lower part is the mass spectrum of peak 8. As shown in the figure, it was confirmed that both peaks 7 and 8 have Mw=256.
[0355] FIG. 1-13 shows the micro-Raman spectrum of the sample of peak 2 (Mw=180) in FIG. 1-9 and the ozonide standard (ozonized oleic acid). In FIG. 1-13, the vertical axis is the intensity, and the horizontal axis is the Raman shift (1 / cm). As shown in FIG. 1-13, peak 2 (Mw=180) showed a micro-Raman spectrum similar to that of ozonide, and was therefore presumed to show a structure similar to that of ozonide. In addition, the micro-Raman spectrum of peak 2 (Mw=180) showed a pattern different from that of peroxide, and therefore peak 2 (Mw=180) was presumed not to be a peroxide. It was confirmed by NMR described later that peak 2 (Mw=180) was the cyclic peroxide of the first invention of the present invention.
[0356] Figure 1-14 shows the peak 2 (Mw=180) in Figure 1-9. 1 The H NMR spectrum is shown. The measurement solvent was methanol-d4 (CD3OD). In the figure, the upper spectrum is an enlarged view of the lower spectrum around 3.4 to 4.9 ppm. 1 Based on the H NMR assignment, Mw=180, and other instrumental analysis data, the structure of the oxidation reaction product of peak 2 (Mw=180) was proven to be a cyclic peroxide represented by the following chemical formula (1). 1In the H NMR spectrum, the peaks indicated by symbols A to F were assigned to the peaks of hydrogen bonded to the carbon atoms indicated by the same symbols A to F in the following chemical formula (1) shown in Figure 1-14. It is also presumed that a small amount of the raw material glycerin remained, and its peak was also detected.
[0357] [ka]
[0358] Figure 1-15 shows the peak 2 (Mw=180) in Figure 1-9. 13 The C NMR spectrum is shown. The measurement solvent was methanol-d4 (CD3OD). In the figure, the upper spectrum is an enlarged view of the lower spectrum around 60 to 105 ppm. 13 Based on the C NMR assignment, Mw=180, and other instrumental analysis data, it was demonstrated that the structure of the oxidation reaction product of peak 2 (Mw=180) is a cyclic peroxide represented by the above chemical formula (1). 13 In the C NMR spectrum, the peaks indicated by symbols A to F were assigned to the peaks of the carbon atoms indicated by the same symbols A to F in the following chemical formula (1) shown in Figure 1-15. In addition, it is presumed that a small amount of the raw material glycerin remained, and its peak was also detected.
[0359] Figure 1-16 shows the two-dimensional ( 1 H- 13The C COSY) NMR spectrum is shown. Methanol-d4 (CD3OD) was used as the measurement solvent. From this 2D NMR assignment, the fact that Mw=180, and other instrumental analysis data, it was demonstrated that the structure of the oxidation reaction product of peak 2 (Mw=180) is a cyclic peroxide represented by the above chemical formula (1). In the 2D NMR spectrum of FIG. 1-16, the peaks indicated by symbols A to F were assigned to the carbon atoms and hydrogen atoms bonded to those carbon atoms represented by the same symbols A to F in the following chemical formula (1) shown in FIG. 1-16. In addition, it is estimated that a small amount of glycerin, the raw material, remained, and its peak was also detected.
[0360] Figure 1-17 also shows the HILIC chromatograms of the TLC1 spot product and glyceraldehyde dimer under the HILIC (high performance liquid chromatography) conditions of Figure 1-9. In Figure 1-17, the "synthetic OG" in the upper row is the HILIC chromatogram of the TLC1 spot product. The lower row is the HILIC chromatogram with glyceraldehyde dimer. As shown in the figure, glyceraldehyde dimer was not detected under the HILIC conditions of Figure 1-9.
[0361] Figure 1-18 shows the HILIC chromatograms of the TLC1 spot product and glyceraldehyde dimer under reversed-phase HILIC (high performance liquid chromatography) conditions. Figure 1-19 shows an enlarged view of a portion of Figure 1-18. In Figures 1-18 and 1-19, the upper row of "synthetic OG" is the HILIC chromatogram of the TLC1 spot product. The lower row is the HILIC chromatogram with glyceraldehyde dimer. As shown in the figure, component separation of the TLC1 spot product could not be confirmed under reversed-phase HILIC conditions. This is thought to be because the column retention was weak and the elution time of the TLC1 spot product was fast. On the other hand, the retention time of the glyceraldehyde dimer was slightly different from that of the TLC1 spot product (synthetic OG). From this, it is inferred that the TLC1 spot product did not contain glyceraldehyde dimer.
[0362] Figure 1-20 shows the ESR spectrum of the TLC1 spot product and peak 2 (Mw=180) in Figure 1-9. In Figure 1-20, the vertical axis is intensity and the horizontal axis is magnetic flux density (G). Water was used as the measurement solvent. As shown in the figure, the spectra of the TLC1 spot product and peak 2 (Mw=180) component in Figure 1-9 almost completely overlap, and the peak appearance positions are almost completely identical for both. Both the TLC1 spot product and peak 2 (Mw=180) component in Figure 1-9 showed the spectrum of DMPO (spin trap agent) characterized by six lines. This spectral pattern is similar to that of ozonide.
[0363] Figure 1-21 shows the ESR spectrum of ozonized methyl linolenate. Acetone was used as the measurement solvent. Ozonized methyl linolenate is a known ozonide. As shown in the figure, the ESR spectrum of ozonized methyl linolenate shows a spectrum in the presence of DMPO (a spin trapping agent) that is characterized by six lines, which are characteristic of ozonides. This spectrum pattern is similar to the pattern of the TLC 1 spot and peak 2 (Mw=180) in Figure 1-20.
[0364] Figure 1-22 shows the ESR spectrum of peaks 1 to 8 in Figure 1-9. Water was used as the measurement solvent. The top is an ESR spectrum of a blank (solvent only) for comparison. As shown in the figure, it was confirmed that all of the components of peaks 1 to 8 have radical activity.
[0365] The graph in Figure 1-23 shows the results of measuring the activity of peaks 1 to 8 in Figure 1-9 by chemiluminescence. In this figure, the vertical axis is the luminescence intensity (relative intensity) at all wavelengths. The numbers "1" to "8" on the horizontal axis indicate each fraction of peaks 1 to 8. The numbers below each number indicate the molecular weight of each fraction confirmed by mass spectrometry. As shown in the figure, it was confirmed that components that show activity by chemiluminescence were generated in addition to the molecular weight of 180.
[0366] (4) Confirmation of TRP channel activity The TLC1 spot product produced in the above "(1) Production of oxidation reaction product containing cyclic peroxide of the first invention of the present invention" was used as it is without fractionation (purification) to confirm TRP channel activity. In the following, "G" indicates glycerin that is not oxidized by ozone. In the following, "OG" indicates glycerin oxidized by ozone using an oxygen generator (ozonized glycerin). In the production of "OG", the ozone oxidation of glycerin using an oxygen generator was performed under the following condition A using a gas with an ozone concentration of about 37000 ppm obtained by converting air into high-concentration oxygen (oxygen concentration of 70% or more) using an oxygen generator and ozonizing the oxygen via an ozone generator. In the following, "LOG" indicates "OG" that has been further oxidized. The production of "LOG" by oxidation of "OG" was performed under the following condition B using a gas with an ozone concentration of about 37000 ppm obtained by ozonizing oxygen from an oxygen cylinder (oxygen concentration of 99% or more) via an ozone generator. That is, the "LOG" below is the same as the glycerin solution in which ozone oxidized glycerin is dissolved at a final concentration of 4000 ppm, which was produced in the above "(1) Production of an oxidation reaction product containing a cyclic peroxide according to the first aspect of the present invention". Therefore, the "LOG" below is the glycerin solution of the TLC 1 spot product. In addition, in the following, "HOG" refers to "OG" heated (heat-treated) at 80°C for 168 hours. (Condition A: Production of "OG") Glycerin with a concentration of 98% by weight or more ("G", i.e., non-ozonized glycerin) was placed in a tank. Next, using an air diffuser, the gas with an ozone concentration of about 37,000 ppm was aerated into "G" in the tank for about 7 days, and a glycerin solution in which ozone oxidized products of glycerin were dissolved at a final concentration of 4,000 ppm was obtained. This ozone-treated glycerin solution was used as "OG". (Condition B: Production of "LOG") The "OG" produced under the condition A was placed in a tank. Next, the gas with an ozone concentration of about 37000 ppm was aerated into the "OG" in the tank for about 7 days using an aeration tube, to produce an ozone-treated glycerin solution with a hydrogen peroxide concentration of 2000 ppm. This ozone-treated glycerin solution was used as "LOG".
[0367] Figure 1-24 shows the effect of adding G, OG, LOG and HOG to TRPM2 (expressing cells) and Vector (TRPM2 non-expressing cells). The graph on the left side of Figure 1-24 is a graph for TRPM2 (expressing cells), and the graph on the right side is a graph for Vector (TRPM2 non-expressing cells). The horizontal axis indicates time (seconds). G, OG, LOG and HOG were added at 120 seconds (2 minutes). G, OG, LOG and HOG were each used as a 10% by mass aqueous solution. The vertical axis indicates intracellular Ca 2+ The graph at the bottom of Figure 1-24 shows the net intracellular Ca 2+ As shown in the figure, G, OG and LOG increased intracellular Ca2+ levels relative to HOG. 2+ The large increase confirmed that TRP channel activity was high, and that OG and LOG had higher TRP channel activity than G.
[0368] For G and OG, the TRP channel activity against TRPM2 (expressing cells) was confirmed under the same conditions as in Figure 1-24, except that the concentration (mass%) of the aqueous solution was changed. The results are shown in Figure 1-25. The graph on the left side of Figure 1-25 shows the results for G, and the graph on the right side of Figure 1-25 shows the results for OG. The horizontal axis shows time (seconds). The vertical axis shows intracellular Ca 2+ The graph at the bottom of Figure 1-25 shows the changes in the concentrations of G and OG (horizontal axis, mass%) and the net intracellular Ca 2+ The correlation between the amount of increase (vertical axis) and the amount of increase (vertical axis) is shown. As shown in the figure, G had higher TRP channel activity at high concentrations, but OG showed high TRP channel activity even at low concentrations.
[0369] For G, OG, LOG, and HOG, the TRP channel activity against TRPM2 (expressing cells) was confirmed under the same conditions as in Figure 1-24, except that the concentration of the aqueous solution was changed from 10% by mass to 1% by mass. The results are shown in Figure 1-26. The horizontal axis shows time (seconds). The vertical axis shows intracellular Ca 2+ As shown in Figure 1-26, under these conditions, only LOG showed high TRP channel activity.
[0370] For LOG and OG, the TRP channel activity against TRPM2 (expressing cells) was confirmed under the same conditions as in Figure 1-24, except that 500 units / ml of catalase was added, and compared with the case where catalase was not added. The results are shown in Figure 1-27. The graph on the left side of Figure 1-27 shows the results for LOG, and the graph on the right side of Figure 1-27 shows the results for OG. The horizontal axis shows time (seconds). The vertical axis shows intracellular Ca 2+ The graphs at the bottom of Figure 1-27 show the net intracellular Ca concentration changes for LOG and OG with and without catalase added. 2+ The increase in TRP channel activity was confirmed by adding catalase to both OG and LOG.
[0371] For OG and LOG, the TRP channel activity against TRPM2 (expressing cells) was confirmed under the same conditions as in Figure 1-24, except that the concentration (mass%) of the aqueous solution was changed. The results are shown in Figure 1-28. The graph on the left side of Figure 1-28 shows the results for OG, and the graph on the right side of Figure 1-28 shows the results for LOG. The horizontal axis shows time (seconds). The vertical axis shows intracellular Ca 2+ The graph at the bottom of Figure 1-28 shows the concentration change of OG and LOG (horizontal axis) and intracellular Ca 2+ The correlation with concentration change (vertical axis) is shown. As shown in the figure, LOG showed high TRP channel activity even at a 1000-fold dilution, but OG at the same concentration showed no TRP channel activity.
[0372] For 0.1 mass% LOG, TRP channel activity for TRPM2 (expressing cells) was confirmed under the same conditions as in Figure 1-24, except that catalase was added at 100 units / ml or PJ34 (trade name of Chemscene) was added at 1 μm, and compared with the results when catalase and PJ34 were not added. The results are shown in Figure 1-29. The graph in the upper left of Figure 1-29 shows the comparison results between the cases where catalase was added and not added. The graph in the lower left of Figure 1-29 shows the comparison results between the cases where PJ34 was added and not added. The horizontal axis shows time (seconds). The vertical axis shows intracellular Ca 2+ The graph in the upper right of Figure 1-29 shows the net intracellular Ca concentration change with and without catalase (Control). 2+ The vertical axis indicates the increase in intracellular Ca2+ (Ca2+) in the control group. 2+ The increase in activity (vertical axis) is shown. As shown in the figure, it was confirmed that the addition of either catalase or PJ34 inactivated TRP channel activity. PJ34 is a substance represented by the following chemical formula:
[0373] [ka]
[0374] For 0.1% by mass LOG, TRP channel activity for TRPM2 (expressing cells) was confirmed under the same conditions as in Figure 1-24, except that 100 μM dipyridyl (α,α'-dipyridyl) was added, and compared with the case where dipyridyl was not added. The results are shown in Figure 1-30. The graph on the left side of Figure 1-30 shows the comparison results between the case where dipyridyl was added and the case where it was not added. The horizontal axis indicates time (seconds). The vertical axis indicates intracellular Ca 2+ The graph on the right side of Figure 1-30 shows the net intracellular Ca concentration change with and without the addition of dipyridyl (Control). 2+ The increase in activity (vertical axis) is shown. As shown in the figure, it was confirmed that the addition of dipyridyl inactivated TRP channel activity.
[0375] For LOG, the TRP channel activity for each cell was confirmed under the same conditions as in Figure 1-24, except that the concentration of the aqueous solution (mass%) was changed and TRPM1 HEK (expressing cells) or HEK (expressing cells) was used instead of TRPM2 (expressing cells). The results are shown in Figure 1-31. The graph in the upper left of Figure 1-31 shows the results for TRPM1 HEK (expressing cells), and the graph on the right of Figure 1-31 shows the results for HEK (expressing cells). The horizontal axis shows time (seconds). The vertical axis shows intracellular Ca 2+ The graph at the bottom of Figure 1-31 shows the change in LOG concentration (horizontal axis, mass%) and net intracellular Ca 2+ The correlation between the amount of increase (vertical axis) and the amount of increase (vertical axis) is shown. As shown in the figure, LOG showed TRP channel activity in TRPM1 HEK (expressing cells), but showed almost no TRP channel activity in HEK (expressing cells).
[0376] The TLC1 spot product was further purified so that the component with a molecular weight of 180 was the main component. This component was used at various concentrations to verify the TRP channel activity for TRPM2 (expressing cells) and TRPMA1 (expressing cells) in the same manner as in Figure 1-31. The results are shown in Figures 1-32 and 1-33. In Figures 1-32 and 1-33, "F7" indicates the component obtained by purifying the TLC1 spot product described above so that the component with a molecular weight of 180 was the main component. As shown in Figures 1-32 and 1-33, F7 did not exhibit TRP channel activity for TRPM2, but did exhibit TRP channel activity for TRPA1 (expressing cells).
[0377] As described above, according to this Example 1, a TRP channel activator having oxidizing power could be produced from glycerin, which is a substance that is not an olefin and has no double bonds, in a simple manner by ozone oxidation.
[0378] The TLC1 spot was separated into peaks 1-8 in Figure 1-9, and the TRP channel activity was confirmed in the same manner as described above by separating them into glycerin solutions of the same concentration as OG. As a result, it was confirmed that all of peaks 1-8 had TRP channel activity, and therefore had oxidizing power. However, it was confirmed that OG, which was a mixture of peaks 1-8, had stronger TRP channel activity than any of peaks 1-8, and therefore had stronger oxidizing power.
[0379] [Example of the second invention]
[0380] Next, the above-mentioned Example 2 will be described. However, the second invention of the present invention is not limited to the following Example. Commercially available reagents were used according to their protocols unless otherwise specified.
[0381] [Example 2] An oxidation reaction product containing the cyclic peroxide was produced by ozone oxidation of glycerin. Furthermore, the skin whitening effect of the produced oxidation reaction product was confirmed. This example corresponds to an example in which the cyclic peroxide was produced and used, as well as an example in which the oxidation reaction product was produced and used, and further corresponds to an example of a method for producing the oxidation reaction product.
[0382] (1) Production of an oxidation reaction product containing the cyclic peroxide Concentrated glycerin was subjected to gas-liquid contact with ozone to produce an ozone-treated glycerin solution (ozonized glycerin) containing the oxidation reaction product as described below. Here, concentrated glycerin means glycerin having a concentration of 98% by weight or more of the Japanese Pharmacopoeia product. The oxidation reaction product of the second invention of the present invention produced in this example contains the cyclic peroxide of the second invention of the present invention, as described below.
[0383] A 50 L Teflon tank was used as the contact tank. An aeration tube was installed at the bottom of the tank, so that ozone could be supplied into the tank as fine bubbles. A silent discharge ozone generator was used, which uses high-concentration oxygen gas containing 90% or more by volume as the raw material and has an ozone generating capacity of 100 g per hour.
[0384] 22 kg of the concentrated glycerin was placed in the tank, and 20 L of the high-concentration oxygen gas was fed into the ozone generator at a rate of 20 L per minute to generate a gas containing ozone. The generated gas was released from the air diffuser into the tank for 7 days or more to obtain a glycerin solution in which ozone oxidized glycerin was dissolved at a final concentration of 4000 ppm. This ozone oxidized glycerin corresponds to the oxidation reaction product. In addition, this ozone oxidized glycerin contained the cyclic peroxide, as described below. The whitening activity of the ozone oxidized glycerin containing the peroxide was confirmed.
[0385] (2) Confirmation of whitening effect The subjects were 48 healthy women (aged 41 years or older and 59 years or younger). Each subject was fully informed in advance based on an explanatory document (including a consent form), and written consent was obtained.
[0386] To confirm the whitening effect, the test samples of Example 2-1A, Example 2-1B, Reference Example 2-1A, and Reference Example 2-1B were prepared. Specifically, the test sample of Example 2-1A was prepared by adding an equal amount of water to the ozonized glycerin of Example 2(1) to obtain a 50% ozonized glycerin aqueous solution, and then pentylene glycol and xanthan gum were added. The test sample of Example 2-1B was prepared by adding 9 times the amount of water to the ozonized glycerin of Example 2(1) to obtain a 10% ozonized glycerin aqueous solution, and then pentylene glycol, xanthan gum, and sodium hyaluronate were added. As a result, the final concentration of ozone oxidants in the ozonized glycerin obtained in Example 2(1) was 80 ppm or 800 ppm for the test samples of Example 2-1A and Example 2-1B. The test samples of Reference Example 2-1A and Reference Example 2-1B were prepared in the same manner, except that the concentrated glycerin was used instead of the ozonized glycerin.
[0387] The subjects were divided into the following two groups (24 people per group). After washing their face twice a day (morning and night), each subject took two pumps (about 1 ml) of each test product and applied it to the designated half of the face. From the start of the study until the end of the study, each subject did not change any cosmetics (lotion, milky lotion, whitening lotion, cream, etc.) other than the test product, and did not start using any new facial products. The confirmation test was conducted from April to June in an environment where melanin production occurs over time. After being reviewed and approved by the ethical review committee, this study was conducted in compliance with the Declaration of Helsinki and the ethical guidelines for medical research involving human subjects. (Test group 1) Half face: Test sample of Example 2-1A The other half of the face: Test sample of Reference Example 2-1A (Study group 2) Half face: Test sample of Example 2-1B The other half of the face: Test sample of Reference Example 2-1B
[0388] In addition, melanin measurements were performed five times on the left and right cheeks of each subject on the first day of application of each test product (week 0), and 4 and 8 weeks after the start of application. The melanin measurements were performed using a Mexameter (registered trademark) MX18 (Courage+Khazaka electronic GmbH, Cologne, Germany). Next, the maximum and minimum values of the five measurements were removed. The average value of the remaining three measurements was used as the melanin measurement value for each subject. In addition, the change in the melanin measurement value was measured based on the melanin measurement value at the start of the test. Statistical tests were performed using Student t-test, and a significant difference was determined when p<0.05. These results are shown in Figures 2-1 and 2-2.
[0389] FIG. 2-1 is a graph showing the results of melanin measurements over time. In FIG. 2-1, (A) shows the results of Example 2-1A and Reference Example 2-1A, and (B) shows the results of Example 2-1B and Reference Example 2-1B. In FIG. 2-1(A) and (B), the horizontal axis shows the number of weeks after the start of the test, and the vertical axis shows the melanin measurement value (Melanin index). FIG. 2-2 is a graph showing the change in melanin measurement value over time. In FIG. 2-2, (A) shows the results of Example 2-1A and Reference Example 2-1A, and (B) shows the results of Example 2-1B and Reference Example 2-1B. In FIG. 2-2(A) and (B), the horizontal axis shows the number of weeks after the start of the test, and the vertical axis shows the change in melanin measurement value (ΔMelanin index). As shown in Figure 2-1 and Figure 2-2, in the skin area where the test product of Example 2-1A and the test product of Example 2-1B are applied, the melanin measurement value is reduced compared with the skin area where the test product of Reference Example 2-1A and the test product of Reference Example 2-1B are applied, and the reduction amount increases with time.From these results, it is found that the cyclic peroxide contained in the ozone oxidant has the activity of reducing the amount of melanin in the skin, that is, has a whitening effect.
[0390] The compound with a molecular weight of 180 (chemical formula (1)) described below can be eliminated from ozonized glycerin by subjecting the ozonized glycerin to a heat treatment. When the change in the measured melanin value was examined in the same manner using the ozonized glycerin after the heat treatment, the activity of reducing the measured melanin value disappeared. For this reason, the compound with a molecular weight of 180 (chemical formula (1)) described below can be said to be an active ingredient for whitening. In addition, since the compound with a molecular weight of 180 is a cyclic peroxide, it was presumed to exhibit a whitening effect by decomposing melanin via its oxidizing ability.
[0391] (3) Analysis of reaction mixture In order to identify the active whitening ingredient in the ozonized glycerin, cyclic peroxides not found in glycerin were extracted from the ozonized glycerin of Example 2(1) and analyzed. Glycerin was removed from the glycerin solution containing the ozone oxidized product of glycerin produced in the above "Example 2(1) Production of oxidation reaction product containing the cyclic peroxide" using a silica gel column to obtain a reaction mixture containing the cyclic peroxide (hereinafter sometimes referred to as "TLC 1 spot product").
[0392] The NMR spectrum of the reaction mixture (TLC 1 spot) was measured at 300K (27°C) using DMSO-d6 as a solvent. The spectrum is shown in Figures 2-3 to 2-8. Figure 2-3 shows 1 1 H NMR spectrum. 13 C NMR spectrum. Figure 2-5 shows 13 C DEPT135 NMR spectrum. Figure 2-6 is a COSY NMR spectrum. Figure 2-7 is an HSQC NMR spectrum. Figure 2-8 is an HMBC NMR spectrum. As shown in Figures 2-3 to 2-8, complex peaks were observed, so it was speculated that the TLC1 spot was a mixture of multiple substances. Furthermore, according to LCMS, this TLC1 spot contained m / z 198,203 components.
[0393] (4) Separation and analysis of the reaction mixture The reaction mixture (TLC 1 spot product) was adjusted (diluted) to about 3% by mass with acetonitrile, filtered through a membrane filter, and the filtrate was subjected to LC measurement to optimize the separation conditions. Next, the mass of the peak observed in the LC measurement under the optimized conditions was confirmed, and precise separation of Mw=180 (peak 2) was performed. The obtained fraction solution was then freeze-dried, and the dried fraction was subjected to microscopic LR measurement and various NMR measurements. The measurement equipment (analyzer) and measurement conditions are as follows. [Measuring equipment (analyzer)] 1) Precision preparative LC: Waters, ACQUITY UPLC H-class Bio 2) Microscope LR: SNOM / AFM / Raman combination machine WITec alpha300RSA 3)NMR:Bruker Biospin,AVANCEIII-600 with Cryo Probe [Measurement conditions] 1)Precision preparative LC Column: Shodex Asahipak NH2P-50 (4.6 mmφ × 250 mm, 5 μm) Eluent composition: Water / acetonitrile gradient Time(min): 0 5 15 20 Wed: 5 10 50 50 Acetonitrile: 95 90 50 50 Flow rate: 1.0mL / min Detector: MS (QDa) Column temperature: 40℃ Injection volume: 50μL Ionization method: ESI (NEG.) Measurement mass range (m / z): 50-500 2) Microscope LR Excitation wavelength: 532 nm Measurement wave number range: approx. 125 to 3800 cm -1 Objective lens: x100 Detector: EMCCD 3) NMR Observation frequency: 600MHz (1 H), 150MHz ( 13 C) Measurement solvent: methanol-d4 Measurement temperature: 300K Chemical shift standard: measurement solvent [3.30 ppm ( 1 H), 49.80 ppm ( 13 C)]
[0394] FIG. 2-9 shows total ion chromatograms (ESI-negative mode) in the precision preparative LC (liquid chromatography) of a sample prepared (diluted) with acetonitrile to about 3% by mass from the reaction mixture (TLC1 spot product) and a blank. In FIG. 2-9, the vertical axis is intensity and the horizontal axis is retention time (min). In FIG. 2-9, the lower row "synthetic OG" is a chromatogram of the TLC1 spot product sample, and the upper row is a chromatogram of the blank (acetonitrile). As shown in the figure, components A to L were confirmed in the TLC1 spot product. Components A to L were separated and the presence or absence of coloring was confirmed with potassium iodide starch test paper, and component H was the most strongly colored.
[0395] Figure 2-10 also shows the mass spectra of peaks F, G, and H (F fraction, G fraction, and H fraction) in Figure 2-9. In Figure 2-10, the vertical axis is intensity, and the horizontal axis is mass-to-charge ratio (m / z). As shown in the figure, it was confirmed that peak F had Mw=180, peak G had Mw=226, and peak H had Mw=256.
[0396] Furthermore, Figure 2-11 shows the results of the study on the improvement of separation (improvement of separation conditions) in HILIC (high performance liquid chromatography). In Figure 2-11, the vertical axis is intensity and the horizontal axis is retention time (min), which is the same as in Figures 2-19 to 2-21. In Figure 2-11, the upper part is a chromatogram before separation improvement (same conditions as in Figure 2-10), and the lower part is a chromatogram after separation improvement. As shown in the figure, peaks 1 to 8 were observed after separation improvement. The molecular weights of each peak were confirmed to be as shown in Figure 2-11 by mass spectrometry, which will be described later.
[0397] Figure 2-12 shows the mass spectra (after improved separation) of peaks 1 to 3 in Figure 2-11. In Figure 2-12, the upper part is the mass spectrum of peak 1, the middle part is the mass spectrum of peak 2, and the lower part is the mass spectrum of peak 3. As shown in the figure, it was confirmed that peak 1 has Mw=196, peak 2 has Mw=180, and peak 3 has Mw=240.
[0398] Figure 2-13 shows the mass spectrum (after improved separation) of peaks 4 to 6 in Figure 2-11. In Figure 2-13, the upper part is the mass spectrum of peak 4, the middle part is the mass spectrum of peak 5, and the lower part is the mass spectrum of peak 6. As shown in the figure, it was confirmed that peak 4 has Mw=240, peak 5 has Mw=240, and peak 6 has Mw=226.
[0399] Figure 2-14 shows the mass spectrum (after separation improvement) of peaks 7 and 8 in Figure 2-11. In Figure 2-14, the upper part is the mass spectrum of peak 7, and the lower part is the mass spectrum of peak 8. As shown in the figure, it was confirmed that both peaks 7 and 8 have Mw=256.
[0400] FIG. 2-15 shows the micro-Raman spectrum of the sample of peak 2 (Mw=180) in FIG. 2-11 and the ozonide standard (ozonized oleic acid). In FIG. 2-15, the vertical axis is the intensity, and the horizontal axis is the Raman shift (1 / cm). As shown in FIG. 2-15, peak 2 (Mw=180) showed a micro-Raman spectrum similar to that of ozonide, and was therefore presumed to show a structure similar to that of ozonide. In addition, the micro-Raman spectrum of peak 2 (Mw=180) showed a pattern different from that of peroxide, and therefore peak 2 (Mw=180) was presumed not to be a peroxide. It was confirmed by NMR described later that peak 2 (Mw=180) was the cyclic peroxide.
[0401] Figure 2-16 shows the peak 2 (Mw=180) in Figure 2-11. 1 The H NMR spectrum is shown. The measurement solvent was methanol-d4 (CD3OD). In the figure, the upper spectrum is an enlarged view of the lower spectrum around 3.4 to 4.9 ppm. 1 Based on the H NMR assignment, Mw=180, and other instrumental analysis data, the structure of the oxidation reaction product of peak 2 (Mw=180) was proven to be a cyclic peroxide represented by the following chemical formula (1). 1 In the H NMR spectrum, the peaks indicated by symbols A to F were assigned to the peaks of hydrogen bonded to the carbon atoms indicated by the same symbols A to F in the following chemical formula (1) shown in Figure 2-16. In addition, it is presumed that a small amount of the raw material glycerin remained, and its peak was also detected.
[0402] [ka]
[0403] Figure 2-17 shows the peak 2 (Mw=180) in Figure 2-11. 13The C NMR spectrum is shown. The measurement solvent was methanol-d4 (CD3OD). In the figure, the upper spectrum is an enlarged view of the lower spectrum around 60 to 105 ppm. 13 Based on the C NMR assignment, Mw=180, and other instrumental analysis data, it was demonstrated that the structure of the oxidation reaction product of peak 2 (Mw=180) is a cyclic peroxide represented by the above chemical formula (1). 13 In the C NMR spectrum, the peaks indicated by symbols A to F were assigned to the peaks of the carbon atoms indicated by the same symbols A to F in the following chemical formula (1) shown in Figure 2-17. In addition, it is presumed that a small amount of the raw material glycerin remained, and its peak was also detected.
[0404] Figure 2-18 shows the two-dimensional ( 1 H- 13 The C COSY) NMR spectrum is shown. Methanol-d4 (CD3OD) was used as the measurement solvent. From this 2D NMR assignment, the fact that Mw=180, and other instrumental analysis data, it was demonstrated that the structure of the oxidation reaction product of peak 2 (Mw=180) is a cyclic peroxide represented by the above chemical formula (1). In the 2D NMR spectrum of FIG. 2-18, the peaks indicated by symbols A to F were assigned to the carbon atoms and hydrogen atoms bonded to those carbon atoms represented by the same symbols A to F in the following chemical formula (1) shown in FIG. 2-18. In addition, it is estimated that a small amount of glycerin, the raw material, remained, and its peak was also detected.
[0405] Figure 2-19 also shows the HILIC chromatograms of the TLC1 spot product and glyceraldehyde dimer under the HILIC (high performance liquid chromatography) conditions of Figure 2-11. In Figure 2-19, the "synthetic OG" in the upper row is the HILIC chromatogram of the TLC1 spot product. The lower row is the HILIC chromatogram with glyceraldehyde dimer. As shown in the figure, glyceraldehyde dimer was not detected under the HILIC conditions of Figure 2-11.
[0406] Figure 2-20 also shows the HILIC chromatograms of the TLC1 spot product and glyceraldehyde dimer under reversed-phase HILIC (high performance liquid chromatography) conditions. Figure 2-21 shows an enlarged view of a portion of Figure 2-20. In Figures 2-20 and 2-21, the upper row "synthetic OG" is the HILIC chromatogram of the TLC1 spot product. The lower row is the HILIC chromatogram with glyceraldehyde dimer. As shown in the figure, component separation of the TLC1 spot product could not be confirmed under reversed-phase HILIC conditions. This is thought to be because the column retention was weak and the elution time of the TLC1 spot product was fast. On the other hand, the retention time of the glyceraldehyde dimer was slightly different from that of the TLC1 spot product (synthetic OG). From this, it is inferred that the TLC1 spot product did not contain glyceraldehyde dimer.
[0407] Figure 2-22 shows the ESR spectrum of the TLC1 spot product and peak 2 (Mw=180) in Figure 2-11. In Figure 2-22, the vertical axis is intensity and the horizontal axis is magnetic flux density (G). Water was used as the measurement solvent. As shown in the figure, the spectra of the TLC1 spot product and peak 2 (Mw=180) component in Figure 2-11 almost completely overlap, and the peak appearance positions are almost completely identical for both. Both the TLC1 spot product and peak 2 (Mw=180) component in Figure 2-11 showed a spectrum of DMPO (spin trap agent) characterized by six lines. This spectral pattern is similar to that of ozonide.
[0408] Figure 2-23 shows the ESR spectrum of ozonized methyl linolenate. Acetone was used as the measurement solvent. Ozonized methyl linolenate is well known. As shown in the figure, the ESR spectrum of ozonized methyl linolenate shows a spectrum in the presence of DMPO (a spin trapping agent) that features six lines characteristic of ozonides. This spectrum pattern is similar to the pattern of the TLC 1 spot and peak 2 (Mw=180) in Figure 2-22.
[0409] Figure 2-24 shows the ESR spectrum of peaks 1 to 8 in Figure 2-11. Water was used as the measurement solvent. The top is an ESR spectrum of a blank (solvent only) for comparison. As shown in the figure, it was confirmed that all of the components of peaks 1 to 8 have radical activity.
[0410] The graph in Figure 2-25 shows the results of measuring the activity of peaks 1 to 8 in Figure 2-11 by chemiluminescence. In this figure, the vertical axis is the luminescence intensity (relative intensity) at all wavelengths. The numbers "1" to "8" on the horizontal axis indicate each fraction of peaks 1 to 8. The numbers below each number indicate the molecular weight of each fraction confirmed by mass spectrometry. As shown in the figure, it was confirmed that components that show activity by chemiluminescence were generated in addition to the molecular weight of 180.
[0411] [Example of the third invention] Next, the above-mentioned Example 3 will be described. However, the third invention of the present invention is not limited to the following Example. Commercially available reagents were used according to their protocols unless otherwise specified.
[0412] [Example 3-1] An oxidation reaction product containing the cyclic peroxide was produced by ozone oxidation of glycerin. Furthermore, the expression-inducing effect of the produced oxidation reaction product on skin barrier function-related genes was confirmed. This example corresponds to an example in which the cyclic peroxide was produced and used, and also corresponds to an example in which the oxidation reaction product was produced and used, and further corresponds to an example of a method for producing the oxidation reaction product.
[0413] (1) Production of an oxidation reaction product containing the cyclic peroxide Concentrated glycerin was subjected to gas-liquid contact with ozone to produce an ozone-treated glycerin solution (ozonized glycerin) containing the oxidation reaction product as described below. Here, concentrated glycerin means glycerin having a concentration of 98% by weight or more of the Japanese Pharmacopoeia product. The oxidation reaction product of the third invention of the present invention produced in this example contains the cyclic peroxide of the third invention of the present invention, as described below.
[0414] A 50 L Teflon tank was used as the contact tank. An aeration tube was installed at the bottom of the tank, so that ozone could be supplied into the tank as fine bubbles. A silent discharge ozone generator was used, which uses high-concentration oxygen gas containing 90% or more by volume as the raw material and has an ozone generating capacity of 100 g per hour.
[0415] 22 kg of the concentrated glycerin was placed in the tank, and 20 L of the high-concentration oxygen gas was fed into the ozone generator at a rate of 20 L per minute to generate a gas containing ozone. The generated gas was released from the air diffuser into the tank for 7 days or more to obtain a glycerin solution in which ozone oxidized glycerin was dissolved at a final concentration of 4000 ppm. This ozone oxidized glycerin corresponds to the oxidation reaction product. In addition, this ozone oxidized glycerin contained the cyclic peroxide, as described below. The expression-inducing activity of skin barrier function genes was confirmed for the ozone oxidized glycerin containing the peroxide.
[0416] (2) Confirmation of the induction of skin barrier function genes Using human epidermal keratinocytes, it was confirmed whether the ozonized glycerin can induce the expression of skin barrier function genes. Specifically, normal human epidermal cells (NHEK: manufactured by Kurabo Industries, Ltd.) were suspended in a medium (HuMedia-KG2 (KG2), manufactured by Kurabo Industries, Ltd.), and then 2.0 × 10 4The cells were seeded in a 96-well plate at 100 μl / well and cultured for 24 hours under conditions of 37° C. and 5% CO2 (the same applies below for culture conditions). After the culture, the medium in each well was replaced with KG2 medium (100 μl / well) containing the ozonized glycerin of Example 3-1(1) at a predetermined concentration (1, 2, or 4 (v / v)%), and the cells were further cultured for 24 hours. Next, after removing the medium from each well, the cells were washed with phosphate buffer (PBS(-)), and RNA was extracted using an RNA extraction kit (Ambion (registered trademark) Cells-to-CT (trademark) Kits, manufactured by Thermo). cDNA was synthesized from the obtained RNA by reverse transcription reaction.
[0417] Using the cDNA, real-time PCR reagents and a PCR device (StepOne™ Real-Time PCR System, Applied Biosystems) were used to calculate the mRNA expression levels of the profilaggrin gene, involucrin gene, and serine palmitoyltransferase gene (ΔΔCt method). The following primer sets were used to amplify the mRNA of each gene, and the expression level of each gene was calculated as a relative value of the mRNA expression level of the GAPDH gene. A comparative example was carried out in the same manner, except that the concentrated glycerin was used instead of the ozonized glycerin. These results are shown in Figure 3-1.
[0418] -Profilaggrin gene primer set Forward primer (SEQ ID NO: 1) 5'-CATGGCAGCTATGGTAGTGCAGA-3' Reverse primer (SEQ ID NO:2) 5'-ACCAAACGCACTTGCTTTACAGA-3' Primer set for involucrin gene Forward primer (SEQ ID NO:3) 5'-GCTGGAGCAGCCTGTGTTTG-3' Reverse primer (SEQ ID NO: 4) 5'-CTGGACACTGCGGGTGGTTA-3' Primer set for serine palmitoyltransferase gene Forward primer (SEQ ID NO:5) 5'-GCCTGTCAGCAGCTCATACCAA-3' Reverse primer (SEQ ID NO:6) 5'-GGCCTGTCCAGTAGAGGTACCAA-3' Primer set for GAPDH gene Forward primer (SEQ ID NO: 7) 5'-GCACCGTCAAGGCTGAGAAC-3' Reverse primer (SEQ ID NO:8) 5'-TGGTGAAGACGCCAGTGGA-3'
[0419] FIG. 3-1 is a graph showing the expression level of skin barrier function-related genes. In FIG. 3-1, (A) shows the expression level of profilaggrin gene, (B) shows the expression level of involucrin gene, and (C) shows the result of serine palmitoyltransferase gene. In FIG. 3-1(A) to (C), the horizontal axis shows the concentration of the sample, and the vertical axis shows the relative expression level of each gene. As shown in FIG. 3-1(A) to (C), the expression levels of profilaggrin gene, involucrin gene, and serine palmitoyltransferase gene were increased in the ozonized glycerin treatment group (OG) compared with the comparative example treatment group (Glycerin). From these results, it was found that the ozonized glycerin can induce the expression of skin barrier function-related genes. As described later, when the components of the ozonized glycerin and the concentrated glycerin are compared, the ozonized glycerin is different in that it contains a compound of the chemical formula (1) described later. Therefore, it was demonstrated that the compound of chemical formula (1) contained in the ozonized glycerin induces the expression of genes related to skin barrier function.
[0420] (3) Confirmation of the induction of antioxidant stress response genes Using human epidermal keratinocytes, it was confirmed whether the ozonized glycerin can induce the expression of antioxidant stress response genes. cDNA was prepared in the same manner as in Example 3-1(2). For the cDNA, the expression levels of the heme oxygenase 1 gene and the NAD(P)H quinone oxidoreductase 1 gene were calculated in the same manner as in Example 3-1(2) (ΔΔCt method). The following primer set was used to amplify the mRNA of each gene, and the expression level of each gene was calculated as a relative value of the expression level of the GAPDH gene mRNA. A comparative example was carried out in the same manner, except that the concentrated glycerin was used instead of the ozonized glycerin. These results are shown in Figure 3-2.
[0421] Primer set for heme oxygenase 1 gene Forward primer (SEQ ID NO: 9) 5'-TTGCCAGTGCCACCAAGTTC-3' Reverse primer (SEQ ID NO: 10) 5'-TCAGCAGCTCCTGCAACTCC-3' Primer set for NAD(P)H quinone oxidoreductase 1 gene Forward primer (SEQ ID NO: 11) 5'-GTGGCAGTGGCTCCATGTACTC-3' Reverse primer (SEQ ID NO: 12) 5'-GAGTGTGCCCAATGCTATATGTCAG-3'
[0422] FIG. 3-2 is a graph showing the expression level of antioxidant stress response genes. In FIG. 3-1, (A) shows the expression level of heme oxygenase 1 gene, and (B) shows the expression level of NAD(P)H quinone oxidoreductase 1 gene. In FIG. 3-2(A)-(B), the horizontal axis shows the concentration of the sample, and the vertical axis shows the relative expression level of each gene. As shown in FIG. 3-2(A)-(B), the expression levels of heme oxygenase 1 gene and NAD(P)H quinone oxidoreductase 1 gene were increased in the ozonized glycerin treatment group (OG) compared with the comparative example treatment group (Glycerin). From these results, it was found that the ozonized glycerin can induce the expression of antioxidant stress response genes. As described later, when the components of the ozonized glycerin and the concentrated glycerin are compared, the ozonized glycerin is different in that it contains a compound of the chemical formula (1) described later. Therefore, it was demonstrated that the compound of chemical formula (1) contained in the ozonized glycerin induces the expression of antioxidant stress response genes.
[0423] Next, in the same manner as in Example 3-1(2), the cells were cultured for 24 or 48 hours in the presence of KG2 medium containing a predetermined concentration of ozonized glycerin. After the culture, the medium in each well was removed. Next, 100 μl / well of 0.5% Triton (registered trademark) X-100 solution was added to each well to dissolve the cells, and a cell lysate was prepared. 175 μl of reaction solution (0.1 mol / l phosphate buffer containing 2 mmol / l NADPH, 0.12 units / ml glutathione reductase, and 0.5 mmol / l EDTA) and 25 μl of cell lysate were added to a new plate, mixed, and incubated at 37° C. for 10 minutes. Then, 25 μl of color developing solution (10 mmol / l (5,5'-dithio-bis-(2-nitrobenzoic acid):DTNB) was added to each well, and the absorbance (405 nm) was measured using an absorption spectrometer. The amount of glutathione was calculated from the obtained absorbance. The amount of glutathione was calculated as a relative amount to the total amount of protein used in the assay. These results are shown in Figure 3-3.
[0424] FIG. 3-3 is a graph showing the amount of peptides of glutathione. In FIG. 3-3, (A) shows the amount of peptide expression after 24 hours of culture, and (B) shows the amount of peptide expression after 48 hours of culture. In FIG. 3-3(A)-(B), the horizontal axis shows the concentration of the sample, and the vertical axis shows the relative peptide expression amount of glutathione. As shown in FIG. 3-3(A)-(B), the peptide expression amount of glutathione was increased in the ozonized glycerin treatment group (OG) compared with the treatment group of the comparative example (Glycerin). From these results, it was found that the ozonized glycerin can induce the expression of antioxidant proteins. As described later, when the components of the ozonized glycerin and the concentrated glycerin are compared, the ozonized glycerin is different in that it contains a compound of the chemical formula (1) described later. Therefore, it was shown that the compound of the chemical formula (1) contained in the ozonized glycerin induces the expression of glutathione, which is an antioxidant protein.
[0425] (4) Confirmation of cytotoxicity Using human epidermal keratinocytes, it was confirmed that the ozonized glycerin had no cytotoxicity. Specifically, in the same manner as in Example 3-1(3), the cells were cultured for 24 or 48 hours in the presence of KG2 medium containing a predetermined concentration of ozonized glycerin. After the culture, the medium in each well was removed. Then, the medium was replaced with a medium containing 0.003% Neutral Red (NR: manufactured by Sigma-Aldrich) and cultured at 37°C for 2 hours. After washing each well with PBS(-), 1 mol / l hydrochloric acid solution containing 30 (v / v)% methanol was added at 100 μl / l to extract NR. The absorbance (measurement wavelength: 550 nm, reference wavelength: 650 nm) of the obtained extract was measured using the absorption spectrometer, and the cell viability was calculated. These results are shown in Figure 3-4.
[0426] FIG. 3-4 is a graph showing the cell viability. In FIG. 3-4, the horizontal axis shows the concentration of the sample, and the vertical axis shows the relative expression level of glutathione. As shown in FIG. 3-4, the ozonized glycerin treatment group (OG) had a cell viability equivalent to that of the comparative treatment group (Glycerin). From these results, it was confirmed that the ozonized glycerin does not exhibit cytotoxicity.
[0427] (5) Confirmation of anti-inflammatory effect Using human epidermal keratinocytes, it was confirmed that the ozonized glycerin exhibits an anti-inflammatory effect. Specifically, three-dimensionally cultured epidermis (LabCyte EPI-MODEL, manufactured by J-TEC) was set in a 24-well plate to which 500 μl of the attached assay medium had been added, and cultured overnight under conditions of 37° C. and 5% CO2 for acclimation. After the culture, 30 μl of assay medium containing the ozonized glycerin at a predetermined concentration (0 or 1 (v / v)%) was applied from the stratum corneum side, and cultured at 37° C. for 24 hours. After the culture, the assay medium containing the ozonized glycerin was removed with a cotton swab, and the stratum corneum surface was washed once with 500 μl of PBS(-). Next, the PBS(-) was removed from the stratum corneum surface with a cotton swab, and then UVB was irradiated (280-315 nm, 600 mJ / cm2). 2 The three-dimensionally cultured epidermis was then transferred to a plate to which 500 μl of fresh assay medium had been added, and further cultured for 24 hours under conditions of 37° C. and 5% CO 2 .
[0428] Next, the three-dimensional cultured epidermis was transferred to a well plate to which 500 μl of alamarBlue (registered trademark) Reagent (manufactured by Thermo) solution (diluted 100-fold with assay medium) had been added, and further cultured for 2 hours under conditions of 37° C. and 5% CO2. Thereafter, the fluorescence intensity of the three-dimensional cultured epidermis was measured using a fluorometer (Ex / Em=570 nm / 590 nm) to measure the cell viability. In addition, Interleukin-1α (IL-1α: R&D systems) and Prostaglandin E2 (PGE2: manufactured by Cayman) were quantified by ELISA using the culture supernatant in the culture. In the comparative example, the quantification was performed in the same manner except that UVB was not irradiated or PBS (-) or 40% glycerin-containing assay medium was used instead of the ozonized glycerin-containing assay medium. These results are shown in Figures 3-5 and 3-6.
[0429] FIG. 3-5 is a graph showing the amount of IL-1α produced. FIG. 3-6 is a graph showing the amount of prostaglandin E2 produced. In FIG. 3-5 and FIG. 3-6, the horizontal axis shows UV treatment and the type and concentration of the sample, and the vertical axis shows the amount of IL-1α produced or the amount of PGE2 produced. As shown in FIG. 3-5 and FIG. 3-6, the amount of IL-1α produced and the amount of PGE2 produced were reduced in the ozonized glycerin treatment group (OG) compared with the comparative example treatment group (Glycerin). From these results, it was found that the ozonized glycerin exhibits an anti-inflammatory effect. As described later, when the components of the ozonized glycerin and the concentrated glycerin are compared, the ozonized glycerin is different in that it contains a compound of the chemical formula (1) described later. For this reason, it was concluded that the compound of the chemical formula (1) contained in the ozonized glycerin exhibits an anti-inflammatory effect.
[0430] [Example 3-2] It was confirmed that the active ingredient in the ozonized glycerin was a cyclic peroxide.
[0431] (1) Analysis of reaction mixture In order to identify the active ingredient in the ozonized glycerin that induces the expression of genes related to skin barrier function, cyclic peroxides not found in glycerin were extracted from the ozonized glycerin of Example 3-1(1) and analyzed. Glycerin was removed from the glycerin solution containing the ozone oxidized product of glycerin produced in the above "Example 3-1(1) Production of oxidation reaction product containing the cyclic peroxide" using a silica gel column to obtain a reaction mixture containing the cyclic peroxide (hereinafter sometimes referred to as "TLC 1 spot product").
[0432] The NMR spectrum of the reaction mixture (TLC 1 spot product) was measured at a temperature of 300 K (27° C.) using DMSO-d6 as a solvent. The spectrum diagrams are shown in FIG. 3-7 to FIG. 3-12. FIG. 3-7 shows, 1 1 H NMR spectrum. 13 C NMR spectrum. Figure 3-9 shows 13 C DEPT135 NMR spectrum. Figure 3-10 is a COSY NMR spectrum. Figure 3-11 is an HSQC NMR spectrum. Figure 3-12 is an HMBC NMR spectrum. As shown in Figures 3-7 to 3-12, complex peaks were observed, so it was speculated that the TLC1 spot was a mixture of multiple substances. Furthermore, according to LCMS, this TLC1 spot contained m / z 198,203 components.
[0433] (2) Separation and analysis of the reaction mixture The reaction mixture (TLC 1 spot product) was adjusted (diluted) to about 3% by mass with acetonitrile, filtered through a membrane filter, and the filtrate was subjected to LC measurement to optimize the separation conditions. Next, the mass of the peak observed in the LC measurement under the optimized conditions was confirmed, and precise separation of Mw=180 (peak 2) was performed. The obtained fraction solution was then freeze-dried, and the dried fraction was subjected to microscopic LR measurement and various NMR measurements. The measurement equipment (analyzer) and measurement conditions are as follows. [Measuring equipment (analyzer)] 1) Precision preparative LC: Waters, ACQUITY UPLC H-class Bio 2) Microscope LR: SNOM / AFM / Raman combination machine WITec alpha300RSA 3)NMR:Bruker Biospin,AVANCEIII-600 with Cryo Probe [Measurement conditions] 1)Precision preparative LC Column: Shodex Asahipak NH2P-50 (4.6 mmφ × 250 mm, 5 μm) Eluent composition: Water / acetonitrile gradient Time(min): 0 5 15 20 Wed: 5 10 50 50 Acetonitrile: 95 90 50 50 Flow rate: 1.0mL / min Detector: MS (QDa) Column temperature: 40℃ Injection volume: 50μL Ionization method: ESI (NEG.) Measurement mass range (m / z): 50-500 2) Microscope LR Excitation wavelength: 532 nm Measurement wave number range: approx. 125 to 3800 cm -1 Objective lens: x100 Detector: EMCCD 3) NMR Observation frequency: 600MHz ( 1 H), 150MHz ( 13 C) Measurement solvent: methanol-d4 Measurement temperature: 300K Chemical shift standard: measurement solvent [3.30 ppm ( 1 H), 49.80 ppm ( 13 C)]
[0434] FIG. 3-13 shows total ion chromatograms (ESI-negative mode) in the precision preparative LC (liquid chromatography) of a sample prepared (diluted) with acetonitrile to about 3% by mass of the reaction mixture (TLC1 spot product) and a blank. In FIG. 3-13, the vertical axis is intensity and the horizontal axis is retention time (min). In FIG. 3-13, the lower row "synthetic OG" is a chromatogram of the TLC1 spot product sample, and the upper row is a chromatogram of the blank (acetonitrile). As shown in the figure, components A to L were confirmed in the TLC1 spot product. Components A to L were separated and the presence or absence of coloring was confirmed with potassium iodide starch test paper, and component H was the most strongly colored.
[0435] Figure 3-14 also shows the mass spectra of peaks F, G, and H (F fraction, G fraction, and H fraction) in Figure 3-13. In Figure 3-14, the vertical axis represents intensity, and the horizontal axis represents mass-to-charge ratio (m / z). As shown in the figure, it was confirmed that peak F had Mw=180, peak G had Mw=226, and peak H had Mw=256.
[0436] Furthermore, Figure 3-15 shows the results of the study on the improvement of separation (improvement of separation conditions) in HILIC (high performance liquid chromatography). In Figure 3-15, the vertical axis is intensity and the horizontal axis is retention time (min), which is the same for Figures 3-23 to 3-25. In Figure 3-15, the upper part is a chromatogram before separation improvement (same conditions as Figure 3-14), and the lower part is a chromatogram after separation improvement. As shown in the figure, peaks 1 to 8 were observed after separation improvement. The molecular weights of each peak were confirmed to be as shown in Figure 3-15 by mass spectrometry, which will be described later.
[0437] Figure 3-16 shows the mass spectra (after improved separation) of peaks 1 to 3 in Figure 3-15. In Figure 3-16, the upper row is the mass spectrum of peak 1, the middle row is the mass spectrum of peak 2, and the lower row is the mass spectrum of peak 3. As shown in the figure, it was confirmed that peak 1 had Mw=196, peak 2 had Mw=180, and peak 3 had Mw=240.
[0438] Figure 3-17 shows the mass spectra (after improved separation) of peaks 4 to 6 in Figure 3-15. In Figure 3-17, the upper part is the mass spectrum of peak 4, the middle part is the mass spectrum of peak 5, and the lower part is the mass spectrum of peak 6. As shown in the figure, it was confirmed that peak 4 has Mw=240, peak 5 has Mw=240, and peak 6 has Mw=226.
[0439] Figure 3-18 shows the mass spectrum (after separation improvement) of peaks 7 and 8 in Figure 3-15. In Figure 3-18, the upper part is the mass spectrum of peak 7, and the lower part is the mass spectrum of peak 8. As shown in the figure, it was confirmed that both peaks 7 and 8 have Mw=256.
[0440] FIG. 3-19 shows the micro-Raman spectrum of the sample of peak 2 (Mw=180) in FIG. 3-15 and the ozonide standard (ozonized oleic acid). In FIG. 3-19, the vertical axis is the intensity, and the horizontal axis is the Raman shift (1 / cm). As shown in FIG. 3-19, peak 2 (Mw=180) showed a similar micro-Raman spectrum to ozonide, and was therefore presumed to show a similar structure to ozonide. In addition, the micro-Raman spectrum of peak 2 (Mw=180) showed a different pattern from that of peroxide, and therefore peak 2 (Mw=180) was presumed not to be a peroxide. It was confirmed by NMR described later that peak 2 (Mw=180) was the cyclic peroxide.
[0441] Figure 3-20 shows the peak 2 (Mw=180) in Figure 3-15. 1 The H NMR spectrum is shown. The measurement solvent was methanol-d4 (CD3OD). In the figure, the upper spectrum is an enlarged view of the lower spectrum around 3.4 to 4.9 ppm. 1 Based on the H NMR assignment, Mw=180, and other instrumental analysis data, the structure of the oxidation reaction product of peak 2 (Mw=180) was proven to be a cyclic peroxide represented by the following chemical formula (1). 1In the H NMR spectrum, the peaks indicated by symbols A to F were assigned to the peaks of hydrogen bonded to the carbon atoms indicated by the same symbols A to F in the following chemical formula (1) shown in Figure 3-20. It is also presumed that a small amount of the raw material glycerin remained, and its peak was also detected.
[0442] [ka]
[0443] Figure 3-21 shows the peak 2 (Mw=180) in Figure 3-15. 13 The C NMR spectrum is shown. The measurement solvent was methanol-d4 (CD3OD). In the figure, the upper spectrum is an enlarged view of the lower spectrum around 60 to 105 ppm. 13 From the C NMR assignment, Mw=180, and other instrumental analysis data, it was demonstrated that the structure of the oxidation reaction product of peak 2 (Mw=180) is a cyclic peroxide represented by the above chemical formula (1). 13 In the C NMR spectrum, the peaks indicated by symbols A to F were assigned to the peaks of the carbon atoms indicated by the same symbols A to F in the following chemical formula (1) shown in Figure 3-21. It is also presumed that a small amount of the raw material glycerin remained, and its peak was also detected.
[0444] Figure 3-22 shows the two-dimensional ( 1 H- 13The C COSY) NMR spectrum is shown. Methanol-d4 (CD3OD) was used as the measurement solvent. From this 2D NMR assignment, the fact that Mw=180, and other instrumental analysis data, it was demonstrated that the structure of the oxidation reaction product of peak 2 (Mw=180) is a cyclic peroxide represented by the above chemical formula (1). In the 2D NMR spectrum of Figure 3-22, the peaks indicated by symbols A to F were assigned to the carbon atoms and hydrogen atoms bonded to those carbon atoms represented by the same symbols A to F in the following chemical formula (1) shown in Figure 3-22. In addition, it is estimated that a small amount of glycerin, the raw material, remained, and its peak was also detected.
[0445] Figure 3-23 also shows HILIC chromatograms of the TLC1 spot product and glyceraldehyde dimer under the HILIC (high performance liquid chromatography) conditions of Figure 3-15. In Figure 3-23, the "synthetic OG" in the upper row is a HILIC chromatogram of the TLC1 spot product. The lower row is a HILIC chromatogram with glyceraldehyde dimer. As shown in the figure, glyceraldehyde dimer was not detected under the HILIC conditions of Figure 3-23.
[0446] Figure 3-24 also shows the HILIC chromatograms of the TLC1 spot product and glyceraldehyde dimer under reversed-phase HILIC (high performance liquid chromatography) conditions. Figure 3-25 shows an enlarged view of a portion of Figure 3-24. In Figures 3-24 and 3-25, the upper row of "synthetic OG" is the HILIC chromatogram of the TLC1 spot product. The lower row is the HILIC chromatogram with glyceraldehyde dimer. As shown in the figure, component separation of the TLC1 spot product could not be confirmed under reversed-phase HILIC conditions. This is thought to be because the column retention was weak and the elution time of the TLC1 spot product was fast. On the other hand, the retention time of the glyceraldehyde dimer was slightly different from that of the TLC1 spot product (synthetic OG). From this, it is inferred that the TLC1 spot product did not contain glyceraldehyde dimer.
[0447] Figure 3-26 shows the ESR spectrum of the TLC1 spot product and peak 2 (Mw=180) in Figure 3-15. In Figure 3-26, the vertical axis is intensity and the horizontal axis is magnetic flux density (G). Water was used as the measurement solvent. As shown in the figure, the spectra of the TLC1 spot product and peak 2 (Mw=180) component in Figure 3-15 almost completely overlap, and the peak appearance positions are almost completely identical for both. Both the TLC1 spot product and peak 2 (Mw=180) component in Figure 3-15 showed the spectrum of DMPO (spin trap agent) characterized by six lines. This spectral pattern is similar to that of ozonide.
[0448] Figure 3-27 shows the ESR spectrum of ozonized methyl linolenate. Acetone was used as the measurement solvent. Ozonized methyl linolenate is well known. As shown in the figure, the ESR spectrum of ozonized methyl linolenate shows a spectrum in the presence of DMPO (a spin trapping agent) that features six lines characteristic of ozonides. This spectrum pattern is similar to the pattern of the TLC 1 spot and peak 2 (Mw=180) in Figure 3-26.
[0449] Figure 3-28 shows the ESR spectrum of peaks 1 to 8 in Figure 3-15. Water was used as the measurement solvent. The top is an ESR spectrum of a blank (solvent only) for comparison. As shown in the figure, it was confirmed that all of the components of peaks 1 to 8 have radical activity.
[0450] The graph in Figure 3-29 shows the results of measuring the activity of peaks 1 to 8 in Figure 3-15 by chemiluminescence. In this figure, the vertical axis is the luminescence intensity (relative intensity) at all wavelengths. The numbers "1" to "8" on the horizontal axis indicate each fraction of peaks 1 to 8. The numbers below each number indicate the molecular weight of each fraction confirmed by mass spectrometry. As shown in the figure, it was confirmed that components that show activity by chemiluminescence were generated in addition to the molecular weight of 180.
[0451] [Example of the fourth aspect of the invention] Next, the above-mentioned Example 4 will be described. However, the fourth invention of the present invention is not limited to the following Example. Commercially available reagents were used according to their protocols unless otherwise specified.
[0452] [Example 4-1] An oxidation reaction product containing the cyclic peroxide was produced by ozone oxidation of glycerin. Furthermore, the anti-glycation effect of the produced oxidation reaction product was confirmed. This example corresponds to an example in which the cyclic peroxide was produced and used, as well as an example in which the oxidation reaction product was produced and used, and further corresponds to an example of a method for producing the oxidation reaction product.
[0453] (1) Production of an oxidation reaction product containing the cyclic peroxide Concentrated glycerin was subjected to gas-liquid contact with ozone to produce an ozone-treated glycerin solution (ozonized glycerin) containing the oxidation reaction product as described below. Here, concentrated glycerin means glycerin having a concentration of 98% by weight or more of the Japanese Pharmacopoeia product. The oxidation reaction product according to the fourth aspect of the present invention produced in this example contains the cyclic peroxide according to the fourth aspect of the present invention, as described below.
[0454] A 50 L Teflon tank was used as the contact tank. An aeration tube was installed at the bottom of the tank, so that ozone could be supplied into the tank as fine bubbles. A silent discharge ozone generator was used, which uses high-concentration oxygen gas containing 90% or more by volume as the raw material and has an ozone generating capacity of 100 g per hour.
[0455] 22 kg of the concentrated glycerin was placed in the tank, and 20 L of the high-concentration oxygen gas was fed into the ozone generator at a rate of 20 L per minute to generate a gas containing ozone. The generated gas was released from the air diffuser into the tank for 7 days or more to obtain a glycerin solution in which ozone-oxidized glycerin was dissolved at a final concentration of 4000 ppm. This ozone-oxidized glycerin corresponds to the oxidation reaction product. Furthermore, this ozone-oxidized glycerin contained the cyclic peroxide, as described below. The AGEs decomposition activity of the ozone-oxidized glycerin containing the peroxide was confirmed.
[0456] (2) Confirmation of AGEs cross-linking activity The activity of cleaving AGEs cross-linked structures was measured according to Reference 1 (Sara Vasan et al. Nature, 382, pp. 275-278 (1996)). Specifically, 1-Phenyl-1,2-propanedione (PPD), a reaction substrate for an AGEs cross-linked model with an α-diketone structure, was used as the substrate, and the activity of cleaving AGEs cross-linked structures was measured by detecting the cleavage of PPD. As a positive control, N-phenacylthiazolium bromide (PTB), which is known to have the activity of cleaving AGEs cross-linked structures, was used.
[0457] 100 μl (n=5) of the following sample solution, 20 μl of 10 mmol / L PPD (solvent: 50% acetonitrile), and 80 μl of 2 mol / l phosphate buffer (pH 7.4) were mixed and reacted at 37° C. for 2 hours. After the reaction, 40 μl of 2 mol / l hydrochloric acid was added to the resulting reaction solution to stop the reaction. After the reaction was stopped, 20 μl of 100 mmol / l sodium dehydroacetate was added to each reaction solution as an internal standard. (Sample liquid) Diluted solution of ozonized glycerin: A solution obtained by diluting the ozonized glycerin of Example 4-1(1) with water so that the concentration of ozone oxidized products becomes 10, 100, or 1000 ppm. Concentrated glycerin solution 5 or 10mmol / l PTB (solvent: 50% acetonitrile) Hydrogen peroxide solution: A solution diluted with water to a H2O2 concentration of 1 or 10 mmol / l.
[0458] Next, the mixture obtained was centrifuged at 3,000×g at 20° C. for 10 minutes, and 20 μl of the supernatant was taken as a measurement sample, and the amount of benzoic acid in the measurement sample was analyzed by reversed-phase HPLC. The reversed-phase HPLC was performed under the following measurement conditions. In addition, a measurement sample containing a known concentration of benzoic acid was analyzed in the same manner. (Measurement conditions for reverse phase HPLC) Column: Cadenza CD-C18 75mm x 4.6mm ID (Imtakt Co., Ltd.) Mobile phase: 0.2% acetic acid / acetonitrile (70:30) (Contains 2mmol / l EDTA-2Na) Flow rate: 1ml / min Measurement wavelength: 230nm
[0459] A calibration curve was created using the peak area of the chromatogram (benzoic acid: 2.4 min) obtained from the measurement sample containing a known concentration of benzoic acid, and then the content of benzoic acid in the measurement sample derived from each sample solution was quantified. In addition, to eliminate the background benzoic acid content, each sample solution was quantified in the same manner. Since 1 mol of PPD produces 1 mol of benzoic acid, the anti-glycation rate (crosslink cleavage rate) was calculated from the following formula (1). These results are shown in Figure 4-1. Anti-glycation rate (%)={(AB) / C}×100 ···(1) A: Amount of benzoic acid in the measurement sample B: Amount of benzoic acid in the sample solution C: Amount of PPD (substrate amount) used in the reaction
[0460] FIG. 4-1 is a graph showing the anti-glycation rate. In FIG. 4-1, the horizontal axis shows the type and concentration of the sample liquid, and the vertical axis shows the anti-glycation rate. As shown in FIG. 4-1, the anti-glycation rate of ozonized glycerin increased in a concentration-dependent manner. In addition, ozonized glycerin showed an anti-glycation rate equal to or higher than that of the positive controls PTB and hydrogen peroxide (H2O2). From these results, it was found that ozonized glycerin exhibits a very high activity of cleaving the crosslinked structure of AGEs, that is, anti-glycation activity. In addition, as described later, when the components of the ozonized glycerin and the concentrated glycerin were compared, the ozonized glycerin was different in that it contained a compound of the chemical formula (1) described later. Therefore, it was shown that the compound of the chemical formula (1) contained in the ozonized glycerin exhibits anti-glycation activity.
[0461] From the above, it was found that the oxidation reaction product containing the cyclic peroxide, i.e., the compound of chemical formula (1), produced by the ozone oxidation of glycerin exhibits anti-glycation activity.
[0462] [Example 4-2] It was confirmed that the active ingredient in the ozonized glycerin was a cyclic peroxide.
[0463] (1) Analysis of reaction mixture In order to identify the active ingredient of the anti-glycation component in the ozonized glycerin, cyclic peroxides not found in glycerin were extracted from the ozonized glycerin of Example 4-1(1) and analyzed. Glycerin was removed from the glycerin solution containing the ozone oxidized product of glycerin produced in the above "Example 4-1(1) Production of an oxidation reaction product containing the cyclic peroxide" using a silica gel column to obtain a reaction mixture containing the cyclic peroxide (hereinafter sometimes referred to as "TLC 1 spot product").
[0464] The NMR spectrum of the reaction mixture (TLC 1 spot) was measured at 300K (27°C) using DMSO-d6 as a solvent. The spectrum is shown in Figures 4-2 to 4-7. Figure 4-2 shows 11 H NMR spectrum. 13 C NMR spectrum. 13 4-1 is a C DEPT135 NMR spectrum. FIG. 4-5 is a COSY NMR spectrum. FIG. 4-6 is an HSQC NMR spectrum. FIG. 4-7 is an HMBC NMR spectrum. As shown in FIG. 4-2 to FIG. 4-7, complex peaks were observed, so it was speculated that the TLC1 spot was a mixture of multiple substances. According to LCMS, the TLC1 spot contained m / z 198,203 components.
[0465] (2) Separation and analysis of the reaction mixture The reaction mixture (TLC 1 spot product) was adjusted (diluted) to about 3% by mass with acetonitrile, filtered through a membrane filter, and the filtrate was subjected to LC measurement to optimize the separation conditions. Next, the mass of the peak observed in the LC measurement under the optimized conditions was confirmed, and precise separation of Mw=180 (peak 2) was performed. The obtained fraction solution was then freeze-dried, and the dried fraction was subjected to microscopic LR measurement and various NMR measurements. The measurement equipment (analyzer) and measurement conditions are as follows. [Measuring equipment (analyzer)] 1) Precision preparative LC: Waters, ACQUITY UPLC H-class Bio 2) Microscope LR: SNOM / AFM / Raman combination machine WITec alpha300RSA 3)NMR:Bruker Biospin,AVANCEIII-600 with Cryo Probe [Measurement conditions] 1)Precision preparative LC Column: Shodex Asahipak NH2P-50 (4.6 mmφ × 250 mm, 5 μm) Eluent composition: Water / acetonitrile gradient Time(min): 0 5 15 20 Wed: 5 10 50 50 Acetonitrile: 95 90 50 50 Flow rate: 1.0mL / min Detector: MS (QDa) Column temperature: 40℃ Injection volume: 50μL Ionization method: ESI (NEG.) Measurement mass range (m / z): 50-500 2) Microscope LR Excitation wavelength: 532 nm Measurement wave number range: approx. 125 to 3800 cm -1 Objective lens: x100 Detector: EMCCD 3) NMR Observation frequency: 600MHz ( 1 H), 150MHz ( 13 C) Measurement solvent: methanol-d4 Measurement temperature: 300K Chemical shift standard: measurement solvent [3.30 ppm ( 1 H), 49.80 ppm ( 13 C)]
[0466] FIG. 4-8 shows total ion chromatograms (ESI-negative mode) in the precision preparative LC (liquid chromatography) of a sample prepared (diluted) with acetonitrile to about 3% by mass of the reaction mixture (TLC1 spot product) and a blank. In FIG. 4-8, the vertical axis is intensity and the horizontal axis is retention time (min). In FIG. 4-8, the lower row "synthetic OG" is a chromatogram of the TLC1 spot product sample, and the upper row is a chromatogram of the blank (acetonitrile). As shown in the figure, components A to L were confirmed in the TLC1 spot product. Components A to L were separated and the presence or absence of coloring was confirmed with potassium iodide starch test paper, and component H was the most strongly colored.
[0467] Figure 4-9 also shows the mass spectra of peaks F, G, and H (F fraction, G fraction, and H fraction) in Figure 4-8. In Figure 4-9, the vertical axis represents intensity, and the horizontal axis represents mass-to-charge ratio (m / z). As shown in the figure, it was confirmed that peak F had Mw=180, peak G had Mw=226, and peak H had Mw=256.
[0468] Furthermore, Figure 4-10 shows the results of the study on the improvement of separation (improvement of separation conditions) in HILIC (high performance liquid chromatography). In Figure 4-10, the vertical axis is intensity and the horizontal axis is retention time (min), and the same is true for Figures 4-18 to 4-20. In Figure 4-10, the upper part is a chromatogram before separation improvement (same conditions as Figure 4-9), and the lower part is a chromatogram after separation improvement. As shown in the figure, peaks 1 to 8 were observed after separation improvement. The molecular weights of each peak were confirmed to be as shown in Figure 4-10 by mass spectrometry, which will be described later.
[0469] Figure 4-11 shows the mass spectra (after improved separation) of peaks 1 to 3 in Figure 4-10. In Figure 4-11, the upper part is the mass spectrum of peak 1, the middle part is the mass spectrum of peak 2, and the lower part is the mass spectrum of peak 3. As shown in the figure, it was confirmed that peak 1 has Mw=196, peak 2 has Mw=180, and peak 3 has Mw=240.
[0470] Figure 4-12 shows the mass spectra (after improved separation) of peaks 4 to 6 in Figure 4-10. In Figure 4-12, the upper part is the mass spectrum of peak 4, the middle part is the mass spectrum of peak 5, and the lower part is the mass spectrum of peak 6. As shown in the figure, it was confirmed that peak 4 has Mw=240, peak 5 has Mw=240, and peak 6 has Mw=226.
[0471] Figure 4-13 shows the mass spectrum (after separation improvement) of peaks 7 and 8 in Figure 4-10. In Figure 4-13, the upper part is the mass spectrum of peak 7, and the lower part is the mass spectrum of peak 8. As shown in the figure, it was confirmed that both peaks 7 and 8 have Mw=256.
[0472] FIG. 4-14 shows the micro-Raman spectrum of the sample of peak 2 (Mw=180) in FIG. 4-10 and the ozonide standard (ozonized oleic acid). In FIG. 4-14, the vertical axis is the intensity and the horizontal axis is the Raman shift (1 / cm). As shown in FIG. 4-14, peak 2 (Mw=180) showed a micro-Raman spectrum similar to that of ozonide, and was therefore presumed to show a structure similar to that of ozonide. In addition, the micro-Raman spectrum of peak 2 (Mw=180) showed a pattern different from that of peroxide, and therefore peak 2 (Mw=180) was presumed not to be a peroxide. It was confirmed by NMR described later that peak 2 (Mw=180) was the cyclic peroxide.
[0473] Figure 4-15 shows the peak 2 (Mw=180) in Figure 4-10. 1 The H NMR spectrum is shown. The measurement solvent was methanol-d4 (CD3OD). In the figure, the upper spectrum is an enlarged view of the lower spectrum around 3.4 to 4.9 ppm. 1 Based on the H NMR assignment, Mw=180, and other instrumental analysis data, the structure of the oxidation reaction product of peak 2 (Mw=180) was proven to be a cyclic peroxide represented by the following chemical formula (1). 1 In the H NMR spectrum, the peaks indicated by symbols A to F were assigned to the peaks of hydrogen bonded to the carbon atoms indicated by the same symbols A to F in the following chemical formula (1) shown in Figure 4-15. It is also presumed that a small amount of the raw material glycerin remained, and its peak was also detected.
[0474] [ka]
[0475] Figure 4-16 shows the peak 2 (Mw=180) in Figure 4-10. 13The C NMR spectrum is shown. The measurement solvent was methanol-d4 (CD3OD). In the figure, the upper spectrum is an enlarged view of the lower spectrum around 60 to 105 ppm. 13 Based on the C NMR assignment, Mw=180, and other instrumental analysis data, it was demonstrated that the structure of the oxidation reaction product of peak 2 (Mw=180) is a cyclic peroxide represented by the above chemical formula (1). 13 In the C NMR spectrum, the peaks indicated by symbols A to F were assigned to the peaks of the carbon atoms indicated by the same symbols A to F in the following chemical formula (1) shown in Figure 4-16. In addition, it is presumed that a small amount of the raw material glycerin remained, and its peak was also detected.
[0476] Figure 4-17 shows the two-dimensional ( 1 H- 13 The C COSY) NMR spectrum is shown. Methanol-d4 (CD3OD) was used as the measurement solvent. From this 2D NMR assignment, the fact that Mw=180, and other instrumental analysis data, it was demonstrated that the structure of the oxidation reaction product of peak 2 (Mw=180) is a cyclic peroxide represented by the above chemical formula (1). In the 2D NMR spectrum of Figure 4-17, the peaks indicated by symbols A to F were assigned to the carbon atoms and hydrogen atoms bonded to those carbon atoms represented by the same symbols A to F in the following chemical formula (1) shown in Figure 4-17. In addition, it is estimated that a small amount of glycerin, the raw material, remained, and its peak was also detected.
[0477] Figure 4-18 also shows HILIC chromatograms of the TLC1 spot product and glyceraldehyde dimer under the HILIC (high performance liquid chromatography) conditions of Figure 4-10. In Figure 4-18, the "synthetic OG" in the upper row is a HILIC chromatogram of the TLC1 spot product. The lower row is a HILIC chromatogram with glyceraldehyde dimer. As shown in the figure, glyceraldehyde dimer was not detected under the HILIC conditions of Figure 4-18.
[0478] Figure 4-19 shows the HILIC chromatograms of the TLC1 spot product and glyceraldehyde dimer under reversed-phase HILIC (high performance liquid chromatography) conditions. Figure 4-20 shows an enlarged view of a portion of Figure 4-19. In Figures 4-19 and 4-20, the upper row "synthetic OG" is the HILIC chromatogram of the TLC1 spot product. The lower row is the HILIC chromatogram with glyceraldehyde dimer. As shown in the figure, component separation of the TLC1 spot product could not be confirmed under reversed-phase HILIC conditions. This is thought to be because the column retention was weak and the elution time of the TLC1 spot product was fast. On the other hand, the retention time of the glyceraldehyde dimer was slightly different from that of the TLC1 spot product (synthetic OG). From this, it is inferred that the TLC1 spot product did not contain glyceraldehyde dimer.
[0479] Figure 4-21 shows the ESR spectrum of the TLC1 spot product and peak 2 (Mw=180) in Figure 4-10. In Figure 4-21, the vertical axis is intensity and the horizontal axis is magnetic flux density (G). Water was used as the measurement solvent. As shown in the figure, the spectra of the TLC1 spot product and peak 2 (Mw=180) component in Figure 4-10 almost completely overlap, and the peak appearance positions are almost completely identical for both. Both the TLC1 spot product and peak 2 (Mw=180) component in Figure 4-10 showed a spectrum of DMPO (spin trap agent) characterized by six lines. This spectral pattern is similar to that of ozonide.
[0480] Figure 4-22 shows the ESR spectrum of ozonized methyl linolenate. Acetone was used as the measurement solvent. Ozonized methyl linolenate is a known ozonide. As shown in the figure, the ESR spectrum of ozonized methyl linolenate shows a spectrum in the presence of DMPO (a spin trapping agent) that features six lines characteristic of ozonides. The pattern of this spectrum is similar to that of the TLC 1 spot and peak 2 (Mw=180) in Figure 4-21.
[0481] Figure 4-23 shows the ESR spectrum of peaks 1 to 8 in Figure 4-10. Water was used as the measurement solvent. The top is an ESR spectrum of a blank (solvent only) for comparison. As shown in the figure, it was confirmed that all of the components of peaks 1 to 8 have radical activity.
[0482] The graph in Figure 4-24 shows the results of measuring the activity of peaks 1 to 8 in Figure 4-10 by chemiluminescence. In this figure, the vertical axis is the luminescence intensity (relative intensity) at all wavelengths. The numbers "1" to "8" on the horizontal axis indicate each fraction of peaks 1 to 8. The numbers below each number indicate the molecular weight of each fraction confirmed by mass spectrometry. As shown in the figure, it was confirmed that components that show activity by chemiluminescence were generated in addition to the molecular weight of 180.
[0483] Although the present invention has been described above with reference to the embodiments and examples, the present invention is not limited to the above-mentioned embodiments and examples. Various modifications that can be understood by those skilled in the art can be made to the configuration and details of the present invention within the scope of the present invention.
[0484] This application claims priority based on Japanese Patent Application No. 2021-134732 filed on August 20, 2021, Japanese Patent Application No. 2021-195536 filed on December 1, 2021, Japanese Patent Application No. 2021-202053 filed on December 13, 2021, and Japanese Patent Application No. 2021-212094 filed on December 27, 2021, the disclosures of which are incorporated herein in their entireties.
[0485] <Additional Notes> Some or all of the above-described embodiments and examples may be described as follows, but are not limited to the following: (Appendix 1) A cyclic peroxide represented by the following chemical formula (I): [ka] In the above chemical formula (I), R100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, may or may not have a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure, and may be a monocyclic ring or a condensed ring; R 1 is a substituent, which may be one, multiple, or absent, and when multiple, they may be the same or different. (Appendix 2) In the above chemical formula (I), R 100 The cyclic peroxide according to claim 1, wherein the ring structure has 5 to 10 ring members. (Appendix 3) A cyclic peroxide according to appendix 1 or 2, represented by the following chemical formula (II): [ka] In the above chemical formula (II), Each R 11 may be the same or different, and each is a hydrogen atom or a substituent. Two R 11 may be joined together to form an oxo group (=O) or a thioxo group (=S). (Appendix 4) R in the above chemical formula (II) 11 4. The cyclic peroxide according to claim 3, wherein the substituent is a hydroxyl group (-OH), an aldehyde group (formyl group), a hydroxyalkyl group, a sulfo group, a nitro group, a diazo group, an alkyl group, an unsaturated aliphatic hydrocarbon group, an aryl group, a heteroaryl group, a halogen, a mercapto group (-SH), or an alkylthio group (-SR, R is an alkyl group). (Appendix 5) A cyclic peroxide according to any one of claims 1 to 4, represented by the following chemical formula (1): [ka] (Appendix 6) An oxidation reaction product comprising a cyclic peroxide, the oxidation reaction product being obtained by oxidizing an alcohol. (Appendix 7) 7. The oxidation reaction product according to claim 6, wherein the oxidation of the alcohol is at least one of ozone oxidation and hydrogen peroxide oxidation. (Appendix 8) 8. The oxidation reaction product of claim 6 or 7, which is a mixture containing a plurality of oxidation reaction products. (Appendix 9) 9. The oxidation reaction product according to any one of claims 6 to 8, having oxidizing ability. (Appendix 10) 10. The oxidation reaction product according to any one of claims 6 to 9, having reducing ability. (Appendix 11) 11. The oxidation reaction product of any one of claims 6 to 10, comprising a TRP channel active substance. (Appendix 12) 12. The oxidation reaction product according to any one of claims 6 to 11, wherein the alcohol is a saturated alcohol. (Appendix 13) 13. The oxidation reaction product according to any one of claims 6 to 12, wherein the alcohol is a polyhydric alcohol. (Appendix 14) 14. The oxidation reaction product according to any one of claims 6 to 13, wherein the alcohol is at least one of glycerin and a glycerin derivative. (Appendix 15) 15. The oxidation reaction product according to any one of claims 6 to 14, comprising an oxidation reaction product obtained by bonding two or more molecules of the alcohol. (Appendix 16) 16. The oxidation reaction product of any one of claims 6 to 15, comprising a cyclic peroxide of any one of claims 1 to 5. (Appendix 17) 17. A method for producing an oxidation reaction product according to any one of claims 6 to 16, comprising an alcohol oxidation step of oxidizing the alcohol. (Appendix 18) 18. The method for producing an oxidation reaction product according to claim 17, wherein in the alcohol oxidation step, the alcohol is oxidized by at least one of ozone oxidation and hydrogen peroxide oxidation. (Appendix 19) 19. The method for producing an oxidation reaction product according to claim 17 or 18, wherein the reaction time in the alcohol oxidation step is 24 hours or longer. <Whitening composition> (Appendix 20) Contains glycerin and / or a glycerin derivative and a skin whitening ingredient, The whitening composition, wherein the whitening ingredient contains, as an active ingredient, a cyclic peroxide represented by the following chemical formula (I) or a salt thereof: [ka] In the above chemical formula (I), R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, may or may not have a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure, and may be a monocyclic ring or a condensed ring; R 1 is a substituent, which may be one, multiple, or absent, and when multiple, they may be the same or different. (Appendix 21) In the above chemical formula (I), R 100 is a cyclic structure having 5 to 10 ring members. (Appendix 22) The whitening composition according to claim 20 or 21, wherein the cyclic peroxide represented by the chemical formula (I) is represented by the following chemical formula (II): [ka] In the above chemical formula (II), Each R 11 may be the same or different, and each is a hydrogen atom or a substituent. Two R 11 may be joined together to form an oxo group (=O) or a thioxo group (=S). (Appendix 23) R in the above chemical formula (II) 11wherein the substituent is a hydroxyl group (-OH), an aldehyde group (formyl group), a hydroxyalkyl group, a sulfo group, a nitro group, a diazo group, an alkyl group, an unsaturated aliphatic hydrocarbon group, an aryl group, a heteroaryl group, a halogen, a mercapto group (-SH), or an alkylthio group (-SR, R is an alkyl group). (Appendix 24) A whitening composition according to any one of claims 20 to 23, wherein the cyclic peroxide represented by the chemical formula (I) is represented by the following chemical formula (1): [ka] (Appendix 25) Contains glycerin and / or a glycerin derivative and a skin whitening ingredient, The whitening composition comprises, as an active ingredient, an oxidation reaction product containing a cyclic peroxide or a salt thereof obtained by oxidizing an alcohol. (Appendix 26) The whitening composition according to claim 25, wherein the oxidation of the alcohol is at least one of ozone oxidation and hydrogen peroxide oxidation. (Appendix 27) 27. The skin whitening composition according to claim 25 or 26, which is a mixture containing a plurality of oxidation reaction products. (Appendix 28) 28. The whitening composition according to any one of claims 25 to 27, wherein the oxidation reaction product has an oxidizing ability. (Appendix 29) 29. The whitening composition according to any one of claims 25 to 28, wherein the oxidation reaction product has reducing ability. (Appendix 30) 30. The skin-whitening composition according to any one of claims 25 to 29, wherein the oxidation reaction product has melanin decomposition activity, melanin production inhibition activity, and / or melanin excretion promotion activity. (Appendix 31) 31. The whitening composition according to any one of claims 25 to 30, wherein the alcohol is a saturated alcohol. (Appendix 32) 32. The whitening composition according to any one of claims 25 to 31, wherein the alcohol is a polyhydric alcohol. (Appendix 33) 33. The whitening composition according to any one of claims 25 to 32, wherein the alcohol is at least one of glycerin and a glycerin derivative. (Appendix 34) 34. The whitening composition according to any one of claims 25 to 33, comprising an oxidation reaction product obtained by bonding two or more molecules of the alcohol. (Appendix 35) 35. A skin-whitening composition according to any one of claims 25 to 34, comprising a cyclic peroxide according to any one of claims 20 to 24. (Appendix 36) A whitening composition according to any one of Appendices 20 to 35, for use on the skin. (Appendix 37) The whitening composition according to any one of Appendices 20 to 36, wherein the composition is a cosmetic. <Whitening agent> (Appendix 38) A skin whitening agent comprising a cyclic peroxide represented by the following chemical formula (I) or a salt thereof: [ka] In the above chemical formula (I), R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, may or may not have a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure, and may be a monocyclic ring or a condensed ring; R 1 is a substituent, which may be one, multiple, or absent, and when multiple, they may be the same or different. (Appendix 39) In the above chemical formula (I), R 100 is a cyclic structure having 5 to 10 ring members. (Appendix 40) The skin whitening agent according to claim 38 or 39, wherein the cyclic peroxide represented by the chemical formula (I) is represented by the following chemical formula (II): [ka] In the above chemical formula (II), Each R 11 may be the same or different, and each is a hydrogen atom or a substituent. Two R 11 may be joined together to form an oxo group (=O) or a thioxo group (=S). (Appendix 41) R in the above chemical formula (II) 11 wherein the substituent is a hydroxyl group (-OH)...
Claims
1. The present invention comprises an ozone oxidation reaction product of glycerin obtained by oxidizing glycerin having a concentration of 75% by weight to 98.5% by weight with ozone for 24 hours or more, A profilaggrin mRNA expression promoter having an effect of promoting the expression of profilaggrin mRNA which produces profilaggrin from the profilaggrin gene.
2. The present invention comprises an ozone oxidation reaction product of glycerin obtained by oxidizing glycerin having a concentration of 75% by weight to 98.5% by weight with ozone for 24 hours or more, An involucrin mRNA expression promoter having an effect of promoting the expression of involucrin mRNA which produces involucrin from the involucrin gene.
3. The present invention comprises an ozone oxidation reaction product of glycerin obtained by oxidizing glycerin having a concentration of 75% by weight to 98.5% by weight with ozone for 24 hours or more, A serine palmitoyltransferase mRNA expression promoter, characterized by having an effect of promoting the expression of serine palmitoyltransferase mRNA which produces serine palmitoyltransferase from a serine palmitoyltransferase gene.
4. The present invention comprises an ozone oxidation reaction product of glycerin obtained by oxidizing glycerin having a concentration of 75% by weight to 98.5% by weight with ozone for 24 hours or more, A heme oxygenase 1 mRNA expression promoter, characterized by having an effect of promoting the expression of heme oxygenase 1 mRNA which produces heme oxygenase 1 from the heme oxygenase 1 gene.
5. The present invention comprises an ozone oxidation reaction product of glycerin obtained by oxidizing glycerin having a concentration of 75% by weight to 98.5% by weight with ozone for 24 hours or more, An NAD(P)H quinone oxidoreductase 1 mRNA expression promoter, characterized by having an effect of promoting the expression of NAD(P)H quinone oxidoreductase 1 mRNA that produces NAD(P)H quinone oxidoreductase 1 from the NAD(P)H quinone oxidoreductase 1 gene.
6. The present invention comprises an ozone oxidation reaction product of glycerin obtained by oxidizing glycerin having a concentration of 75% by weight to 98.5% by weight with ozone for 24 hours or more, A glutathione production promoter characterized by having an effect of promoting glutathione production.
7. The present invention comprises an ozone oxidation reaction product of glycerin obtained by oxidizing glycerin having a concentration of 75% by weight to 98.5% by weight with ozone for 24 hours or more, An IL-1α production inhibitor characterized by having an IL-1α production inhibitory effect.
8. The present invention comprises an ozone oxidation reaction product of glycerin obtained by oxidizing glycerin having a concentration of 75% by weight to 98.5% by weight with ozone for 24 hours or more, Prostaglandin E 2 Prostaglandin E 2 Production inhibitors.
9. The present invention comprises an ozone oxidation reaction product of glycerin obtained by oxidizing glycerin having a concentration of 75% by weight to 98.5% by weight with ozone for 24 hours or more, An anti-glycation agent characterized by having an effect of cleaving cross-linked structures between polypeptides and / or proteins generated by glycation reactions.
10. The agent described in any one of claims 1 to 9, wherein the ozone oxidation reaction product of glycerin is an ozone oxidation reaction product of glycerin obtained by ozone oxidizing glycerin having a concentration of 75% by weight to 98.5% by weight for 24 hours or more but less than 7 days.
11. A composition for improving skin barrier function, which is either a composition for improving skin barrier function for promoting profilaggrin mRNA expression, containing as an active ingredient the profilaggrin mRNA expression promoter described in claim 1; a composition for improving skin barrier function for promoting involucrin mRNA expression, containing as an active ingredient the involucrin mRNA expression promoter described in claim 2; or a composition for improving skin barrier function for promoting serine palmitoyltransferase mRNA expression, containing as an active ingredient the serine palmitoyltransferase mRNA expression promoter described in claim 3.
12. An antioxidant composition which is any one of an antioxidant composition for promoting heme oxygenase 1 mRNA expression containing as an active ingredient the heme oxygenase 1 mRNA expression promoter described in claim 4, an antioxidant composition for promoting NAD(P)H quinone oxidoreductase 1 mRNA expression containing as an active ingredient the NAD(P)H quinone oxidoreductase 1 mRNA expression promoter described in claim 5, and an antioxidant composition for promoting glutathione production containing as an active ingredient the glutathione production promoter described in claim 6.
13. An anti-inflammatory composition which is either an anti-inflammatory composition for suppressing IL-1α production containing as an active ingredient the IL-1α production inhibitor described in claim 7, or an anti-inflammatory composition for suppressing prostaglandin E 2 production containing as an active ingredient the prostaglandin E 2 production inhibitor described in claim 8.
14. An anti-glycation composition comprising the anti-glycation agent according to claim 9 as an active ingredient.
15. A cosmetic preparation comprising an agent according to any one of claims 1 to 9.
16. A topical skin preparation comprising an agent according to any one of claims 1 to 9.
